[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
PROCEDURE S IN CASE OF EMERGEN CY 
 
Table 1: Emergency Contact [CONTACT_28096], MD, MBA  [ADDRESS_27359]  
San Diego, CA [ZIP_CODE] 
Office: (858) 550- 0780  x230 
Mobile Phone: ( 310) 922- 8039 
Email: rshazer @traconpharma.com  
Secondary Medical Monitor  Charles Theuer , MD, PhD [ADDRESS_27360]  
San Diego, CA [ZIP_CODE] Office: (858) 550- 0780 x233 
Mobile Phone: (858) 344- 9400 
Email: [EMAIL_437]   
 
Page 2 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
1. SYNOPSIS 
Name [CONTACT_790]/Company: TRACON Pharmaceuticals, Inc.  
Name [CONTACT_791]: TRC105  
Name [CONTACT_3261]: TRC105  
Title of Study:  
A SINGLE PAT IENT PROTOCOL  OF TRC105 COMBINED WITH STANDARD- DOSE 
BEVACIZUMAB FOR A SINGLE PATIENT WITH METASTATIC AND REFRACTORY 
CHORIOCARCINOMA  
Study center(s): This study will be performed at one US center  in one patient . 
Investigators: Neil Horowitz, MD  
Studied period (years):  
Estimated date  patient enrolled: January 2015 Phase of development: 2 
 
Rational e:  
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) that inhibits 
angiogenesis and extends survival in patients with a wide variety of solid tumor types.  TRC105, a 
monoclonal antibody to endoglin, an angiogenic target highly expressed on the tumor vessels and the 
tumor cells in choriocarcinoma.  TRC105 has been well tolerated when dosed with bevacizumab in 
more than 50 patients with advanced cancer.  Together, these antibodies may be efficacious in 
metastatic and refractory ch oriocarcinoma , a tumor type that is highly vascular and expresses 
endoglin.    
Objectives  
Primary:  
• To determin e PFS and ORR  of one patient with metastatic and refractory 
choriocarcinoma by [CONTACT_393] 1.1 including measurement  of serum  β- hCG  
Secondary:  
• To determine the frequency and severity of adverse events as assessed by [CONTACT_4652] 
(Version 4.0)  
• To explore the effects of TRC105 and bevacizumab on circulating angiogenic protein 
biomarkers  
Methodology:  
This is a single patient  study of TRC105 in combination with standard dose bevacizumab in a patient 
with metastatic and refractory choriocarcinoma  for whom curative therapy is unavailable.  TRC105 
will be administered weekly in combination with bevacizumab .  The p atient will rece ive bevacizumab 
on days [ADDRESS_27361] weekly dose of TRC105 will be split with 
3 mg/kg administered on cycle 1 day 8 and  7 mg/kg  administered on cycle 1 day 11, and then the full 
dose of 10 mg/kg given on cycle 1 day 15 and weekly thereafter.  
Number of patients (planned):  
One patient  
Page 3 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Diagnosis and main criteria for inclusion:  
Inclusion Criteria:  
1. Willing ness and ab ility to consent for self to participate in study   
2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and 
other study procedures  
3. Measurable disease by [CONTACT_393] 1.1  and elevated serum β -hCG  
4. Histologically proven choriocarcinoma that has  progressed despi[INVESTIGATOR_28051]:   
1. Prior treatment with TRC105  
2. Serious dose -limiting toxicity related to prior bevacizumab  
3. Current treatment on another therapeutic clinical trial  
4. Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despi[INVESTIGATOR_28052] (initiation or adjustment of BP medication prior to study entry  is allowed provided 
that the average of 3 BP readings at a visit prior to e nrollment is < 140/90 mm Hg)  
5. Symptomatic pericardial or pleural effusions  
6. Uncontrolled peritoneal effusions requiring paracentesis more frequently than every 2 weeks  
7. Active bleeding or pathologic condition that carries a high risk of bleeding (i.e. heredi tary 
hemorrhagic telangiectasia)  
8. Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within [ADDRESS_27362] day of study therapy  
9. Cardiac dysrhythmias of NCI CTCAE grade  ≥ [ADDRESS_27363] 6 months, unless treated for the condition and complete resolution has been documented by [CONTACT_28097] 
(EGD) within 28 days of starting study treatment  
13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness  
14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality th at 
may increase the risk associated with study participation or may interfere with the 
interpretation of study results and, in the judgment of the Investigator, would make the patient 
inappropriate for this study  
 
Page 4 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27364]  dose and mode of administration:  
Following the appropriate premedication regiment, TRC105 is to be administered intravenously over 
1 to 4 hours (+/ - 15 minutes) on days 8, 11, 15, and 22  of cycle 1 and on days 1, 8, 15 and 22 of all 
subsequent cycles.   There is a +/ - 15 minute window for all infusions.    
Duration of treatment:  
The p atient may continue on treatment  until disease progression, unacceptable toxicity or withdrawal 
of consent, or other reasons.   
The patient should be withdrawn from study treatment if, in the opi[INVESTIGATOR_689], it is 
medically necessary, or if it is the wish of the patient.  In addition, the patient will be withdrawn from 
treatment in the case of:  
1. Disease Progression.  Progressive Disease as defined in RECIST 1.[ADDRESS_27365] to follow -up or noncompliant.  
4. Any TRC105 dose delay ≥ 8 weeks OR discontinuation of study therapy for > 6 months 
following CR . 
5. Arterial thrombosis of any grade (including cerebrovascular isc hemia, cardiac 
ischemia/infarction, or peripheral or visceral arterial ischemia) or grade 4 thromboembolism. 
For grade 3 venous thromboembolism hold bevacizumab treat ment .  IF the planned duration 
of full dose anticoagulation is < 2 weeks, bevacizumab shou ld be held until the full dose 
anticoagulation period is over.  If the planned duration of full dose anticoagulation is > [ADDRESS_27366]  a pathologic condition that carries high risk of 
bleeding (i.e. tumor involving major vessels).  2.  Subject has not had any hemorrhagic events on study.  3.  The subject has a stable dose of heparin or have an in -range INR (usually 2 -3) 
on a stable dose of warfarin prior to restarting bevacizumab.  4.  I f thromboemboli sm 
worsens/recurs upon resumption of bevacizumab, despi[INVESTIGATOR_28053], bevacizumab should be discontinued.  
Reference therapy, dosage and mode of administration:  
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the 
biologic activity of human vascular endothelial growth factor (VEGF).  Bevacizumab will be 
administered intravenously at a dose of 1 0 mg/kg on day  1 and 15 of each 2 8-day cycle p rior to 
TRC105  (except on cycle 1 day 1 when TRC105 is not to be administered) .  The initial bevacizumab 
dose should be delivered over [ADDRESS_27367] infusion is well tolerated, the second infusion 
may be administered over 60 minutes. If the 60 -minute infusion is well tolerated, all subsequent 
infusions may be administered over 30 minutes.  Following bevacizumab, the line should be flushed 
with normal saline before TRC105 administration 30 minutes later.  
Page 5 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Criteria for evaluation:  
Safety : 
A formally chartered in -house TRACON Safety Review Team will review safety data. Safety 
assessments include adverse events (AEs), physical exams, performance status, laboratory results 
(complete blood counts and serum chemistry) and 12 -lead ECG’s (i f the patient develop s an 
arrhythmia ).   
Efficacy : 
Preliminary evidence of antitumor activity will be assessed by [CONTACT_393] 1.1 and regression in β- hCG 
tumor marker.   
Statistical methods:  
No statistical analyses are planned . 
Page 6 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27368] OF FIGURES  ....................................7  
2. INTRODUCTION  ......................................................................................................14  
2.1. Background  .................................................................................................................14  
2.1.1.  Angiogenesis and Cancer  ...........................................................................................14  
2.1.2.  CD105 and Angiogenesis  ...........................................................................................14  
2.2. TRC105 Background  ..................................................................................................16  
2.2.1.  Studies with TRC105  ..................................................................................................16  
[IP_ADDRESS].  105ST101 Phase 1 Monotherapy  ................................................................................17  
[IP_ADDRESS].  Phase 1b 105ST102 Study with Bevacizumab  ...........................................................19  
2.2.2.  Description of Bevacizumab  .......................................................................................22  
[IP_ADDRESS].  Rationale for Adding TRC105 to Bevacizumab  .........................................................[ADDRESS_27369]  .......................................................................................................................26  
3. TRIAL OBJECTIVES AND  PURPOSE  ....................................................................27  
3.1. Primary:  ......................................................................................................................27  
3.2. Secondary:  ..................................................................................................................27  
4. INVESTIGATIONAL PLAN .....................................................................................28  
4.1. Overall Study Design and Plan: Description  ..............................................................28  
4.1.1.  Trial Overview  ............................................................................................................28  
4.1.2.  Trial Procedures  ..........................................................................................................28  
[IP_ADDRESS].  Screening  ....................................................................................................................28  
[IP_ADDRESS].  Trial Period  .................................................................................................................[ADDRESS_27370] AWAL OF PATIENTS  ..............................................35  
Page 7 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
5.1. Patient Inclusion Criteria  ............................................................................................35  
5.2. Exclusion Criteria  .......................................................................................................35  
5.3. Patient Withdrawal Criteria  ........................................................................................36  
6. TREATMENT OF PATIENTS  ..................................................................................37  
6.1. Description of TRC105 Study Drug ...........................................................................37  
6.2. Composition of TRC105 .............................................................................................37  
6.3. TRC105 Dose Levels  ..................................................................................................37  
6.4. TRC105 Packaging and Labeling ...............................................................................37  
6.5. TRC105 Storage and Shippi[INVESTIGATOR_007]  ...................................................................................37  
6.6. TRC105 Preparation  ...................................................................................................37  
6.7. TRC105 Administration  .............................................................................................38  
6.7.1.  TRC105 Dose Modification/Dose Interruptions  ........................................................39  
6.7.2.  Management of TRC105 Infusion Reactions  .............................................................40  
6.7.3.  TRC105 Study Drug Accountability  ..........................................................................41  
6.7.4.  TRC105 Study Drug Handling and Disposal  .............................................................41  
6.8. Bevacizumab Packaging  .............................................................................................41  
6.9. Bevacizumab Preparation  ...........................................................................................42  
6.10.  Bevacizumab Administration  .....................................................................................42  
6.10.1.  Bevacizumab Dose Modification  ...............................................................................42  
6.11.  Bevacizumab Drug Accountability  .............................................................................42  
6.12.  Bevacizumab Handling and Disposal  .........................................................................42  
6.13.  Concomitant Medications  ...........................................................................................42  
6.14.  Treatment Compliance  ................................................................................................43  
6.14.1.  TRC105.......................................................................................................................43  
6.14.2.  Bevacizumab ...............................................................................................................43  
6.15.  Patient Enrollment  ......................................................................................................43  
7. ASSESSMENT OF EFFICA CY ................................................................................44  
7.1. Radiological Tumor Assessment  ................................................................................44  
7.2. Recording Tumor Measurements  ...............................................................................44  
7.2.1.  Definitions of Tumor Response  ..................................................................................45  
[IP_ADDRESS].  Target Lesions  ............................................................................................................45  
[IP_ADDRESS].  Non-Target Lesions  ....................................................................................................45  
[IP_ADDRESS].  Determination of Overall Response by [CONTACT_28098]  .....................................46  
Page 8 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
8. ASSESSMENT OF SAFETY .....................................................................................47  
8.1. Safety Parameters  .......................................................................................................47  
8.1.1.  Laboratory Safety Assessments  ..................................................................................47  
[IP_ADDRESS].  Hematology, Serum Chemistry, Coagulation  .............................................................47  
[IP_ADDRESS].  Urinalysis  ....................................................................................................................47  
8.1.2.  Other Safety Assessments ...........................................................................................47  
[IP_ADDRESS].  Physical Examination  .................................................................................................47  
[IP_ADDRESS].  Vital Signs  ..................................................................................................................48  
[IP_ADDRESS].  Performance Status  .....................................................................................................48  
[IP_ADDRESS].  ECG  ............................................................................................................................48  
8.2. Adverse Events  ...........................................................................................................48  
8.2.1.  Definition of Adverse Event  .......................................................................................48  
8.2.2.  Serious Adverse Events  ..............................................................................................49  
[IP_ADDRESS].  Hospi[INVESTIGATOR_059]  ............................................................................................................50  
8.3. Reporting Adverse Events  ..........................................................................................51  
8.3.1.  Eliciting Adverse Event Information  ..........................................................................51  
8.3.2.  Adverse Event Reporting Period  ................................................................................51  
8.3.3.  Reporting Requirements  .............................................................................................51  
8.3.4.  Recording Adverse Events in the Case Report Forms  ................................................52  
8.3.5.  Grading of Adverse Event Severity  ............................................................................52  
8.3.6.  Relationship to TRC105 Study Drug ..........................................................................53  
8.3.7.  Expectedness ...............................................................................................................53  
8.3.8.  Exposure in Utero  .......................................................................................................53  
8.3.9.  Follow -up of Unresolved Adverse Events  ..................................................................53  
8.4. Safety Monitoring .......................................................................................................54  
9. OTHER ASSESSMENTS  ..........................................................................................55  
9.1. Other Laboratory Assessments  ...................................................................................55  
9.1.1.  Protein Biomarker  .......................................................................................................55  
10. STATISTICS  ..............................................................................................................56  
10.1.  Data Analysis  ..............................................................................................................56  
10.1.1.  Analysis of Primary Objective....................................................................................56  
10.1.2.  Analysis of Secondary Objectives  ..............................................................................56  
[IP_ADDRESS].  Protein Biomarkers  .....................................................................................................56  
Page 9 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27371] ACCESS TO SOURCE DATA/DOCUMENT S .........................................[ADDRESS_27372] (IRB)/Independent Ethics Committee (IEC)  ..................[ADDRESS_27373] of the Study  ......................................................................................59  
13.3.  Written Informed Consent  ..........................................................................................59  
13.4.  Patient Comp ensation  .................................................................................................59  
14. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  .......................................................60  
14.1.  Inspection of Records  .................................................................................................60  
14.2.  Retention of Records  ..................................................................................................60  
15. DEFINITION OF END OF  TRIAL  ...........................................................................62  
15.1.  End of Trial  .................................................................................................................62  
15.2.  TRACON Discontinuation Criteria  ............................................................................62  
16. PUBLICATION OF TRIAL  RESULTS  ....................................................................63  
17. FINANCING AND INSURANCE  .............................................................................64  
18. INVESTIGATOR PROTOCO L AGRE EMENT: 105CC201 AMEN DMENT 
#3 ................................................................................................................................65  
19. REFERENCES  ...........................................................................................................66  
20. APPENDICES  ............................................................................................................70  
20.1.  Appendix 1:  National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE)  .......................................................................70  
20.2.  Appendix 2:  ECOG Performance Status  ...................................................................71  
20.3.  Appendix 3:  Avastin Package Insert  ..........................................................................[ADDRESS_27374] OF TABLES  
Table 1:  Emergency Contact [CONTACT_7171]  ...................................................................................2  
Table 2:  Abbreviations and Specialist Terms  ...........................................................................11  
Table 3:   Schedule of Assessments  ............................................................................................32  
Table 4:  Allowable TRC105 Dose Modifications  ....................................................................39  
Table 5:  Management of TRC105 Infusion Reactions  .............................................................40  
Table 6:  Response Evaluation Criteria in Solid Tumors  ..........................................................46  
Table 7:  Adverse Event Grading  ...............................................................................................52  
 
Page 10 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Table  2: Abbreviations and Specialist Terms  
Abbreviation or specialist 
term  Explanation  
ADCC  Antibody -Dependent Cell -mediated Cytotoxicity  
AE Adverse Event  
AFP Alpha Fetoprotein  
AIDS  Acquired Immunodeficiency Syndrome  
ALKs  Activin receptor -Like Kinases  
ALT  Alanine Aminotransferase  
ANC  Absolute Neutrophil Count  
AST  Aspartate Aminotransferase  
AUC  Area Under the Curve  
AUClast  Time of Last Measurable Concentration of Area Under the Curve  
BALB/c mice  Mouse Strain  
BUN  Blood Urea Nitrogen  
β-hCG  Beta human chorionic gonadotropin  
CA-125 Cancer Antigen -125 
CABG  Coronary Artery By[CONTACT_28099]® Prednisone  
CL Clearance  
Cmax Maximum Serum Concentration  
CPA  Cyclophosphamide  
CR Complete Response  
CRF  Case Report Form  
CT Computed Tomography  
CTC  Common Terminology Criteria  
dL Deciliter  
DLT  Dose Limiting Toxicity  
DVT  Deep Vein Thrombosis  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
ECM  Extracellular Matrix  
EGFR  Epi[INVESTIGATOR_28054] -Linked ImmunoSorbent Assay  
EOS  End of Study  
FDA  Food and Drug Administration  
g Gram  
GCP  Good Clinical Practice  
GTD  Gestational Trophoblastic Disease  
GTN  Gestational Trophoblastic Neoplasia  
HACA  Human Anti -Chimeric Antibodies  
HAMA  Human Anti -Murine Antibodies  
Her-2 Human epi[INVESTIGATOR_3506] 2 
HHT -1 Hereditary Hemorrhagic Telangiectasia Type 1  
HIF-1-α Hypoxia -Inducible Factor -1-α 
Page 11 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27375]  Response Evaluation Criteria in Solid Tumors  
SAE  Serious Adverse Event  
sCD105  Soluble CD105/endoglin  
SCID  Severe Combined Immunodeficient  
SD Stable Disease  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
Page 12 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27376]  Upper Limit of Normal  
US [LOCATION_002] of America  
VEGF  Vascular Endothelial Growth Factor  
Page 13 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
2. INTRODUCTION  
2.1. Background  
2.1.1. Angiogenesis and Cancer  
Angiogenesis is required for the survival and growth of solid cancers [1, 2].  It is  generally 
accepted that solid cancers have two phases, an avascular phase and a vascular phase [2].  During 
the initial avascular phase, tumors exist  as small aggregates of malignant cells supported by 
[CONTACT_28100].  The progressive growth of solid cancers beyond 
clinically occult sizes requires the continuous formation of new blood vessels, a process known 
as tumor angiogen esis.  Tumor growth and metastasis require angiogenesis.  Therefore, 
inhibition of tumor angiogenesis and selective inhibition of the tumor vasculature represent 
potentially effective strategies for the prevention and treatment of solid cancers.   
Therapie s that are directed against targets implicated in the development of tumor angiogenesis 
are attractive for many reasons.  First, except for female reproduction and wound healing, 
angiogenesis in adults is generally part of a pathologic process such as tumo r growth or 
choroidal neovascularization.  Second, treatments that interrupt tumor angiogenesis should apply 
broadly to all solid cancers.  Third, angiogenic targets are present in the plasma or on endothelial 
cells themselves.  These targets are readily accessible to antibody treatments, in contrast to 
targets expressed within tumors that are more difficult for antibodies to access.  Fourth, angiogenic targets on vascular endothelial cells are less prone to genetic mutation than targets 
expressed by [CONTACT_28101].  As a result, development of resistance may be 
more predictable for agents that target endothelial cell functions than for those targeting cancer 
cells.  
Indeed, agents that target pathways required for tumor angiogenesis have an important role in the therapy of cancer patients.  The monoclonal antibody bevacizumab, which binds to the angiogenic cytokine VEGF, significantly prolongs overall survival for patients with advanced 
colorectal cancer or non -small cell lung cancer when added to standard chemotherapy regimens 
[3, 4].   Bevacizumab is also indicated for renal cell cancer, breast cancer and malignant glioma 
[5-7] with published evidence of clinical benefit in other solid tumor types.  Orally available 
small molecule VEGF inhibitors include sunitinib, sorafenib, pazopanib and axitinib, all of which hav e been shown to prolong survival in patients with metastatic renal cell cancer and/or 
hepatocellular cancer [8-11].   
2.1.2. CD105 and Angiogenesis  
CD105 (endoglin) is a homodimeric cell membrane glycoprotein that was initially identified as a human leukemia- associated antigen [12] and later also found on endothelial cells [13, 14].  The 
expression pattern of CD105 is relatively restricted and CD105 is mainly expressed on immature 
B-lineage/myeloid leukemia cells and endothelial cells [12, 13]. CD105 is a TGF -β coreceptor 
that is  essential for angiogenesis [15, 16].  CD105 is strongly expressed on the proliferating 
vascular endothelium of solid tumors [14, 17]. All of these properties make CD105 a good target 
for the antiangiogenic therapy of cancer [18]. Vascular targeted therapy may be more effective 
for destroying large established tumors than conventional antiangiogenic therapy such as anti -
VEGF therapy [19].  In animal models, CD105 targeted therapy has demonstrated both vascular 
Page 14 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
targeting eff ects and antiangiogenic effects by [CONTACT_28102] [14 , 20-23]. 
Therefore, CD105 offers a novel alternative ta rget relative to the VEGF inhibitors currently 
available for antiangiogenesis therapy.  CD105 expression is required for endothelial cell 
proliferation, and CD105 is upregulated in the setting of hypoxia through the induction of 
hypoxia -inducible factor -1-α (HIF -1-α) [24, 25].  CD105 has also been show to protect hypoxic 
cells from apoptosis [26].   
CD105 acts to modulate signaling of multiple kinase receptor complexes of the TGF -β 
superfamily, including TGF -β receptors, activin receptor -like kinases (ALKs) and activin 
receptors [27].  In the absence of CD105, activation of TGF -β receptors results in 
phosphorylation of SMAD proteins that inhibit endothelial cell growth.  However, activation of CD105 by [CONTACT_4722] -β modulates SMAD protein phosphorylation.  The end result is release of the 
growth inhibitory effects of TGF -β receptor activation on endothelial.  Not surprisingly, 
prevention of CD105 activation by [CONTACT_14181] -CD105 antibody acts synergistically with TGF -β to 
inhibit endothelial cell growth [28].   
The expression of CD105 by [CONTACT_28103].  Targeted inactivation (knockout) of murine CD105 results in defective vascular 
development.  Mice lacking CD105 die in utero from defective vascular development by 
[CONTACT_28104] 11 [16].   
CD105 is critical for normal human blood vessel development [29].  CD105 haplotype insufficiency causes a well -described syndrome known as hereditary hemorrhagic telangiectasia 
type 1 (HHT -1 or Rendu-Osler -Weber Syndrome).  HHT -1 is a rare autosomal dominant genetic 
disorder characterized by [CONTACT_28105], buccal, gastrointestinal mucosa and skin microvasculature.  Angiodysplasia also occurs in vessels from internal organs including the lungs, liver and brain [30].  The genotype is manifested in utero, but the phenotype 
does not become apparent for many years following birth.  A ffected patients commonly present 
with epi[INVESTIGATOR_28055].  The phenotype of this disorder is limited to vascular 
effects, indicating the specific role of CD105 in the vasculature [31].   
CD105 is highly expressed on the proliferating endothelial cells of tumor vessels including lung, breast, colorectal, gastric, liver, endometrial, renal cell, head an d neck, and ovarian cancers.  In 
adults, CD105 expression can be measured on activated monocytes and endothelial cells, and 
expression levels on endothelial cells exceed those on activated monocytes by [CONTACT_3450] 10 -
fold [32, 33].   
Importantly, CD105 expression is increased following inhibition of the VEGF pathway.  CD105 
expression increased more than two -fold in human pancreatic cancers grown in mice treated with 
an antibody that binds VEGF [34].  As well, treatment of human bladder cancers grown in mice 
with an antibody that blocks activation of the VEGF receptor increased CD105 expression within 
the core tumor vasculature [35].   
CD105 e xpression is a prognostic factor in solid tumor patients.  Higher numbers of tumor 
vessels expressing CD105 have been correlated with poor prognosis in clinical studies of breast cancer [36, 37], lung cancer [38], prostate cancer [39, 40], colorectal cancer [41, 42], gastric 
cancer [43], endometrial cancer [44 ], astrocytic brain tumors [45], hepatocellular carcinoma [46], 
ovarian cancer [47, 48], esophageal adenocarcinoma [49], and head and neck cancer [50, 51].   
Page 15 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Plasma CD105 levels measur ed by [CONTACT_28106].  In one study, the mean plasma CD105 concentration in 76 patients with 
colorectal cancer 4 -fold higher than the mean value in 40 healthy subjects without cancer [41].   
In the study, a positive correlation was observed between CD105 concentration and stage of 
disease.  For example, patients with advanced cancer had higher plasma CD105 levels than those 
with early -stage disease (r=0.20, p=0.0470).  In another study, the mean sCD105 concentration 
in 59 patients with advanced metastatic solid cancer was 63.8 ng/mL versus 41.0 ng/mL in 
cancer patients without metastases, and 28.3 ng/mL in patients without a cancer diagnosis [52].  
In a study of breast cancer patients receiving hormonal therapy, the upper limit of normal for soluble CD105 was determined to be  8.70 ng/mL, and patients with elevated CD105 had shorter 
overall survival than those who did not [37].  These sCD105 concentrations are relatively low 
compared to TRC105 concentrations > 100,000 ng/mL that were safely achieved in cancer patients treated with TRC105 monotherapy on Study 105ST101.  
CD105 is expressed directly on certa in cancers in addition to its expression on the tumor vessels. 
Choriocarcinoma is a vascular cancer that arises form trophoblast tissue that densely expresses CD105.  CD105 has been shown to  induce trophoblastic outgrowth and migration.  Hence, 
patients wi th choriocarcinoma are viewed as excellent candidates for treatment with 
angiogenesis inhibitors, especially a therapy that directly targets CD105 expressed on choriocarcinoma.  
2.2. TRC105 Background   
TRC105 is a genetically engineered human/murine chimeric mon oclonal antibody directed 
against human CD105 [53], a growth proliferation receptor found on the surface of normal and 
proliferating endothelial cells.   
The antibody is an IgG1 kappa immunoglobulin containing murine variable region sequences 
and human constant region sequences [53] .  TRC105 has an approximate molecular weight of 
148 kDa. TRC105 has a binding avidity for human CD105 of approximately 5 pM. TRC105 is formulated as a phosphate -buffered saline (PBS) solution at a concentration of 7 mg/mL.   
SN6j, the murine parent antibody of TRC105, binds to human umbilical vein endotheli al cells 
(HUVECs) with nearly identical avidity as TRC105.  SN6j has been shown to bind the tumor vasculature of malignant tissues including breast, colon, rectum, kidney and lung cancers and to inhibit the growth of tumor xenografts [21].  Reactivity with tumor tissues is restricted to the 
tumor endothelium, as CD105 is not generally expressed on epi[INVESTIGATOR_28056] [21].  TRC105 
induces ADCC on proliferating HUVECs at low conentrations and induces apoptosis and growth inhibition at higher concentrations.  
In trophoblastic cell line TRC105 was shown to directly inhibit  growth in a dose dependent and methotrexate independent  manner .  
2.2.1. Studies with TRC105  
Several studies with TRC105 are underway or have been completed.  An open- label, phase 1, 
multicenter study of TRC105 (Study 105ST101) enrolled fifty patients, who were treated until disease progression with TRC105 at 0.01- 15 mg/kg/q2wk or 10 -15 mg/kg/wk.  Studies of 
TRC105 in prostate, bladder, and ovarian cancer and a phase 1b study of TRC105 in 
Page 16 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27377] cancer, a phase 1b study of TRC105 
in combination with sorafenib in liver cancer, a phase 1b study of TRC105 in combination with axitinib in renal cell carcinoma, and phase 2 studies of TRC105 monotherapy in liver cancer and 
in combination with bevacizumab in glioblastoma multiforme (2 studies) and renal cell 
carcinoma.   
[IP_ADDRESS]. 105ST101 Phase 1 Monotherapy  
[IP_ADDRESS].1. 105ST101 Phase 1 Monotherapy Pharmacokinetics  
In Study 105ST101, TRC105 pharmacokinetics were assessed on patients enrolled at doses up to 
15 mg/kg weekly.  Circulating TRC105 was not measurable above the lower limit of quantitation of the assay (78 ng/mL) in patients receiving doses below 0.3 mg/kg.  T RC105 was measurable 
above the target concentration based on preclinical data (200 ng/mL) for 4 hours at 0.3 mg/kg, 1 
day at 1 mg/kg, 5 days at 3 mg/kg, and 7 days at 10 mg/kg TRC105 dosed every two weeks.  
Serum concentrations expected to saturate CD105 binding sites (≥ 200 ng/mL) were achieved continuously at 15 mg/kg q2wk and 10 mg/kg weekly, and TRC105 accumulated at 15 mg/kg 
weekly.  
[IP_ADDRESS].2. 105ST101 Phase 1 Monotherapy Immunogenicity 
In Study 105ST101, serum samples for evaluation of TRC105 immunogenicity, inc luding 
HAMA and HACA, were collected pre- dose on day 1 of each 28 day cycle, at the end of study, 
and then at 4 and 12 weeks after the end of study visit. 
HAMA and HACA data are available from the phase 1 monotherapy TRC105 trial.  Neither 
HAMA nor HACA we re detected in patients treated with CHO -produced TRC105, which will be 
used for all future clinical trials, including this study.  
[IP_ADDRESS].3. 105ST101 Phase 1 Monotherapy Safety  
A total of 50 patients were treated on Study 105ST101 with escalating doses of TRC105 at  0.01, 
0.03, 0.1, 0.3, 1, 3, 10 and 15 mg/kg every two weeks and then 10 and 15 mg/kg weekly.  Dose 
escalation proceeded stepwise until the top dose was reached.  The maximum tolerated dose was 
exceeded at 15 mg/kg weekly and the recommended phase 2 dose o f TRC105 was therefore 
determined to be 10 mg/kg weekly.  Three of 4 patients at 15 mg/kg weekly developed grade 3 
hypoproliferative anemia (without leucopenia or thrombocytopenia) in cycle 2, and one of the 
three progressed to grade 4 in cycle 3.  Anemia was associated with accumulation of TRC105 and characterized by a low reticulocyte production index.  Additional laboratory and clinical 
evaluations excluded common causes of anemia including blood loss, hemolysis, plasma volume 
expansion, inadequate erythropoietin, iron deficiency, and vitamin B -12 or folate deficiency.  
The anemia is believed to result from TRC105 -mediated suppression of  proerythroblasts, the 
only cells in the bone marrow known to express substantial levels of CD105 [55].  Anemia was reversible and manageable with dose reduction and standard supportive measures including erythropoietin and blood transfusion.   
Page 17 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27378] common adverse events, were usually with the initial 
TRC105 dose and included one or more of the following signs or symptoms: rigors, 
bronchospasm, urticaria, hypertension, hypotension, tachycardia or bradycardia.  Infusion reactions were initially reported at 1 mg/kg every 2 weeks for patients receiving TRC 105 
produced in NS0 cells without premedication.  TRC105 produced in CHO cells was known to more potently engage ADCC in vitro  than TRC105 produced in NS0 cells.  Because of this, the 
initial dose level for patients receiving CHO -produced TRC105 was de -escalated to 0.3 mg/kg.  
Despi[INVESTIGATOR_28057]- escalation, the first two patients at 0.3 mg/kg treated with CHO -produced 
TRC105 experienced grade [ADDRESS_27379] dose in the absence of premedication.  The protocol was therefore amend ed to require a glucocorticoids - based 
premedication regimen and extend the initial infusion duration from 1 to 4 hours.   
The amendment mandating premedication and extended initial infusion duration successfully reduced the frequency and severity of infus ion reactions and allowed dose escalation to continue. 
One additional patient who received CHO -produced TRC105 at 1 mg/kg developed a grade [ADDRESS_27380] dose given over 2 hours.  This patient had experienced a grade 2 infusion reaction when the dose was administered over 4 hours.  In all three patients with grade 3 
infusion reactions, TRC105 was not detectable in serum at the time of dosing, which allowed de 
novo binding of TRC105 to CD105 expressing endothelium within the vasculature.  Grade 3 
infusion reactions were not observed in patients dosed at 10 or 15 mg/kg who maintained 
TRC105 serum levels known to saturate CD105 binding sites for the full dosing interval.  At dose levels where continuous TRC105 serum levels were achieved, gl ucocorticoids were safely 
discontinued and the infusion duration reduced to 1 hour.  
Three patients developed grade 1 cutaneous telangiectasia on the trunk early in the course of therapy, all at dose levels of 10 or 15 mg/kg weekly that resulted in continuous serum levels of TRC105 known to saturate CD105 sites on human endothelium.  Grade  1 or 2 hemorrhage was 
reported, including intermittent postcoital vaginal bleeding (that also occurred prior to TRC105 treatment), epi[INVESTIGATOR_3940], and superficial gingival bleeding.    
Grade 1 or 2 headaches were observed, mainly in patients treated at doses o f TRC105 above 3 
mg/kg.  Headaches began the day following infusion and were generally manageable with 
acetaminophen.  However, grade 2 headache in one patient at 15 mg/kg weekly prompted discontinuation prior to completion of the dose -limiting toxicity ev aluation period.  Fatigue was 
one of the more common adverse events attributable to TRC105 and was more prevalent at doses above 3 mg/kg.   
One patient developed dose- limiting toxicity of grade 4 hemorrhage presenting as melena from a 
gastric ulcer within 5 days of the initial TRC105 infusion at 0.1 mg/kg.  He discontinued TRC105 treatment, was transfused 2 units of packed red blood cells and the bleeding resolved with nonsurgical management by [CONTACT_28107].  Serious bleeding was not 
observed following protocol amendment to exclude patients with a history of peptic ulcer disease 
(unless healing was documented) and patients on ulcerogenic medications including non -
steroidal anti -inflammatory drugs.  
Page 18 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Classic toxicities associated with VEGF inhib ition, including hypertension, proteinuria and 
thrombosis were not prominent.  One patient with recurrent anal cancer treated at 0.1 mg/kg 
developed proteinuria considered possibly related to TRC105, but proteinuria was also noted prior to TRC105 dosing.  Transient hypertension (156/112) without QT changes occurred in a 
single patient one day following infusion of 15 mg/kg, and was controlled by a single dose of 
oral antihypertensive medication. There were no arterial or venous thromboembolic events, nor gastrointestinal or other perforations in these patients.    
[IP_ADDRESS].4. 105ST101 Phase 1 Monotherapy Efficacy 
In study 105ST101 stable disease ≥ 2 months was observed in 21 of 45 patients (47%) and stable disease ≥ 4 months in 6 of 44 patients (14%).  Decreases in CEA, PSA, or CA -125 were noted in 
7 of 21 patients (33%) and a global decrease in key angiogenic biomarkers was observed with 
treatment.  One patient with castrate- refractory prostate cancer remains on TRC105 treatment 
after 6 years at a TRC105 dose of 0.01 mg /kg every 2 weeks.  He has an ongoing complete PSA 
response, with resolution of bone pain and bone scan normalization. One patient with metastatic carcinosarcoma, manifested decreased tumor burden on computerized tomographic scanning and 
maintained stable disease for 20 months on therapy. The latter is especially notable when one considers that this patient had received three prior treatments --  carboplatin + paclitaxel for [ADDRESS_27381] favorable clinical outcome and did so as a fourth- line therapy.   
[IP_ADDRESS]. Phase 1b 105ST102 Study with Bevacizumab  
[IP_ADDRESS].1. 105ST102 Summary of Safety  
Administration of TRC105 at a dose of 3 mg/kg weekly in combination with bevacizumab was well tolerated by [CONTACT_28108] (DLT) and dose escalation occurred per the protocol to cohort 2 (6 mg/kg TR105 weekly).  However, the 
concurrent administration of 6 mg/kg T RC105 and bevacizumab on day 1 resulted in the 
development of moderate or severe headaches (including two grade 3 headaches) in four of five 
treated patients.  The 6 mg/kg dose of TRC105 was tolerated when the initial TRC105 dose was delayed one week follo wing bevacizumab dosing at 10 mg/kg every two weeks.  Tolerability 
was further improved when the initial dose of TRC105 was given over two days during the first week of TRC105 dosing, and dose escalation proceeded to the recommended phase 2 dose of 10 mg/k g TRC105 weekly.  At the recommended phase 2 dose of both drugs (10 mg/kg), TRC105 
serum concentration were present above target concentration continuously and immunogenicity was rarely observed.  
A total of [ADDRESS_27382] adverse events were graded as 1 or 2 and Grade 4 and 
5 suspected adverse events were not observed. Grade 3 suspected adverse reactions included anemia (the dose limiting toxicity of TRC105 established as a single agent; 9 patients), headache (4 pati ents; three of which occurred prior to adjusting the schedule of TRC105), fatigue (2 
patients), brain abscess (1 patient), infusion reaction (in a patient dosed at 6 mg/kg), and 
Page 19 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
decreased appetite (1 patient). Headache was the most common suspected adverse event and 
occurred in 31 patients (86.1%); three patients (7.9%) experienced migraine headaches (two of 
grade 1 and one of grade 2 severity). Headaches were treated with triptans and NSAIDs.  
Two patients experienced serious adverse suspected events as des cribed below.  One of the grade 
3 headaches (in a patient dosed at 8 mg/kg without splitting the initial TRC105 dose over two days) resulted in hospi[INVESTIGATOR_28058].  One patient dosed at 10 mg/kg of TRC105 experienced a serious suspected event of grade 3 brain abscess.  Serious adverse events, 
considered unrelated to TRC105 treatment, included: grade [ADDRESS_27383] myocardial infarction during a period of 
hemodynami c instability while hospi[INVESTIGATOR_057]; grade 3 ileus at the time of symptomatic disease 
progression; grade 5 disease progression; grade 3 left foot cellulitis; grade 3 recurrent pneumothorax; grade 3 small bowel obstruction; grade [ADDRESS_27384] one sign  of the triad of epi[INVESTIGATOR_3940], gingival bleeding and telangiectasia, reflecting vascular 
ectasia characteristic of the Osler -Weber -Rendu syndrome of endoglin haplotype insufficiency 
(i.e., an autosomal dominant genetic disorder of heterozygous endoglin expres sion) was observed 
frequently.  One of these signs or symptoms (of grade 1 or 2 severity) was noted in one of three 
patients treated at 3 mg/kg, four of eight patients treated at 6 mg/kg, four of eight patients treated 
at 8 mg/kg and in all nineteen patien ts treated at 10 mg/kg of TRC105, generally within the first 
month of dosing.  These signs and symptoms are an expected pharmacologic effects of TRC105 
binding to the endoglin receptor (i.e., they are characteristic of the Rendu -Osler -Weber 
syndrome, that is caused by [CONTACT_28109]), and were also observed routinely 
within the first month of dosing of 10 mg/kg weekly in the single agent TRC105 dose escalation 
study.   
Infusion reactions were, as expected, more notable at lower doses, and were rare at the MTD of TRC105 of 10 mg/kg, when TRC105 serum concentrations were maintained continuously.  Two 
of nineteen patients (10%) dosed with 10 mg/kg of TRC105 each experienced a single infusion 
reaction of grade 2 severity, both with the initial dose of TRC105, that required a brief interruption of the infusion prior to completion of the scheduled dose.  
Clinically significant anemia was not reported in patients dosed with 3 mg/kg or 6 mg/kg of TRC105, was reported in three of seven patients (43%; all g rade 3) dosed with 8 mg/kg of 
TRC105, and was observed in nine of 19 (47%; three of grade 2 and six of grade 3 severity) of 
patients dosed with 10 mg/kg of TRC105.  Anemia prompted transfusion of packed red blood 
cells in 10 patients and growth factors wer e used in five patients.  
Other, less frequent, suspected adverse reactions included hypothyroidism, periorbital edema 
(which was generally noted prior to splitting the initial dose of TRC105), gingival pain, nausea, 
oral pain, vomiting, edema, decreased ap petite, dyspnea, nasal congestion, rash and flushing.  
Other adverse events characteristic of each individual drug were not increased in frequency or 
severity when the two drugs were administered together.  Of note, the concurrent administration 
of bevacizu mab and TRC105 did not potentiate the known toxicities of bevacizumab of 
hypertension, hemorrhage (including tumor- associated hemorrhage, and pulmonary hemorrhage 
or hemoptysis), or proteinuria.  Reversible posterior leukoencephalopathy syndrome (RPLS), congestive heart failure, fistulae, gastrointestinal perforation impaired wound healing, and 
arterial thromboembolic events, were not observed.  
Page 20 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Notably, hypertension and proteinuria , known adverse events of bevacizumab, were rarely 
observed when bevacizumab was given with TRC105.  Mild and transient clinically significant 
hypertension or blood pressure increases were observed in five patients (13%; grade 3 in one case (prior to dosing with study drugs) and grade 2 in four cases) and mild transient proteinuria  
was observed in two patients (5%; both grade 2).  
[IP_ADDRESS].2. 105ST102 Summary of Efficacy 
The combination of TRC105 and bevacizumab was active in patients with advanced refractory cancer who had progressed on prior bevacizumab or other VEGF inhibitor treatment.  Thirty -
three patients had measurable disease (31 patients) or evaluable disease (2 patients) at baseline and received at least one follow up scan and were evaluable for the primary efficacy outcome of ORR by [CONTACT_393] 1.1.  Eighteen patients with measureable disease (58%) had a best response of 
stable disease or partial response.  Two patients (6%), both of whom had been treated with 
bevacizumab and chemotherapy prior to study entry and were then treated at the top dose level of TRC105 and bevacizumab, had RECIST 1.1-  defined partial responses, including one patient 
with colorectal cancer re mained  on treatment for more than 28 months.  A total of 14 patients 
(45%) had decreases in overall tumor burden, of whom 10 received prior VEGF inhibitor treatment (usually bevacizumab with chemotherapy).  Notably, the duration of treatment with 
TRC105 and bevacizumab of six patients ( 20% of those with measureable disease) exceeded the 
duration of treatment of the most recent treatment regimen containing a VEGF inhibitor (i.e., 
VEGFR TKI or bevacizumab), received prior to study entry.  These six patients h ad decreases in 
tumor burden and several were responders by [CONTACT_28110].  Time to progression 
ranged from 0 to 861 days.  Reductions in tumor markers ranging from 5% to 85% were observed in 15 of 28 (54%) patients with relevant tumor markers.  Three patients demonstrated 
clinical benefit throughout the study (patient 10038102 at cycle 12 day 22, patient 10018106 at 
cycle 7 day 22 and patient 10028101 at cycle 17 day 1); two of them continue to receive treatment under a continuation protocol (105 CON101).  
[IP_ADDRESS].3. Background on Choriocarcinoma  
Gestational trophoblastic disease (GTD) is the term used to describe a group of rare diseases that originate in the placenta and have the potential to locally invade the uterus and metastasize. The pathogenesis of GT D is unique because the maternal tumor arises from gestational rather than 
maternal tissue.  The major histologic entities for this disease include complete molar pregnancy, partial molar pregnancy, invasive mole, and choriocarcinoma.  Molar pregnancies al though 
benign are considered to be premalignant because they have the capability of developi[INVESTIGATOR_28059] a 
malignancy. The term gestational trophoblastic neoplasia (GTN) is used when molar and non-
molar pregnancies become malignant, and comprise the morphologic entities of invasive mole 
and choriocarcinoma.  Choriocarcinoma consists of invasive, highly vascular and anaplastic trophoblastic tissue made up of cytotrophoblasts and syncytiotrophoblasts without villi. Choriocarcinoma metastasizes hematogenously and can follow any type of pregnancy, but most 
commonly develops after comple te hydatidiform mole .  The most common metastatic site is the 
lungs which are involved in over 80 percent of patients with metastases.  Staging for GTN is 
based on a number of unique c riteria that differs from the usual staging procedures and prognosis 
is dependent upon factors that are not reflected in the anatomic extent of disease such as age, 
Page 21 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27385] relapse/resistance to monotherapy, multiagent chemotherapy regimens are used.  T hese regimens include EMA -CO, EMA -EP, TE -TP and are often able to produce cure for 
these women.  Rarely, if standard chemotherapy options have been ineffective there are reports of salvage with use of 5 -FU or stem cell transplant.   
2.2.2. Description of Bevacizu mab 
Bevacizumab (Avastin®) is an IgG1 monoclonal antibody to VEGF -1.  It is a vascular 
endothelial growth factor- specific angiogenesis  inhibitor indicated for the treatment of metastatic 
colorectal cancer, non -squamous non- small cell lung cancer, metastati c breast cancer, 
glioblastoma, and metastatic renal cell carcinoma.   
[IP_ADDRESS]. Rationale for Adding TRC105 to Bevacizumab  
TRC105 is a novel angiogenesis inhibitor that complements bevacizumab in preclinical models.  Together, these antibodies may result in more effective angiogenesis inhibition in a patient with choriocarcinoma, given the vascular nature of this tumor and dir ect expression of CD105 on the 
cancer cells.  
2.3. Patient Background  
The patient that will be treated as part of this protocol is a [ADDRESS_27386] therapy, she then initiated EMA -CO (etoposide, methotrexate, actinomycin -D, 
cyclophosphamide, oncovorin) and had a hysterectomy, which confirmed a diagnosis of 
choriocarcinoma.  Despi[INVESTIGATOR_6831], her β -hCG marker continued to rise.  She was subsequently 
switched to EMA -EP (same as above but cisplatin instead of oncovorin) and went into remission 
in October 2013 after 7 cycles, followed by 3 cycles of consolidation chemotherapy.  
Page 22 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
In December , 2013 she recurred with multiple pulmonary met astases. She had 3 cycles of TP/TE 
(Taxol, cisplatin /Taxol,  etoposide) but progressed, then received 2 cycles ICE (ifosfamide, 
carboplatin, etoposide ).   
She failed to go into remission, so in May , [ADDRESS_27387] a rising β -hCG.  
She was subsequently treated with Xeloda. She had a good initial response, but now is 
progressing after 5 cycles.  She developed isolated brain metastases that were treated with stereotactic brain radiation on 11/25/ 2014.  Subsequent brain MRI on 12/[ADDRESS_27388] scan. 
As of the writing of this protocol there are no proven therapi[INVESTIGATOR_28060] . 
2.4. Potential Risks and Benefits to Human Patient s 
2.4.1. Potential Risks  
TRC105 
Grade 3 anemia has occurred with TRC105 therapy at the recommended phase 2 dose.  All 
patients treated with TRC105 should be monitored closely for anemia and treated appropriately, 
including the possibility of TRC105 dose reductions.  Anemia may be caused by [CONTACT_28111]. The anemia related to TRC105 is hypoproductive in nature and is reversible with interruption of treatment, transfusion, erythropoietin, and other interventions as 
appropriate. 
Gastroint estinal hemorrhage has occurred with TRC105 therapy.  Patients with active ulcer 
disease or risk factors for ulcer disease are excluded from this study.    
Grade 1 and 2 cutaneous telangiectasia related to TRC105 occur early in the course of therapy 
and ha ve been the source of gingival bleeding and epi[INVESTIGATOR_3940].  Telangiectasia are also seen in 
patients with hereditary hemorrhagic telangiectasia (HHT), a disease of CD105 haplotype 
insufficiency.  Patients with HHT are at risk of hemorrhage from abnormal blood vessels and this 
could be exacerbated by [CONTACT_28112]105.  Other contraindications to TRC105 therapy include a history of significant hemorrhage or tumors located in the central chest or another 
location where bleeding is associated with high morbidi ty.  All patients treated with TRC105 
should be monitored for signs of hemorrhage and the risks and benefits of drug treatment 
reevaluated in any patient with hemorrhage.  
Premedication including the use of glucocorticoids is required prior to infusion of T RC105 to 
reduce the frequency and severity of infusion reactions.  Infusion reactions following TRC105 dosing generally occur with the first TRC105 dose and include a grade 4 vasovagal reaction that 
resolved without sequellae.  Signs and symptoms of TRC105 infusion reactions include 
hypertension, hypotension, dyspnea, bronchospasm, chills/rigors, chills, sweats, fever, nausea, tachycardia, bradycardia, EKG changes, flushing, urticaria, pruritus, and headache, generally of 
grade 1 and 2 severity. Potential i nfusion reactions seen with other therapeutic antibodies include 
Page 23 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
angioedema, asthenia, throat irritation, rhinitis, vomiting, joint pain, fatigue and neurologic 
disorders including inflammation of the spi[INVESTIGATOR_20793]/or brain.  
Hypersensitivity reactions with in fusions are a potential risk for sensitized patients, and TRC105 
should be used with caution in patients with known hypersensitivity to any component of the drug product.  Host anti -TRC105 antibodies to the murine or human portions of CHO -produced 
TRC105 a re rare.  In general, the risk of immunogenicity to therapeutic chimeric antibodies is 
small (<10%) and the clinical significance of immunogenicity is not well defined.  The current trial will collect serial blood samples for anti -product antibody concentrations to further 
characterize the immunogenicity of TRC105 and potential clinical implications.  
Grade 3 cerebrovascular hemorrhage resulting in hemiparesis occurred in one patient with hepatocellular cancer who was thrombocytopenic (who entered the study with a platelet count of 
60,000/uL) in a study of TRC105 with sorafenib.  Patients must have a platelet count of > 100,000/uL to enter this study (see inclusion criteria).  A grade 2 transient ischemic attack was 
reported in a study of TRC105 and pazopanib.  Transient Grade 3 hepatic encephalopathy 
occurred in one patient with cirrhosis and hepatocellular carcinoma who received TRC105 in combination with sorafenib.   Grade 3 pancreatitis was also observed in this study.  Grade 5 
intracranial hemorrhage occu rred in one glioblastoma patient with markedly abnormal blood 
clotting parameters in a study of TRC105 with bevacizumab.   A patient with glioblastoma 
developed temporary confusion and slurred speech following treatment with TRC105 and 
bevacizumab that requ ired hospi[INVESTIGATOR_28061].  Another patient with glioblastoma, 
who underwent resection and had a history of an abnormal collection of cerebral spi[INVESTIGATOR_872], 
developed a grade 2 cerebral spi[INVESTIGATOR_28062].   Another patient with glioblastoma with a history 
of recurrent meningitis developed recurrent grade 3 bacterial meningitis while treated with bevacizumab and TRC105. 
Grade 3 myocardial infarction (non- Q wave infarct associated with hypertension following an 
infusion reaction) was observed in a patient with hepatocellular cancer following treatment with 
TRC105 that resolved without sequelae.  In addition, a Grade 5 myocardial infarction occurred in a patient with coronary artery disease who received TRC105 in combination with sorafenib. 
Patients w ith evidence of active coronary artery disease are excluded from participation in this 
trial (see exclusion criteria).   
Adult respi[INVESTIGATOR_28063]105 with pazopanib, from  which the patient recovered.   Of note, interstitial 
lung disease has been added as an adverse drug reaction and warning/precaution to the core 
safety information for pazopanib.  Pneumothorax (collapsed lung) has been observed in trials of 
TRC105 administe red with a VEGFR TKI in patients with lung metastases.  
A patient with renal cell carcinoma treated with TRC105 and axitinib developed grade [ADDRESS_27389] been observed rarely. Grade 3 infected lipoma/cyst was observed in a Phase [ADDRESS_27390] been observed in fewer 
Page 24 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
than 5% of patients and have largely been considered unrelated to treatment with TRC105.   
Reversible grade [ADDRESS_27391] also been reported.  A patient receiving treatment with TRC105 and sorafenib developed self -limited pancreatitis of grade 2 
severity.  
Bevacizumab  
Side effects associated with the use of bevacizumab include gastrointestinal perforation, hypertension, impaired wound healing, an increased incidence of arterial thromboembolic 
events, venous thromboembolic events (including pulmonary embolism), hemorrhage (including 
tumor- associated hemorrhage, mucocutaneous hemorrhage, and pulmonary hemorrhage or 
hemoptysis), proteinuria, rare reports of Reversible Posterior Leukoencephalopathy Syndrome 
(RPLS), congestive heart failure, fistulae, hypothyroidism,  hypersensitivity reactions, headache 
and infusion reactions. Increased rates of severe neutropenia, febrile neutropenia, or infection 
with severe neutropenia (including some fatalities) have been observed in patients treated with 
some myelotoxic chemother apy regimens plus bevacizumab in comparison to chemotherapy 
alone.  
No specific studies in animals have been performed to evaluate the effect of bevacizumab on fertility. There are no adequate and well -controlled studies in pregnant women.  
Immunoglobulins  are excreted in milk, although there are no data specifically for bevacizumab 
excretion in milk. Since bevacizumab could harm infant growth and development, women should be advised to discontinue breastfeeding during bevacizumab therapy and not to breast feed for at 
least [ADDRESS_27392] dose of bevacizumab.   
Computed Tomography (CT) Scans  
Patients will be exposed to a small amount of radiation as a result of the CT scans required in this study.  This degree of exposure has not been associated with harmful health effects. In 
addition, the frequency of CT scans performed in this study is simi lar to the standard of care 
frequency.  
Venipuncture  
Patients could also experience side effects from venipuncture for tests that will be done as part of 
this study including pain, tenderness or bruising at the site of collection, and rarely infection may 
occur at the spot where the needle is inserted.  
Page 25 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27393] ablished.  It is possible 
that the administration of TRC105 in combination with bevacizumab may result in clinical benefit (i.e., tumor response or prolonged stable disease) beyond the benefit that is expected 
from bevacizumab alone.  
2.5. Conduct  
This clinical trial will be conducted in compliance with the protocol, GCP, and the applicable 
regulatory requirements.  
Page 26 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
3. TRIAL OBJECTIVES AND  PURPOSE  
3.1. Primary:  
• To determine PFS , and ORR of one patient with metastatic and refractory 
choriocarcinoma by [CONTACT_393] 1.1  including  measurement of serum  β-hCG  
3.2. Secondary:  
• To determine the frequency and severity of adverse events as assessed by [CONTACT_28113] (Version 4.0) 
• To explore the effects of TRC105 and bevacizumab on circulating angiogenic protein 
biomarkers  
Page 27 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
4. INVESTIGATIONAL PLAN  
4.1. Overa ll Study Design and Plan: Description  
4.1.1. Trial Overview  
This is a single patient study of TRC105 in combination with standard dose bevacizumab in one 
patient with metastatic and refractory choriocar cinoma for whom curative therapy is unavailable. 
TRC105 will be administered weekly in combination with bevacizumab.  The patient will 
receive bevacizumab on days [ADDRESS_27394] weekly dose 
of TRC105 should be split with 3 mg/kg administered on cycle 1 day 8 and  the balance of the weekly TRC105 dose administered on cycle 1 day 11, and then the full dose given on cycle 1 
day 15 and weekly thereafter. 
If the patient achieves complete r emission (normalization of β -hCG on consecutive 
measurements separated by [CONTACT_28114] ), she will be treated with at least [ADDRESS_27395] 4 cycles of 
consolidation therapy she can remain off study treatment for ≤ 6 months and subsequently re -
initiate study  treatment should she  start to relapse (i.e. β -hCG increase on consecutive 
measurements separated by [CONTACT_28115]) during the 6 
months.  
4.1.2. Trial Procedures  
All on -study procedures are permitted within the time window indicated in the Schedule of 
Assessments ( Table 3 ).  
[IP_ADDRESS]. Screening  
The following screening procedures must be performed within [ADDRESS_27396] day of 
study therapy.  Hematology , serum chemistry, coagulation, and urinalysis collected within 7 days 
of cycle 1 day 1 do not need to be repeated. The following will be performed according to the Schedule of Assessments ( Table 3 ).  
• Patient signature [CONTACT_28182] (IRB) approved informed 
consent form. Prior to undergoing any study -specific procedure, the patient must read 
and sign the current Institutional Review Board (IRB) approved informed consent 
form.  The patients may sign consent prior to the 30 day screening period. 
• Medical history, prior cancer therapy, prior cancer surgery, prior radiation therapy, 
drug allergies, disease present at screening, primary diagnosis and demographics.  
• Physical examination including examination of all major body systems, ECOG 
performance status, and vital signs.  
• Hematology, coagulation (PT or INR) and serum chemistry to be performed locally.  
• Urinalysis to be performed locally.  
Page 28 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
• CT or MRI scans of chest, abdomen and pelvis in addition to any other applicable 
sites of disease. Brain and bone scans to be performed if  metastasis is suspected prior 
to starting the study.  
• Single tracing 12 -Lead ECG (QT, PR and QRS intervals and heart rate will be 
captured).  
• Assessment of Adverse Events (serious and nonserious) from the date of informed 
consent. 
• Assessment of concomitant  medications from 30 days prior to the start of study 
treatment.  
[IP_ADDRESS]. Trial Period  
Hematology , blood chemistry, urinalysis, and physical examination  do not need to be repeated 
on cycle 1 day 1 if acceptable screening assessments are performed within 7 days pri or to the 
start of study therapy. On days of dosing, all assessments should be performed prior to dosing with the combination of TRC105 and bevacizumab unless otherwise indicated in the Schedule of 
Assessments. The patients will initially receive 2 cycles (approximately 8 weeks) of treatment.  If the patient demonstrates a response of CR, PR or SD, she  will be eligible for additional 
treatment until progression.  Each cycle is 4 weeks in duration. The following will be performed according to the Schedule of  Assessments ( Table 3 ). 
• Physical examination including examination of all major body systems, ECOG 
performance status, and vital signs.  
o Assessment of vital signs during TRC105 infusion: Vital signs are to be 
assessed pre -infusion (within 30 minutes of starting TRC105 infusions) and 
every 30 minutes during the infusion.  Vital signs should be monitored more frequently and/or beyond the completion of the infusion if medically indicated (e.g. if the patient experiences an infusion reaction that has not yet resolved).  
• Hematology, coagulation (PT or INR) and serum chemistry to be performed locally.  
• Urinalysis to be performed locally. Microscopic analysis shou ld be performed as 
clinically indicated.  
• Blood sampling for tumor markers (e.g. β -hCG), to be analyzed locally.  
• Blood sampling for angiogenic protein biomarkers.  Samples will be analyzed by a 
third party laboratory (see laboratory manual for specific instructions regarding 
collection, processing, storage and shipment). 
• CT or MRI scans of chest, abdomen and/or pelvis in addition to any other applicable 
sites of disease. Scan of the chest, abdomen, and pelvis to be performed on- study as 
outlined in the assessment table. Known areas of disease should be consistently 
followed throughout the study.  Assessments should be performed whenever disease 
progression is suspected.  Allowable window for tumor imaging studies is +/ - 7 days. 
Brain and bone scans are to be performed if metastasis is suspected.  
Page 29 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
• Administration of TRC105. TRC105 diluted in normal saline will be administered 
according to the schedule of assessments as a 1 to 4 hour infusion (+/ - 15 minutes) 
following premedication (see Section  6.7  and Table 3 ). TRC105 will be administered 
intraveno usly utilizing an infusion pump.  TRC105 must be administered using a low 
protein binding, non-DEHP infusion set with a 0.2 micron downstream filter.  
Duration of infusion administration may be increased as medically necessary. The 
allowable dosing window is +/ - 2 days. 
• Administration of bevacizumab on day 1 and 15 of each 28- day cycle as described in 
the bevacizumab package insert.  
• Assessment of TRC105 and bevacizumab drug accountability.  
• Assessment of adverse events.  
• Assessment of concomitant medications  and concomitant treatments.  
4.1.3. Complete Response Discontinuation of Therapy Visit  
Assessments need to be completed if they were not completed during the previo us [ADDRESS_27397] 4 cycles of cons olidation therapy. 
The following will be performed according to the Schedule of Assessments ( Table 3 ). 
• Physical examination including examination of all major body systems, ECOG 
performance status, and vital signs.  
• Hematology, coagulation (PT or INR) and serum chemistry to be performed locally.  
• Urinalysis to be performed locally. Microscopic analysis should be performed as 
clinically indicated.  
• Blood sampling for tumor markers (e.g. serum β -hCG), to be analyzed locally.  
• Blood sampling for angiogenic protein biomarkers.  Samples will be analyzed by a third party laboratory (see laboratory manual for specific instructions regarding 
collection, proc essing, storage and shipment). 
• CT or MRI scans of chest, abdomen and pelvis in addition to any other applicable 
sites of disease.  
• Assessment of adverse events.  
• Assessment of concomitant medications and concomitant treatments.  
4.1.4. End of Study Assessments  
Asse ssments need to be completed if they were not completed during the previous 2 weeks on 
study.  The following will be performed according to the Schedule of Assessments ( Table 3 ). 
• Physical examination including examination of all major body systems, ECOG 
performance status, and vital signs.  
• Hematology, coagulation (PT or INR) and serum chemistry to be performed locally.  
Page 30 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
• Urinalysis to be performed locally . Microscopic analysis should be performed as 
clinically indicated.  
• Blood sampling for tumor markers (e.g. serum β -hCG), to be analyzed locally.  
• Blood sampling for angiogenic protein biomarkers.  Samples will be analyzed by a 
third party laboratory (see la boratory manual for specific instructions regarding 
collection, processing, storage and shipment). 
• CT or MRI scans of chest, abdomen and pelvis in addition to any other applicable sites of disease.  
• Assessment of adverse events.  
• Assessment of concomitant medications and concomitant treatments.  
4.1.5. Post Treatment Follow -up 
The following will be performed according to the Schedule of Assessments ( Table 3 ). Adv erse 
events should be followed for 28 days after completion of study protocol .  The total follow -up 
period will be two years after the CR Discontinuation of Therapy Visit or EOS Visit.  
• Assessment of adverse events. The Investigator should continue to repor t any related 
or possibly related adverse events that occur beyond the adverse event reporting period. 
• Assessment of concomitant medications and concomitant treatments.  
• If the patient has a CR and comes  off study treatment following consolidation therapy 
she will have β -hCG levels measured every month for 6 months or until resumption 
of study therapy; after [ADDRESS_27398] measurement until start of new therapy.  
• Long term survival telephone call every 2 months for 2 years following 
discontinuation.  
 
Page 31 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Table 3:   Schedule of Assessments   
 
 
  
Page 32 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Schedule of Assessments Footnotes 
1. Days of Treatment with TRC105: All assessments should be performed prior to dosing with TRC105/bevacizumab unless otherwise indicated.  
Each cycle is 28 days in duration.  
2. Cycle 1 day 1: Hematology, blood chemistry, urinalysis, and physical examination not required if acceptable screening assessment is performed 
within 7 days prior to the start of treatment on cycle 1 day 1.  
3. CR Discontinuation of Therapy Visit:  Assessments need to be c ompleted if they were not completed during the previous 2 weeks on study 
therapy (previous 4 weeks for radiologic tumor assessments) if the patient discontinues therapy due to CR following at least 4 cycles of 
consolidation therapy.  
4. End of Study Visit:  Assessments need to be completed  if they were not completed during the previous 2 weeks (previous 4 weeks for radiologic 
tumor assessments) if the patient permanently discontinues all study therapy due to AE, patient decision, investigator decisi on, or any  other reason.  
If the patient completed a “CR Discontinuation of Therapy Visit” and subsequently permanently discontinues the trial due to ( 1) continued CR, the 
“End of Study Visit” does not need to be completed and the “CR Discontinuation of Therapy Visi t” will be the end of study visit, or (2) progression, 
adverse event, or any other reason except continued CR, the “End of Study Visit” should be completed.  
5. Informed Consent: Must be obtained prior to undergoing any study specific procedure and may occu r prior to the 30- day screening period.  
6. Medical/Oncologic History and Demographics: To include information on prior anticancer therapy.   
7.  Physical Examination: Examination of major body systems and ECOG performance status.  
8. Vital Signs:  Heart rate, temperature, blood pressure, respi[INVESTIGATOR_697], weight. Assessment of Vital Signs during TRC105 Infusion: Vital si gns are 
to be assessed pre -infusion (within 30 min of starting TRC105 infusions) and every 30 minutes during the infusion.  Vital signs should be monitored 
more frequently and/or beyond the completion of the infusion if medically indicated (e.g. if the patient experiences an infusion reaction that has not 
yet resolved).  
9. Hematology, Chemistry, Coagulation, & TSH:  Testing to be pe rformed locally. Patients who have Monday visits may complete safety lab 
assessments on the Friday prior to the visit. In addition to the assessments scheduled for the clinical trial, patients shoul d undergo assessment as 
appropriate to ensure safe treatme nt. Thyroid stimulating hormone (TSH) is to be collected at screening and on study as clinically indicated.  See 
Section  [IP_ADDRESS]   for specific asses sments to be performed.  
10. Urinalysis:  To be performed locally. Microscopic analysis should be performed as clinically indicated.   
11. TRC105 Administration:  IV TRC105 diluted in normal saline will be administered as outlined in the schedule of assessments.  If TRC105 is 
reintroduced, the initial dose will be split such that 3 mg/kg is given initially and the balance is given three days later ( i.e. 3 mg/kg if the total dose is 
6 mg/kg).  
12.  Bevacizumab Administration:  Commercially available bevacizumab will be administered per the package insert in this study. Patients will 
receive 10 mg/kg as outlined in the schedule of assessments.  
13.  CT or MRI Tumor Imaging:  Images of chest, abdomen, and pelvis to be performed at screening and on -study as outlined in the assessment 
table. Known areas of disease should be consistently followed throughout the study.  Assessments should be performed whenever  disease 
progression is suspected. Allowable window for tumor imaging studies is +/ - [ADDRESS_27399].  
14.  12-Lead ECG:  Single tracing 12 -lead ECG will be p erformed at screening (pre -dose). If the patient develops an arrhythmia, the ECG should be 
repeated on day 1 of each subsequent cycle.  
Page 33 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
15.  Concomitant Medications and Treatments:  Concomitant medications and treatments will be recorded from [ADDRESS_27400] dose of study treatment.  
16.  Baseline Signs and Symptoms and Adverse Events:  Patients must be followed for safety from the day of informed consent until at least [ADDRESS_27401] resolved or are determined to be “chronic” or “ stable”, 
whichever is later.  Adverse events occurring prior to the initiation of the study treatment will be considered "Baseline -Signs and Symptoms” and 
will be recorded on “Medical History and Baseline Signs and Symptoms” case report forms. Events that occur from the time the patient has taken the 
first dose of bevacizumab and/or TRC105 study drug through [ADDRESS_27402] dos e of bevacizumab and/or TRC105 study drug (whichever is 
later) will be recorded on “Adverse Event” CRFs. Any serious AE that is possibly related to TRC105 occurring from the time of  first dose or at any 
point after the reporting period must be promptly reported to TRACON.  
17. Protein biomarkers:  5 mL of plasma (K 3EDTA) will be collected as indicated in the schedule of assessments and stored at approximately - 70°C 
to be analysed by a central laboratory. Samples will be batch shipped every [ADDRESS_27403] -party laboratory for analysis. See separate laboratory 
guide for further collection and shipment information.  
18.  Tumor markers: Will be collected and analysed locally as indicated in the schedule of events (e.g.: β -hCG)  
19.  Cycle 3+ Treatment: Patien ts who demonstrate a response of CR, PR or SD will be eligible for additional treatment until progression as long as 
TRC105 drug supply is available.  
20.  Follow -up:  If the patient has a  CR and comes off study treatment following consolidation therapy, β -hCG levels will be measured every month 
for 6 months or until resumption of study therapy .  The 28 day follow -up visit (occurring 28 days after the CR DC Visit or EOS Visit if applicable)  
should include Concomitant Medications and Adverse Events.  After [ADDRESS_27404] measurement until 
start of new therapy .  The patient will also be contact[CONTACT_12090] 2 months  for 2 years. The allowable visit window  for follow -up assessments 
is +/- 7 days.
Page 34 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27405] 1.1 and elevated serum β -hCG  
4. Histologically proven choriocarcinoma that has  progressed despi[INVESTIGATOR_28064]  
5.2. Exclusion Criteria  
1. Prior treatment with TRC105  
2. Serious dose -limiting toxicity related to  prior bevacizumab  
3. Current treatment on another therapeutic clinical trial  
4. Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despi[INVESTIGATOR_28065] (initiation or adjustment of BP medication prior to study entry is allowed 
provided that the average of 3 BP readings at a visit prior to enrollment is < 140/90 mm 
Hg) 
5. Symptomatic pericardial or pleural effusions  
6. Uncontrolled peritoneal effusions requiring paracentesis more frequently than every 2 weeks  
7. Active bleeding or pathologic condition that carries a high risk of bleeding (i.e. hereditary 
hemorrhagi c telangiectasia)  
8. Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within [ADDRESS_27406] day  of study therapy  
9. Cardiac dysrhythmias of NCI CTCAE grade ≥ [ADDRESS_27407] 6 months, unless treated 
for the condition and complete resolution has been documented by 
[CONTACT_28116] (EGD) within 28 days of starting study treatment  
13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome 
(AIDS) related illness   
14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality 
that may increase the risk associated with study participation or may interfere with the 
Page 35 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27408] her .  In any circumstance, every ef fort 
should be made to document patient outcome.  Data to be collected at the end of study visit are 
described in the Schedule of Assessments ( Table 3 ).  The patient will be followed for at least [ADDRESS_27409] additional data. In addition, the patient will be withdrawn from treatment in the case of:  
1. Disease Progression.  Progressive Disease as defined in RECIST 1.[ADDRESS_27410] to follow -up or noncompliant.  
4. Patient has a TRC105 dose delay ≥ 8 weeks  OR discontinuation of study therapy for > 6 
months following CR. 
5. Arterial thrombosis of any grade (including cerebrovascular ischemia, cardiac 
ischemia/infarction, or peripheral or visceral arterial ischemia)  or grade 4 
thromboembolism . For grade 3 venous thromboembolism hold bevacizumab treated.  I f 
the planned duration of full dose anticoagulation is < 2 weeks, bevacizumab should be held until the full dose anticoagulation period is over.  If the planned duration of full dose 
anticoagulation is > [ADDRESS_27411] a 
pathologic condition that carries high risk of bleeding (i.e. tumor involving major vessels).  2.  Subject has not had any hemorrhagic events on study.  3.  The subject has a stable dose of heparin or have an in -range INR (usually 2 -3) on a stable dose of warfarin 
prior to restarting bevacizumab.  4.  I f thromboemboli sm worsens/recurs upon 
resumption of bevacizumab, despit e anticoagulation, bevacizumab should be 
discontinued. 
Page 36 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
6. TREATMENT OF PATIENT S 
6.1. Description of TRC105 Study Drug 
TRC105 is a genetically engineered human/murine chimeric monoclonal antibody directed 
against human CD105 found on the surface of proliferating endothelial cells.   
6.2. Composition of TRC105  
TRC105 is an IgG1, kappa immunoglobulin containing murine light - and heavy -chain variable 
region sequences and human constant region sequences.  TRC105 has an approximate molecular 
weight of 148 kDa.  
6.3. TRC105 Dose Le vels 
 The p atient will receive  10 mg/kg TRC105 weekly in combination with 10 mg/kg bevacizumab  
every other week on a q 28 day cycle .  
6.4. TRC105 Packaging and Labeling 
TRC105 may be provided in one or more of the following presentations . 
Phosphate Buffered Saline Formulation (7 mg TRC105/mL)  
210 mg TRC105/30 mL single -use vial  
20 mM L -Histidine/L -Histidine Monohydrochloride, 240 mM Trehalose,  
0.01% Polysorbate  20 Formulation (25 mg TRC105/mL)  
100 mg TRC105/4 mL single -use vial  
200 mg TRC105/8 mL single -use vial 
400 mg TRC105/[ADDRESS_27412] be stored upright between 2 °C and 8 °C (36 °F to 46 °F) and protected from light . 
6.6. TRC105 Preparation  
TRC105 will be prepared in the pharmacy and diluted into normal saline us ing appropriate 
aseptic technique.  TRC105 will be administered using an in -line 0.[ADDRESS_27413] been 
observed.  Multiple vials will be required for a single dose.  The following formulae should be used to calculate the volume of TRC105 to be added to normal saline:  
• Patient weight (kg) × dose level (mg/kg) divided by [CONTACT_28117]105 concentration (mg/mL) 
= volume of TRC105 (mL) to be administered.  
The volume of TRC105 that is to b e administered can be rounded up or down to the nearest 1.0 
mL; in the case of an increment of 0.5 mL the volume should be rounded up.  The maximum 
weight that should be used for dose calculation in this study is 85 kg (note: there is not a 
Page 37 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27414] ion for enrollment purposes).   The patient weight will be assessed on the day of 
treatment and used for calculation of each TRC105 dose. The calculated volume of TRC105 will 
be diluted with normal saline.  Appropriate judgment should be exercised in withdr awing an 
adequate amount of saline necessary to permit injection of the appropriate volume of antibody into a normal saline bag in accordance with the dose needed.  The final TRC105 concentration must be between 0. 6 mg/mL and 10 mg/mL.  The prepared TRC105 must be gently inverted 
several times in order to ensure a homogeneous solution. The diluted infusion solution of TRC105 should be used within 8 hours of preparation if stored at room temperature, or within 24 hours of dilution if stored at 2° to 8°C (36º  to 46ºF). The expi[INVESTIGATOR_28066].  If the diluted infusion solution of TRC105 cannot be infused within 8 hours of preparation (i.e.: the prepared infusion is at room temperature for more than 8 hours), a second bag will be prepared that contains the balance of the planned dose that was not already delivered. The 
prepared solution should not be frozen. 
6.7. TRC105 Administration  
Patients should be encouraged to drink abundant fluid (e.g. two eight ounce glasses of water or 
juice) prior to the first treatment.  Intravenous hydration prior to and during therapy is left to the 
discretion of the Investigator, but should be considered if the patient is thought to be volume 
depleted.  
The following TRC105 premedications should be administered  2 hours to 30 minutes prior to the 
start of each infusion:   
• Acetaminophen 650 mg p.o. x 1  
• Methylprednisolone 100 mg i.v. will be given prior to the Cycle 1 Day 8 and Cycle 1 
Day 11 infusions  only .  In addition, methylprednisolone will be given in the cas e of a 
delay of ≥  10 days between any two doses or if the patient develops an infusion 
reaction >  grade 2 during the immediate prior infusion.  
• Famotidine 20 mg i.v. or p.o. (or similar H2 blocker) x 1. Famotidine (or similar H2 
blocker) may be discontinue d starting with Cycle 2 in the absence of infusion 
reactions with the prior dose. 
• Cetirizine 10 mg i.v. or p.o. x 1 (or similar oral or intravenous antihistamine). 
Cetirizine (or similar oral or intravenous antihistimine) may be discontinued starting 
with Cycle [ADDRESS_27415] weekly dose 
Page 38 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
of TRC105 will be split with 3 mg/kg administered on cycle 1 day 8 and infused over 4 hours 
(+/- 15 minutes) and 7 mg/kg adminis tered on cycle 1 day 11 and infused over 2 hours (+/ - 15 
minutes) , and then the full dose of 10 mg/kg given on cycle 1 day 15 and weekly thereafter and 
will be administered over 1 hour (+/ - 15 minutes).  The p atient must complete at least one 4 hour 
infusi on (+/ - 15 minutes) without the development of any infusion reactions, in order to reduce 
the subsequent  TRC105 infusion to 2 hours (+/ - 15 minutes) and complete a 2 hour infusion (+/ - 
15 minutes) without the development of any infusion reactions in order to reduce subsequent TRC105 infusions to 1 hour (+/ - 15 minutes).  If the  patient develop s infusion reactions of any 
kind they should be managed appropriately (see Section  6.7.2 ) and the patient is not permitted to 
reduce the duration of the next planned infusion. 
The rate of TRC105 infusion must not exceed 25 mg/min.  When the i.v. bag containing TRC105 
is empty, flush the i.v. line with a [ADDRESS_27416] be recorded in the source documents.  
If the patient misses a weekly TRC105 dose (i.e., ≥ 10 days between doses), the 
methylprednisolone dose should be reinstituted as per the initial infusion and first TRC105 dose 
should be administered over two days as was done for the initial dose.   
6.7.1. TRC105 Dose Modification/Dose Interruptions  
TRC105 dose reductions are allowed for grade 3 or 4 related adverse events t hat resolve to grade 
1 or baseline (including anemia).  Treatment dose delays cannot exceed 8 consecutive weeks (i.e., both TRC105 and bevacizumab dosing held). However, if the  patient cannot tolerate 
bevacizumab or TRC105 therapy , demonstrates  a response of complete response (CR), partial 
response (PR) or stable disease (SD) with the combination and is thought to benefit from continued single agent therapy , the patient  may continue on study on TRC105 or bevacizumab 
alone.  
TRC105 and bevacizumab should be held for two weeks prior and for two weeks following surgical procedures.  
Table  4: Allowable TRC105 Dose Modifications  
Toxicity Attributed to 
TRC105  Dose Adjustment for Next Dose of TRC105 (% of Starting 
Dose)  
Grade  1 or 2  Maintain Dose Level  
Grade 3 or 4   
• 1st appearance  80% 
• 2nd appearance  60% 
• 3rd appearance  Discontinue treatment permanently  
Note: if the  patient is dose reduced and subsequently misses a dose whereby [CONTACT_28118]105 following the  
break needs to be split into two doses, 3 mg/kg should be given on the first day and the remainder of the dose (i .e., 5 
mg/kg in the case of a dose reduction to 8 mg/kg) will be given 3 days later.  
If the patient develops an  arterial thrombosis or grade 4 venous thrombosis she will be removed 
from study.  If she develops a grade 1, 2 or 3 venous thrombosis  that require s anticoagulation she 
Page 39 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27417] he r TRC105 therapy interrupted.  TRC105 therapy may resume once the following 
criteria are met:   
• The patient is o n a stable dose of heparin, low molecular weight heparin, coumadin, 
or other anticoagulant.  
• If on coumadin, the patient has an in range INR for therapeutic anticoagulation 
(usually between 2 and 3). 
• The patient has a platelet count > 50,000  or baseline.  
• The patient has not had a hemorrhagic event of grade 2 or higher while on study.  
• The patient does not have a pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels). 
• The patient is benefiting from TRC105 therapy (no evidence of disease progression).   
The INR should be monitored weekly before each dose of TRC105 for the first 4 weeks, and 
then once per cycle thereafter (or more often as clinically indicated).  Patients with an INR > 3 should not receive TRC105 until the INR is ≤ 3. 
6.7.2. Management of TRC105 Infusion Reactions  
If the  patient experiences a grade 2 or higher adverse reaction during infusion, the infusion 
should be interrupted and the patient treated accordingly.  Antipyretic, antihistamine, antiemetic, anti-inflammatory, or other symptomatic medications including epi[INVESTIGATOR_28067].  For grade 2 and certain grade 3 infusion reactions, the infusion may be restarted at half of the previous rate if and when the infusion reaction has resolved, and then increased per patient tolerance to a maximum of  25 mg/min .  For grade 4 infusion reactions, the infusion 
should not be restarted and the patient should be discontinued from study treatment.  Infusion reactions will be recorded as AEs in the case report form.  Interventions should be documented as conco mitant medications or concomitant treatments as appropriate.   
Table 5:  Management of TRC105 Infusion Reactions  
Infusion Reaction 
Severity  Recommended Management  
Grade 1 (mild) 1. No intervention  
2. Continue infusion unless symptoms worsen 
Grade 2 (moderate)  1. Interrupt infusion 
2. Treat with symptomatic medicationsa 
3. Resume infusion at half the previous rate when infusion- related 
symptoms improve to grade 1 or less.  
Page 40 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Infusion Reaction 
Severity  Recommended Management  
Grade 3 (severe) 1. Interrupt infusion 
2. Treat with symptomatic medicationsa 
3. Monitor patient until infusion- related symptoms resolve, 
including hospi[INVESTIGATOR_17116]  
4. Withdraw patient from study unless other factors that 
contributed to the infusion reaction are identified and corrected  
Grade 4 (life -
threatening)  1. Discontinue infusion  
2. Treat with symptomatic medicationsa 
3. Hospi[INVESTIGATOR_28068]  
4. Withdraw from study  
aSymptomatic medications may include but are not limited to diphenhydramine 50 mg i.v. and/or hydrocortisone 
100 mg i.v. (for fever, rash, hypoxia, or other hypersensitivity reactions), meperidine 50- 100 mg i.v. (for shaking 
chills/rigors), oxygen by [CONTACT_28119] (for hypoxia), epi[INVESTIGATOR_238] 0.5 mg i.m. (for hypotension or 
bronchospasm), albuterol inhaler or nebulizer (for bronchospasm ), i.v. fluids (for hypotension), and ondansetron 
0.15 mg/kg i.v. (for nausea).  
6.7.3. TRC105 Study Drug Accountability  
The Investigator must maintain an accurate accounting of TRC105 supplied by [CONTACT_28120].  
During the study, the following information must be record ed: 
• Date of receipt, quantity and lot number of the TRC105 study drug received from 
TRACON  
• ID number of the patient to whom the product is dispensed  
• The date(s) and quantity of the product dispensed 
• Dates and quantity of product returned, lost or accidentally or deliberately destroyed  
Investigational Drug Accountability Logs should be maintained by [CONTACT_28121].  
6.7.4. TRC105 Study Drug Handling and Disposal  
TRC105 must be stored upright between 2 °C and 8 °C (36 ° F to 46 °F). The Investigator should 
not return clinical study materials to TRACON unless specifically instructed to do so by 
[CONTACT_28120].  Disposal of TRC105 should occur in accordance with institutional policy. The Site 
Pharmacist will be responsible for docu menting the destruction (according to institutional 
requirements) of used or expi[INVESTIGATOR_28069]. 
6.8. Bevacizumab Packaging 
Bevacizumab is available as 100 mg pack containing one 4 mL single -dose vial and 400 mg pack 
containing one 16 mL single -dose vial.  
Page 41 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
6.9. Bevacizum ab Preparation  
Commercially available bevacizumab will be utilized in this study. The patient will receive 10 
mg/kg on day 1 and day 15 of each 28- day cycle.  Bevacizumab should be prepared according to 
institutional policy and using aseptic technique.  Wi thdraw the necessary amount of 
bevacizumab and dilute to the required administration volume with 0.9% sodium chloride solution.  The concentration of the final bevacizumab solution should be kept within the range of 
1.4-16.5 mg/mL as described in the Avast in PI ( Appendices  – Appendix 3).  
6.10. Bevacizumab Administration  
The p atient will receive 10 mg/kg on day 1 and day 15 of each 4- week cycle.  Bevacizumab 
should be administered as a 90 minute infusion on cycle 1 day 1.  Subsequent infusion times can be reduced by 30 minutes down to a minimum infusion time of 30 minutes if tolerated 
(Appendices  – Appendix 3).  Patient weight will be assessed on the day of treatment and used for 
the calculation of each Bevacizumab dose.  
6.10.1. Bevacizumab Dose Modification  
Dose reduction of bevacizumab for adverse reactions is not  recommended.  If indicated, 
bevacizumab should either be discontinued or temporarily suspended, see bevacizumab package insert for specific information related to different adverse events.  If discontinuation of 
bevacizumab is clinically indicated, patien ts who demonstrate a response of complete response 
(CR), partial response (PR) or stable disease (SD) will be eligible for additional treatment with 
TRC105 alone until progression as long as TRC105 drug supply is available.  
6.11. Bevacizumab Drug Accountability  
Commercial bevacizumab will be utilized in this study , thus the site will follow institutional 
guidelines regarding drug accountability for commercial product.  
6.12. Bevacizumab Handling and Disposal  
Bevacizumab vials [100 mg (NDC [ZIP_CODE] -060- 01) and 400 mg (NDC [ZIP_CODE] -061-01)] are stable 
at 2−8°C (36−46°F). Bevacizumab vials should be protected from light. Do not freeze or shake. 
Diluted bevacizumab solutions may be stored at 2−8°C (36−46°F) for up to [ADDRESS_27418] been observed. Partially used vials should be properly destroyed according to institution guidelines.  
6.13. Concomitant Medications  
No other approve d or investigational anticancer treatment will be permitted during the study 
period, including chemotherapy, biological response modifiers, immunotherapy, or radiotherapy.   
If the patient is on low dose aspi[INVESTIGATOR_28070]. If the  
patient is on NSAIDs on study should also receive peptic ulcer disease (PUD) prophylaxis with an H2 or proton pump blocker. 
Page 42 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Narcotic analgesics, nonsteroidals , anti -inflammatory drugs, and triptans (e.g. sumatriptan) may 
be offered as ne eded for relief of pain or headaches.  Antihistamines and decongestants may be 
offered for the treatment of sinus congestion. 
Packed red blood cell, colony stimulating factors, and platelet transfusions should be 
administered as clinically indicated.   
6.14. Treatment Compliance  
6.14.1. TRC105  
All TRC105 infusions will occur at the trial site under the direct supervision of the treating physician or his or her designee.  
6.14.2. Bevacizumab  
All bevacizumab infusions will occur at the trial site under the direct supervision of  the treating 
physician or his or her designee. 
6.15. Patient Enrollment  
This is a single patient trial.  She will be consented and enrolled at DFCI and followed by [CONTACT_28122] 43 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27419] version 1.1 [54] and by [CONTACT_28123] β -hCG.  
Investigators will make treatment  decisions based on these assessments.  All lesions will be 
classified as Target or Nontarget lesions at the Screening visit.  Each lesion designation will be maintained through the course of the study.  
The same method and technique should be used to characterize each identified and reported 
lesion at Screening, during the study treatment period, and at the End of Study visit. Imaging -
based evaluation over clinical examination is the required technique when both could be used to assess the antitumor effect  of the treatment.  Clinical Oncology review of all tumor 
measurements is desired.  
Whenever possible, clinical evaluation of superficial lesions should not be used as the sole form of measurement.  However, when necessary, color photograph with metric cali ber is acceptable.  
Tumor evaluation by [CONTACT_28124] (PET) scan or by [CONTACT_28125].  
Radiological tumor assessments and serum tumor marker (serum β -hCG) measurements will be 
performed at screening, as outlined in the Schedule of Assessments ( Table 3 ), and whenever 
disease progression is suspected.  Another tumor assessment will be performed at the End of 
Study Visit if an assessment has not been performed within the prior [ADDRESS_27420] 1.1 criteria described below.  
• Measurable:  Lesions that can be accurately measured in at least one dimension  
(longest diameter to be recorded) as ≥ [ADDRESS_27421] scan.  Clinical lesions 
will only be considered measurable when they are superficial (e.g. skin nodules, palpable lymph nodes) and ≥ [ADDRESS_27422] be measured with 
calipers.  
• Non-Measurable:   All other lesions, including small lesions and bone lesions, 
leptomeningeal disease, ascites, pleural or pericardial effusions, lymphangitis of the 
skin or lung, abdominal masses that are not confirmed and followed by [CONTACT_15218], previo usly irradiated lesions, and disease documented by [CONTACT_28126] (e.g. by [CONTACT_28127]).  
7.2. Recording Tumor Measurements  
Measurable lesions up to a maximum of 5 lesions representative of all involved organs (with a maximum of 2 lesions per organ) should be identified as target lesions and measured and 
recorded at Screening and at the stipulated intervals during treatment.  Target lesions should be 
Page 44 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
selected on the basis of their size (lesion with the longest diameters)  and their suitability for 
accurate repetitive measurements (either by [CONTACT_14217]).  Target lesions 
may include lymph nodes with a short axis >  [ADDRESS_27423] diameter will be recorded for each target lesion (with the exception o f lymph nodes, 
where the short axis will be used). The sum of the diameter for all target lesions at Screening will be calculated and recorded as the baseline sum diameter to be used as reference to further 
characterize the objective tumor response of the measurable dimension of the disease during treatment.  All measurements should be performed using a caliper or ruler and should be 
recorded in metric notation in millimeters.  
All other lesions (or sites of disease) should be identified as non- target lesion s and should also be 
recorded at baseline.  Measurements are not required and these lesions should be followed as “present”, “stable”, “absent”, “increased” or “decreased”.  
7.2.1. Definitions of Tumor Response  
[IP_ADDRESS]. Target Lesions  
• Complete response (CR)  is defined as t he disappearance of all target lesions and 
normalization of her ser um β -hCG. 
• Partial response (PR)  is defined as a ≥ 30% decrease in the sum of the dimensions 
of the target lesions taking as a reference the baseline sum dimensions.  
• Progressive disease (PD)  is defined as a ≥ 20% relative increase and ≥ [ADDRESS_27424] sum of the dimensions recorded since the treatment started, or 
the appearance of one or more new les ions and rise of her serum β -hCG.  
• Stable disease (SD)  is defined as neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD taking as a reference the smallest sum of the 
dimensions since the treatment started.  
[IP_ADDRESS]. Non-Target Lesions  
• Complete response (CR)  is defined as the disappearance of all non -target lesions and 
normalization of tumor marker levels to ≤ ULN.  
• non-CR/non -PD is defined as a persistence of ≥ 1 non- target lesions and/or 
maintenance of tumor marker levels > ULN.  
• Progressive disease (PD)  is defined as unequivocal progression of existing non-
target lesions, or the appearance of ≥ 1 new lesions. 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the me asurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease and progressive disease.  
Page 45 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
[IP_ADDRESS]. Determination of Overall Response by [CONTACT_28128]- target lesions are pr esent, individual assessments will be recorded 
separately.  The overall assessment of response will involve all parameters as depi[INVESTIGATOR_28071] [ADDRESS_27425] increase in the size of one or more non- target lesions is usually 
not sufficient to qualify for unequivocal progression status.  
Table 6: Response Evaluation Criteria in Solid Tumors 
Target L esionsa Non-target Lesionsb New Lesionsc Overall Response  
CR CR No CR 
CR non- CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all evaluated  Any Response  Yes or No  Not Evaluable  
PD Any Response  Yes or No  PD 
Any Response  PD Yes or No  PD 
Any Response  Any Response  Yes PD 
aMeasurable lesions only.  
bMay include measurable lesions not followed as target lesions or non -measurable lesions.  
cMeasurable or nonmeasurable lesions.  
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  The patient’s best response assignment will 
depend on the achievement of both measurement and confirmation criteria.  
NOTE:  If the patients has a  global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time her best response should 
be reported as “symptomatic deterioration.”  Every effort should be made to document the 
objective progression even after discontinuation of treatment.   
Page 46 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
8. ASSESSMENT OF SAFETY  
8.1. Safety Parameters  
Safety will be characterized in terms of the incidence, timing, severity (graded by [CONTACT_28129] [NCI] Common Terminology Criteria for Adverse Events [CTCAE], Version 
4.0), seriousness, and relatedness of adverse events and laboratory abnormalities.  In addition, 
physical examination, vital signs, and ECOG performance status will be serially monitored.  Laboratory safety analyses will be based on the local laboratory data, and will include 
hematology, serum chemistry (including liver and kidney function), urinalysis, and coagulation 
profil e.  In addition, an ECG will be recorded at baseline and as clinically indicated throughout 
the study.   
8.1.1. Laboratory Safety Assessments  
Abnormal and clinically significant laboratory tests should be recorded as adverse events.  
[IP_ADDRESS]. Hematology, Serum Chemistry, Coagulation  
Assessments will be performed at the time  points indicated in the Schedule of Assessments  
(Table 3 ) and analyzed at local laboratories.  Investigators may have additional blood tests 
performed for the purpose of planning treatment administration, or for following adverse events as clinically indicated.  
• Hematology: CBC with differential and platelet count  
• Coagulation: Prothrombin Time (PT) or Internalized Normalized Ration (INR) will 
be assessed  
• Serum Chemistry: Total bilirubin, alanine tran saminase (ALT), aspartate 
transaminase (AST), alkaline phosphatase, total protein, albumin, sodium, potassium, 
bicarbonate, chloride, calcium, phosphorus, blood urea nitrogen, creatinine, thyroid 
stimulating hormone (TSH), and glucose  
[IP_ADDRESS]. Urinalysis  
Urine ana lysis will be performed at time points indicated in the Schedule of Assessments ( Table 
3) and analyzed by [CONTACT_28130]. Microscopic analysis sho uld be performed as clinically 
indicated.  
8.1.2. Other Safety Assessments  
[IP_ADDRESS]. Physical Examination  
A physical examination including, but not limited to, general appearance, head, eyes, ears, nose, 
throat, neck, heart, chest, abdomen, musculoskeletal, extremities, sk in, lymph nodes, 
neurological genitourinary (as appropriate), and rectal (as appropriate) will be assessed at time     
points indicated within the Schedule of Assessments (Table 3 ).  The physical examination will 
include examination of known and suspected sites of disease.   
Page 47 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
[IP_ADDRESS]. Vital Signs  
Heart rate, temperature, blood pressure, respi[INVESTIGATOR_28072] ( Table 3 ). Assessment of vital signs during 
TRC105 infusion: Vital signs are to be assessed pre -infusion and every 30 minutes during the 
infusion.  Vital signs should be monitored more frequently and/or beyond the completion of the infusion if medically indicated (e.g. if the patient experiences an infusion reaction that has not 
yet resolved).  
[IP_ADDRESS]. Performance Status  
The ECOG scale will be used to assess performance status at Screening.  
[IP_ADDRESS]. ECG  
A single 12 -lead (with a 10 –second rhythm strip) tracing will be used for all ECGs.  It is 
preferable that the machine used has a capacity to calculate standard intervals automatically. 
ECG will be performed according to the Schedule of Assessments ( Table 3 ) and as clinically 
indicated throughout the study.  
8.2. Adverse Events  
All observed or volunteered adverse events regardless of suspected causal relationship to TRC105 study drug and/or bevacizumab will be reported as described below.  
8.2.1. Definition of Adverse Event  
An adverse event is any untoward medical occurrence in a trial patient who is administered a drug or biologic (medicinal product); the event may or may not have a causal relationship with the medicinal product.  Examples of adverse events include, but are not limited to the following:  
• Clinically significant symptoms and signs includi ng:  
o Worsening of signs and symptoms of the malignancy under trial (disease 
progression without worsening of signs and symptoms assessed by 
[CONTACT_28131]).  
o Signs and symptoms resulting from drug overdose, abuse, misuse, withdrawal, sensitivity, dependency, interaction or toxicity.   
o All possibly related and unrelated illnesses, including the worsening of a 
preexisting illness.  
o Injury or accidents.  Note that  if a medical condition is known to have caused 
the injury or accident (hip fracture from a fall secondary to dizziness), the medical condition (dizziness) and the outcome of the accident (hip fracture 
from a fall) should be reported as 2 separate adverse events.   
o Symptoms or signs resulting from exposure in utero . 
Page 48 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
• Abnormalities in physiological testing or physical examination findings that require 
clinical intervention or further investigation (beyond ordering a repeat confirmatory test).  
• Laboratory abnormalities that meet any of the following (Note: merely repeating an 
abnormal test, in the absence of any of the below conditions, does not constitute an 
adverse event.  Any abnormal test result that is determined to be an error does not 
require reporti ng as an adverse event.):  
o Test result that is associated with accompanying symptoms  
o Test result that requires additional diagnostic testing or medical/surgical intervention  
o Test result that leads to a change in TRC105 study drug dosing outside of 
protocol -stipulated dose adjustments or discontinuation from the trial, 
significant additional concomitant drug treatment, or other therapy  
o Test result that is considered to be an adverse event by [CONTACT_28132]  
8.2.2. Serious Adverse Events  
An adverse event t hat meets one or more of the following criteria/outcomes is classified as 
serious:  
• Results in death  
• Is life- threatening (at immediate risk of death)  
• Requires in patient hospi[INVESTIGATOR_1081]  
• Results in persistent or si gnificant disability/incapacity  
• Results in congenital anomaly/birth defect  
• Other important medical events that may not result in death, be life- threatening, or 
require hospi[INVESTIGATOR_708], based upon appropriate medical judgment , they may jeopardize the patient or may require medical or surgical 
intervention to prevent one of the outcomes listed above. Examples of such events are 
intensive treatment in an emergency room for allergic bronchospasm; blood 
dyscrasias or convulsions t hat do not result in hospi[INVESTIGATOR_059]; or the development of 
drug dependence or drug abuse.  
Serious also includes any other event that the Investigator or sponsor judges to be serious, or which is defined as serious by [CONTACT_28133].   
Progression of the malignancy under study (including signs and symptoms of progression) 
should not be reported as serious adverse events unless the outcome is fatal during the trial or 
within the safety reporting period. Hospi[INVESTIGATOR_602] d ue to signs and symptoms of disease 
progression should not be reported as serious adverse events.  If the malignancy has a fatal 
outcome during the trial or within the safety reporting period, then the event leading to death 
must be recorded as an adverse event and as a serious adverse event with CTC grade 5.  
Page 49 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
The onset date of an SAE is defined as the date on which the event initially met serious criteria 
(e.g., the date of admission to a hospi[INVESTIGATOR_307]).  The end date is the date on which the event no longer 
met serious criteria (e.g., the date the patient was discharged from a hospi[INVESTIGATOR_307]).  
[IP_ADDRESS]. Hospi[INVESTIGATOR_28073] -patient hospi[INVESTIGATOR_059], or prolongation of an existing 
hospi[INVESTIGATOR_059], are considered serious.  Any initial admission, even  if the duration is less than 24 
hours is considered serious. In addition, any transfer within the hospi[INVESTIGATOR_4591]/intensive care unit is considered serious (e.g., transfer from the psychiatric wing to a medical floor or transfer from a medical floor to a coronary care unit). However, the following hospi[INVESTIGATOR_28074]:  
• Rehabilitation facility admission  
• Hospi[INVESTIGATOR_28075]  
• Respi[INVESTIGATOR_4594]  
• Skilled nursing facility admission  
• Nursing home admission 
• Emergency room visit  
• Same day surgery  
• Hospi[INVESTIGATOR_28076]:  
o Admission for treatment of preexisting condition not associated  with the 
development of a new adverse event or with a w orsening of the preexisting 
condition  
o Social admission  
o Administrative admission (e.g. for yearly physical exam)  
o Protocol -specified admission during a clinical trial  
o Optional admission not associated with a precipi[INVESTIGATOR_10244] (e.g. for el ective cosmetic surgery)  
o Preplanned treatments or surgical procedures  
o Admission exclusively for the administration of blood products  
• Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery, 
should not be reported as adverse events.  The medical condition for which the 
procedure was performed should  be reported if it meets the definition of an adverse 
event (e.g. acute appendicitis that begins during the adverse event reporting period 
should be reported as an adverse event and the appendectomy should be recorded as a 
concomitant treatment).  
Page 50 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
8.3. Reporting Adverse Events  
8.3.1. Eliciting Adverse Event Information  
The Investigator is to report all directly observed adverse events and all adverse events 
spontaneously reported by [CONTACT_28134].  In addition, each 
trial patient will be questioned about adverse events at each clinic visit following initiation of treatment.  The question asked will be, “Since your last clinic visit have you had any health 
problems? ” 
8.3.2. Adverse Event Reporting Period  
Safety information for each patient will be collected from the date of informed consent.  Adverse 
events occurring prior to the initiation of the study treatment will be considered "baseline- signs 
and symptoms ” and will be recorded on corresponding case report forms. The adverse event 
reporting period for this trial begins when the patient has taken the first dose of bevacizumab 
and/or TRC105 study drug and ends [ADDRESS_27426] dose of bevacizumab and/or TRC105 
study drug is administered whichever is later.  All adverse events that occur in trial patients 
during the adverse event reporting period specified in the protocol must be reported to 
TRACON, whether or not the event is considered study treatment -related .  In addition, any 
known untoward event that occurs beyond the adverse event reporting period that the Investigator assesses as possibly related to the investigational medication/product should also be 
reported as an adverse event.  
8.3.3. Reporting Requirements  
Each adv erse event is to be classified by [CONTACT_28135].  This 
classification of the gravity of the event determines the reporting procedures to be followed.  If a 
serious adverse event occurs, reporting will follow local and internatio nal regulations, as 
appropriate. 
The Investigator must notify the Sponsor of any event that meets one of the criteria for an SAE 
immediately upon learning of the event.  This notification should be made to:  
Ronald Shazer, MD, MBA  
TRACON Pharmaceuticals Inc. 
[ADDRESS_27427] Phone:  (858) 550 -0780 x230  
Cell Phone:  (310) 922 -8039  
Email: [EMAIL_438]  
Following this notification, the Investigator will report the SAE via the AE CRF via the data 
management system.  The initial AE CRF is to be updated with followed more detailed adverse 
event information within 5 calendar days of the event.  
In the rare event that the Investigator does not become aware of the occurrence of a serious 
adverse event immediately (for example, if a patient initially seeks treatment elsewhere), the 
Page 51 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Investigator is to report the event immediately upon learning of it and document his/her first 
awareness of the serious adverse event.  
TRACON Pharmaceuticals Inc. may also be contact[CONTACT_28136] 24 hours a day at (858) 344-
9400. 
Each SAE should be followed until resolution, or until such time as the Investigator determines 
its cause or determines that it has become stable.  Information pertaining to follow -up of SAEs 
should also be sent to the TRACON Pharmaceuticals Inc.  
Serious adverse events that are unexpected and associated with use of the study medication will be reported to the US Food and Drug Administration (FDA) and all participating clinical sites by [CONTACT_28137].  For events which are fatal or life -threatening, unexpected, and 
associated with use of the investigational product, a [ADDRESS_27428], a written report will 
be made no more than 15 calendar days from the date TRACON learns of the event. 
Participating clinical sites will be notified of these events  in parallel.  
All adverse events, including SAEs, are to be reported on the adverse event CRFs.  
8.3.4. Recording Adverse Events in the Case Report Forms  
The Investigator is to report all directly observed adverse events and all adverse events spontaneously reported by [CONTACT_28138].  In addition, each trial patient will be questioned 
about adverse events. All adverse events that meet the criteria specified in Section  8.2.1 are to be 
recorded on patient source documents and on the CRFs.  Adverse events should be reported using concise medical terminology. 
 
8.3.5. Grading of Adverse Event Severity  
To report adverse events on the CRFs, the Investigator will use the severity grading as described 
in NCI CTCAE Version 4.0.   
Every effort should be made by [CONTACT_28139]. If the Investigator is un able to assess severity because the term is not described in NCI 
CTCAE Version 4.0, severity of MILD, MODERATE, SEVERE, LIFE -THREATENING, or 
FATAL may be used to describe the maximum intensity of the adverse event. For purposes of consistency, these intens ity grades are defined as follows:  
Table 7: Adverse Event Grading  
Grade  Non-CTCAE Severity  Definition  
1 Mild  Does not interfere with patient’s usual function  
2 Moderate  Interferes to some extent with patient’s usual function  
3 Severe  Interferes significantly with patient’s usual function  
4 Life-Threatening  Results in immediate risk of patient’s death  
5 Fatal  Results in patient’s death  
Page 52 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
Note the distinction between the severity and the seriousness of an adverse event.  A severe 
event is not necessarily a serious event.  For example, a headache may be severe (interferes 
significantly with patient’s usual function) but would not be classifi ed as serious unless it met 
one of the criteria for serious events.     
8.3.6. Relationship to TRC105 Study Drug  
In this study, TRC105 study drug is given in combination with bevacizumab.  The relationship of 
an adverse event to TRC105 study drug should be classi fied by [CONTACT_28140]:  
• Suspected Adverse Reaction: There is a reasonable possibility that TRC105 caused the adverse event (i.e.: there is evidence to suggest a causal relationship between 
TRC105 and adverse event). 
• Not rel ated: there is no reasonable possibility that the adverse event is associated with 
TRC105 study drug.  
AEs related to TRC105 study drug or bevacizumab are considered Adverse Drug Reactions 
(ADR). 
8.3.7. Expectedness  
All adverse events and adverse drug reactions are reaction considered “unexpected” if it not 
listed in the investigator brochure or not listed at the specificity or severity that has been 
observed.   For example, under this definition, hepatic necrosis would be unexpected (by [CONTACT_28141] y) if the investigator brochure referred only to elevated hepatic enzymes or 
hepatitis.  Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_14214]) if the investigator brochure listed only cerebral vascular accidents. "Unexpected," as used in this definition, also refers to adverse events or suspected adverse 
reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as 
anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. 
8.3.8. Exposure in Utero  
This patient is status post a hysterectomy so no exposure in utero is possible.   
8.3.9. Follow -up of Unresolved Adverse Events  
All adverse events should be followed until they are resolved or the Investigator assesses them as 
chronic or stable.  Any increase or decrease in adverse event grade should be recorded as a new 
adverse event.  
All serious and those non- serious events asse ssed by [CONTACT_28142]/product should continue to be followed even after the patient’s 
participation in the trial is over.  Such events should be followed until they resolve or until the Investigator assesses them as “chronic” or “stable.”  The event should also be documented on the 
adverse event CRF.  
Page 53 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
8.4. Safety Monitoring 
The TRACON Clinical Team will monitor safety throughout the study via the following 
activities:  
• Surveillance for SAEs according to regulatory guidelines  
• Routine monitoring of non- serious adverse experiences as they are recorded in the 
case report forms and the source documents at study sites  
• A formally chartered TRACON in -house Safety Review Team that includes, among 
other staff, two physicians  
• Periodic teleconferences with the Principal Investigators to share experiences and 
ensure communication  
• Toxicity information that may affect the treatment of patients on this study will be 
promptly communicated in writing to all participating clin ical sites and institutions 
participating in this clinical trial.  
Page 54 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
9. OTHER ASSESSMENTS  
9.1. Other Laboratory Assessments  
9.1.1. Protein Biomarker  
A 5 mL K 3EDTA plasma blood sample will be collected on the days indicated within the 
Schedule of Assessments ( Table 3 ). Samples will be stored at approximately -70 °C and batch 
shipped to Fisher BioServices Inc. (10 Forge Park, Franklin, MA [ZIP_CODE]) for storage until the 
time of analysis. Duke University Medical Center will analyze plasma for several biomarkers 
including but not limited to VEGF, PDGF, and TGFβ. Please see the separate laboratory guide 
for further collection and shipment information.  
Page 55 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
10. STATISTICS  
10.1. Data Analysis  
Due to the exploratory nature of this study, no inferential analyses are planned, and no 
imputation of missing data will be done.   
10.1.1. Analysis of Primary Objective  
PFS and ORR will be calculated form the time of cycle 1 day 1 until the time of progression 
from cancer, if the patient remains on trial at the time of cancer progression. Stable disease will be defined as lack of tumor progression lasting for 2 cycles or longer.  
10.1.2. Analysis of Secondary Objectives  
The secondary objectives including the assessments of frequency and severity of toxicities , 
efficacy, and angiogenic protein biomarkers will be evaluated as described below.  
[IP_ADDRESS]. Protein Biomarkers  
Angiogenic protein biomarker data if the patient received at least one dose of study drug will be 
listed by [CONTACT_28143]. 
Page 56 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27429] ACCESS TO SOU RCE DATA/DOCUMENTS  
All data entered on CRFs/eCRFs must be verifiable within the patients’ source documents 
(written or electronic record).  The I nvestigator/institution guarantees TRACON representatives 
and appropriate regulatory authorities direct access to the original source records for the duration of the agreed study record retention period.  Printouts of source records that are electronically  
obtained and stored will not be acceptable for audit/inspection unless provided as certified exact 
copi[INVESTIGATOR_28077].     
Legally protected subject identification and other personal health information must be securely 
stored with limited access by [CONTACT_28144]. Unless secure provisions are 
established by [CONTACT_28145] (or designee) to perform remote monitoring of 
electronic source records, TRACON (or designee) will review source records/data on site and will not remove any such protected health information.   
 
Page 57 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27430] (IRB) or 
independent ethics committee (IEC) or other appropriate regulatory authority. The trial site is also subject to quality assurance (QA) audits performed by [CONTACT_28146].  
It is important that the Investigator(s) and their relevant personnel are available during the 
monitoring visits, audits, and inspections and that sufficient attention, time, and support is 
devoted to the process.  
TRACON and its representatives will be governed by [CONTACT_28147], good clinical 
practice standards, and internal SOPs for the conduct of monitoring visits and QA audits.    
Page 58 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27431] (IRB)/Independent Ethics Committee 
(IEC) 
It is the responsibility of the Investigator to have approval of the trial protocol, protocol 
amendments, informed consent forms, and advertisements from the IRB/IEC before potential 
patients are consented for participation on the trial. All correspondence and other evidence of 
appropriate and timely communications with  the IRB/IEC should be retained in the 
Investigator/site files. Copi[INVESTIGATOR_28078]/IEC approvals should also be forwarded to TRACON.  
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is where the change is necessary to eliminate apparent immediate hazards to the patients.  In that event, the Investigator must notify the IRB/IEC and TRACON in writing within [ADDRESS_27432] their origin in the 
Declaration of Helsi nki (see ICH E6, § 2.1).  
13.3. Written Informed Consent  
The informed consent form language must be agreed upon by [CONTACT_28148]/IEC and must be in compliance with ICH GCP, local regulatory requirements, and legal requirements. 
The informed consent informati on must not be changed without prior approval by [CONTACT_28149]/IEC. The informed consent form used in this trial, and any changes made during the 
course of the trial, must be approved by [CONTACT_28150]/IEC and TRACON, or designee, before 
use.  
It is the responsibility of the Investigator to give the  patient full and adequate verbal and written 
information regarding the objective and procedures of the trial and the possible risks involved.  
This information must be provided to the patient prior to underta king any trial -related procedure.  
The p atient must be informed about her right to withdraw from the trial at any time.  
Furthermore, it is the responsibility of the Investigator to ensure the patient is  appropriately 
informed before obtaining her signed a nd dated consent. Signatures from the investigator 
conducting the informed consent discussion should also be obtained prior to undertaking any trial-related procedure. Consent by a legally authorized representative is not permitted. Should an 
impartial wit ness be needed, ICHE6 requirements for impartial witnesses will apply.  
The Investigator will retain the original the patient’s signed consent form in the Investigator/site 
files.  
13.4. Patient Compensation  
The patient will not be compensated for participation i n this trial; this will be outlined to  the 
patient informed consent form. 
Page 59 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
14. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  
14.1. Inspection of Records  
CRF’s are required and should be completed for each patient who receives treatment with 
TRC105.  Screen failure CRF’s will not b e collected.  Nevertheless, records of potential patients 
identified and screened shall be retained on site screening logs. The completed original CRFs are the sole property of TRACON and should not be made available in any form to third parties without written permission from TRACON (except for authorized representatives of the HRA 
and in accordance with HIPAA regulations).  
It is the Investigator’s responsibility to ensure completion and to review and approve all CRF 
data. The investigator will sign off on his/her data per patient.  These signatures serve to attest 
that the investigator has reviewed and approved the informati on contained on the case report 
forms and that the information is complete, accurate, and true.   At all times, the Investigator has 
final personal responsibility for the accuracy and authenticity of all clinical and laboratory data 
entered on the CRFs.   
The use of electronic CRFs (eCRFs) to capture study data using automated computerized data capture systems does not change the principles and requirements for collecting study data.  The 
investigator still retains final personal responsibility for eCRF dat a and any associated data 
pertaining to it (e.g. metadata including any record of change to the originally recorded data).  
The investigator’s signed approval of the eCRF data serves to attest that the electronic data and 
all of its associated metadata (in cluding changes) has been reviewed and accepted as complete, 
accurate, and true for each patient in the study.  
All CRF/eCRF data must be verifiable in the patient’s source records by [CONTACT_28151].  TRACON will review CRF data as compared to sourc e records in an attempt to 
identify missing and spurious data and notify the investigator of findings so that proper 
corrections can be made.  TRACON representatives (monitors and auditors), and regulatory 
inspectors shall have direct access to the original source records in its original recorded format: 
electronic or hardcopy.   
TRACON (or its designee) will perform all data management functions associated with the study.  Data will be captured electronically.  Automated data verification (“edit checks”) w ill be 
used to ensure that the data are logical and consistent. Any inconsistencies will be queried for clarification or correction as appropriate by [CONTACT_977].   
14.2. Retention of Records  
To allow for appropriate evaluations and/or audits by [CONTACT_28152], the 
Investigator agrees to keep records, including the identity of all participating patients (sufficient 
information to link records, CRFs and hospi[INVESTIGATOR_1097]), all original signed informed consent 
forms, copi[INVESTIGATOR_4600], sourc e documents, and detailed records of treatment disposition.  The 
Investigator should retain these records according to local regulations or as specified in the 
Clinical Trial Agreement, whichever is longer.   
If the Investigator relocates, retires, or for any reason withdraws from the study, then TRACON 
should be prospectively notified.  The study records must be transferred to an acceptable designee, such as another Investigator, another institution, or to TRACON.  The Investigator 
Page 60 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27433] inform TRACON of an y such transfer of responsibilities and properly identify the person or 
institution assuming the responsibility.  The responsible investigator/institution must obtain 
TRACON’s written permission before disposing of any records.  
Page 61 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
15. DEFINITION OF END OF  TRIAL  
15.1. End of Trial  
End of trial in all participating countries is defined as the time at which the patient enrolled in the 
study has completed treatment on study.  
15.2. TRACON Discontinuation Criteria  
Premature termination of this trial may occur because of a regulat ory authority decision, change 
in opi[INVESTIGATOR_1100]/IEC, drug safety problems, or at the discretion of TRACON.  In addition, 
TRACON retains the right to discontinue development of TRC105 at any time.  
TRACON reserves the right to discontinue the trial pri or to inclusion of the intended number of 
patients, but intends only to exercise this right for valid scientific or administrative reasons. If a trial is prematurely terminated or discontinued, TRACON will promptly notify the Investigator.  
After notificat ion, the Investigator must contact [CONTACT_28153] a [ADDRESS_27434] extent possible.  
Page 62 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
16. PUBLICATION OF TRIAL  RESULTS  
Publication of trial results is discussed in the Clinical Trial Agreement.  
Page 63 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
17. FINANCING AND INSURA NCE  
Financing and Insurance are discussed in the Clinical Trial Agreement.  
Page 64 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
18. INVESTIGATOR PROTOCO L AGREEMENT: 105 CC201 
AMENDMENT #[ADDRESS_27435] be submitted to the appropriate 
IRB/IEC.  
 
 
Investigator Name (PLEASE PRINT):  ______________________________________________ 
 
 
 Signature: _________________________________________________Date: _______________ 
 
 
Please sign and return this agreement to:  
TRACON Pharmaceuticals, Inc.  
Attn: Clinical Operations  
[ADDRESS_27436] 
San Diego, CA  [ZIP_CODE]  
Please keep a copy for your records. 
 
Page 65 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
19. REFERENCES  
1. Carmeliet, P., Angiogenesis in health and disease. Nat Med, 2003. 9(6): p. 653 -60. 
2. Folkman, J. and Y. Shing, Angiogenesis. J Biol Chem, 1992. 267(16): p. [ZIP_CODE] -4. 
3. Hurwitz, H., et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for 
metastatic colorectal cancer.  N Engl J Med, 2004. 350(23): p. 2335 -42. 
4. Sandler, A., et al., Paclitaxel -carboplatin alone or with bevacizumab for non-small -cell 
lung cancer. N Engl J Med, 2006. 355(24): p. [ADDRESS_27437] cancer.  J Clin Oncol, 2005. 23(4): p. 792-9. 
6. Friedman, H.S., et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol, 2009. 27(28): p. 4733 -40. 
7. Escudier, B., et al., Phase III trial of bevacizumab plus interferon alfa-2a in patients with 
metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.  J Clin 
Oncol, 2010. 28(13): p. 2144 -50. 
8. Escudier, B., et al., Sorafenib in advanced clear -cell renal -cell carcinoma.  N Engl J Med, 
2007. 356(2): p. 125 -34. 
9. Llovet, J.M., et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008. 359(4): p. 378 -90. 
10. Motzer, R.J., et al., Sunitinib versus interferon alfa in metastatic renal -cell carcinoma.  N 
Engl J Med, 2007. 356(2): p. 115 -24. 
11. Rini, B.I., Vascular endothelial growth factor -targeted therapy in metastatic renal cell 
carcinoma. Cancer, 2009. 115 ([ADDRESS_27438]): p. 2306- 12. 
12. Haruta, Y. and B.K. Seon, Distinct human leukemia -associated cell surface glycoprotein 
GP160 defined by [CONTACT_28154]6. Proc Natl Acad Sci U S A, 1986. 83(20): p. 7898- 902. 
13. Gougos, A. and M. Letarte, Identification of a  human endothelial cell antigen with 
monoclonal antibody 44G4 produced against a pre -B leukemic cell line.  J Immunol, 
1988. 141(6): p. 1925 -33. 
14. Seon, B.K., et al., Long-lasting complete inhibition of human solid tumors in SCID mice by [CONTACT_28155]. Clin Cancer Res, 1997. 3(7): p. 1031 -44. 
15. Cheifetz, S., et al., Endoglin is a component of the transforming growth factor -beta 
receptor system in human endothelial cells.  J Biol Chem, 1992. 267(27): p. [ZIP_CODE] -30. 
16. Li, D.Y., et al., Defective angiogenesis in mice lacking endoglin.  Science, 1999. 
284(5419): p. 1534 -7. 
17. Burrows, F.J., et al., Up -regulation of endoglin on vascular endothelial cells in human 
solid tumors: implications for diagnosis and therapy. Clin Cancer Res, 1995. 1(12): p. 1623- 34. 
18. Seon, B.K., Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer, 2002. 99(2): p. 310 -1; author reply 312. 
19. Horsman, M.R. and D.W. Siemann, Pathophysiol ogic effects of vascular -targeting agents 
and the implications for combination with conventional therapi[INVESTIGATOR_014]. Cancer Res, 2006. 66(24): p. [ZIP_CODE] -39. 
Page 66 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #[ADDRESS_27439] solid 
tumors by [CONTACT_28156] -endoglin monoclonal 
antibodies. Clin Cancer Res, 1999. 5(2): p. 371- 82. 
21. Takahashi, N., et al., Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by a nti-endoglin (CD105) monoclonal 
antibodies, and synergy between anti -endoglin antibody and cyclophosphamide. Cancer 
Res, 2001. 61(21): p. 7846 -54. 
22. Tsujie, M., et al., Anti -tumor activity of an anti -endoglin monoclonal antibody is 
enhanced in immunocompetent mice.  Int J Cancer, 2008. 122(10): p. 2266 -73. 
23. Uneda, S., H. Toi, and B.K. Seon, Anti -endoglin monoclonal antibodies are effective for 
suppressing metastasis and the primary tumors by [CONTACT_28157]. Int J Cancer, 2009. 125: p. 1446. 
24. Guo, B., et al., CD105 inhibits transforming growth factor -beta -Smad3 signalling. 
Anticancer Res, 2004. 24(3a): p. 1337- 45. 
25. Warrington, K., et al., Functional role of CD105 in TGF -beta1 signalling in murine and 
human endothelial cells.  Anticancer Res, 2005. 25(3B): p. 1851 -64. 
26. Sanchez -Elsner, T., et al., Endoglin expression is regulated by [CONTACT_28158] -beta pathways. J Biol 
Chem, 2002. 277(46): p. [ZIP_CODE] -808. 
27. Barbara, N.P., J. L. Wrana, and M. Letarte, Endoglin is an accessory protein that interacts 
with the signaling receptor complex of multiple members of the transforming growth factor -beta superfamily.  J Biol Chem, 1999. 274(2): p. 584 -94. 
28. She, X., et al., Synergy between  anti-endoglin (CD105) monoclonal antibodies and TGF -
beta in suppression of growth of human endothelial cells. Int J Cancer, 2004. 108(2): p. 251-7. 
29. van Laake, L.W., et al., Endoglin has a crucial role in blood cell -mediated vascular 
repair.  Circulatio n, 2006. 114(21): p. 2288- 97. 
30. Lenato, G.M. and G. Guanti, Hereditary Haemorrhagic Telangiectasia (HHT): genetic 
and molecular aspects. Curr Pharm Des, 2006. 12(10): p. 1173 -93. 
31. Sabba, C., et al., Life expectancy in patients with hereditary haemorrh agic telangiectasia. 
Qjm, 2006. 99(5): p. 327 -34. 
32. Lastres, P., et al., Regulated expression on human macrophages of endoglin, an Arg- Gly-
Asp-containing surface antigen. Eur J Immunol, 1992. 22(2): p. [ADDRESS_27440], 1997. 
100(10): p. 2568 -79. 
34. Bockhorn, M., et al., Differential vascular and transcriptional responses to anti -vascular 
endot helial growth factor antibody in orthotopic human pancreatic cancer xenografts. 
Clin Cancer Res, 2003. 9(11): p. 4221 -6. 
35. Davis, D.W., et al., Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B -V 
bladder cancer xenografts. Cancer Res, 2004. 64(13): p. [ADDRESS_27441] carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res, 1999. 59(4): p. 856 -61. 
Page 67 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
37. Vo, M.N., et al., Elevated plasma endoglin (CD105) predicts decreased response and 
survival in a metastatic breast cancer trial of hormone therapy.  Breast Cancer Res Treat, 
2008. 
38. Tanaka, F., et al., Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti -CD34 antibody and anti -CD105 antibody. Clin Cancer Res, 2001. 7(11): p. 
3410- 5. 
39. El-Gohary, Y.M., et al., Endoglin (CD105) and vascular endothelial growth factor as 
prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol, 2007. 127(4): p. 572-9. 
40. Svatek, R.S., et al., Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.  Clin Cancer Res, 2008. 14(11): p. 3362 -6. 
41. Li, C., et al., Both high intratumoral micr ovessel density determined using CD105 
antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer, 2003. 88(9): p. 1424 -31. 
42. Romani, A.A., et al., The risk of developi[INVESTIGATOR_28079]105-positive vessel count.  J Surg Oncol, 2006. 93(6): p. 446 -55. 
43. Ding, S., et al., Comparative evaluation of microvessel density determined by [CONTACT_398]34 or CD105 in benign and malignant gastric lesions. Hum Pathol, 2006. 37(7): p. 861 -6. 
44. Erdem, O., et al., CD105 expression is an independent predictor of survival in patients with endometrial cancer.  Gynecol Oncol, 2006. 103(3): p. 1007 -11. 
45. Yao, Y., et al., Prognostic significance of microvessel density determined by [CONTACT_2017] -
CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti -
CD31 monoclonal antibody. Neuropathology, 2005. 25(3): p. 201 -6. 
46. Yang, L.Y., et al., Correlation between CD105 expression and postoperative recurrence and metastas is of hepatocellular carcinoma.  BMC Cancer, 2006. 6 : p. 110.  
47. Rubatt, J.M., et al., Independent prognostic relevance of microvessel density in advanced epi[INVESTIGATOR_28080]31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol, 2009. 112(3): p. 469 -74. 
48. Taskiran, C., et al., The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer, 2006. 16 (5): p. 1789 -93. 
49. Saad, R.S., et al., Endoglin (CD105) and vascular endothelial growth factor as 
prognostic markers in esophageal adenocarcinoma. Hum Pathol, 2005. 36(9): p. 955- 61. 
50. Kyzas, P.A., N.J. Agnantis, and D. Stefanou, Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch, 2006. 448(6): p. 768 -75. 
51. Marioni, G., et al., Endoglin expression is associated with poor oncologic outcome in 
oral and oropharyngeal carcinoma. Acta Otolaryngol, 2006. 126(6): p. [ADDRESS_27442] of chemotherapy on the 
serum endoglin. Clin Cancer Res, 2001. 7 (3): p. 524 -32. 
53. Shiozaki, K., et al., Antiangiogenic chimeric a nti-endoglin (CD105) antibody: 
pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. 
Cancer Immunol Immunother, 2006. 55(2): p. 140 -50. 
54. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1). Eur J Cancer, 2009. 45(2): p. 228 -47. 
Page 68 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
55. Rokhlin, O.W., et al., Differential expression of endoglin on fetal and adult hematopoietic cells in 
human bone marrow.  J Immunol, 1995. 154(9): p. 4456 -65. 
 
  
Page 69 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
20. APPENDICES  
20.1. Appendix  1:  National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE)  
The NCI CTCAE (Version 4.0) should be used to assess Adverse Events and may be reviewed 
on-line at the following NCI website:  
http:// evs.nci.nih.gov/ftp1/CTCAE/CTCA E_4.03_2010- 06-14_QuickReference_5x7.pdf  
  
Page 70 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
20.2. Appendix 2:  ECOG Performance Status  
 
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work.  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of waking hours.  
3 Capable of only limited self -care, confined  to bed or chair more than 50% of waking hours.  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair.  
5 Dead.  
 
  
Page 71 of 72  
 
[IP_ADDRESS] Clinical Protocol    105CC201 Protocol Amendment #3  
   17Dec2015 
20.3. Appendix 3:  Avastin Package Insert  
The FDA approved bevacizumab package insert should be referenced and m ay be reviewed on -
line at the following FDA website:  
http://www.gene.com/gene/products/information/pdf/avastin -prescribing.pdf  
 
Page 72 of 72  
 
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
PROCEDURES IN CASE O F EMERGENCY  
Table 1:  Emergency Contact [CONTACT_28159]  [ADDRESS_27443] 
San Diego, CA [ZIP_CODE] Office: (858) 550 -0780 x233 
Mobile Phone: (858) 344 -9400 
Email: [EMAIL_437]
 
 
Page 2 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
1. SYNOPSIS 
Name [CONTACT_790]/Company: TRACON Pharmaceuticals, Inc.  
Name [CONTACT_791]: TRC105 
Name [CONTACT_3261]: TRC105  
Title of Study:  
A SINGLE PATIENT PROTOCOL  OF TRC105 COMBINED WITH STANDARD-
DOSE BEVACIZUMAB FOR A SINGLE PATIENT WITH METAS TATIC AND 
REFRACTORY CHORIOCARCINOMA  
Study center(s): This study will be performed at one US center in one patient . 
Investigator: Neil Horowitz, MD  
Studied period (years):  
Estimated date patient enrolled: October 2015  Phase of development: 2 
 
Rational e:  
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) that 
inhibits angiogenesis and extends survival in patients with a wide variety of solid tumor types.  TRC105, a monoclonal antibody to endoglin, an angiogenic target highly expressed on the tumor vessels and the t umor cells in choriocarcinoma.  TRC105 has been well 
tolerated when dosed with bevacizumab in more than 50 patients with advanced cancer.  Together, these antibodies may be efficacious in metastatic an d refractory choriocarcinoma , a 
tumor type that is highly vascular and expresses endoglin.   
Objectives  
Primary:  
• To determine PFS and ORR of one patient with metastatic and refractory 
choriocarcinoma by [CONTACT_28160] β - hCG  
Secondary:  
• To determine PFS and ORR of one patient with metastatic and refractory choriocarcinoma by [CONTACT_393] 1.1  
• To determine the frequency and severity of adverse events as assessed by [CONTACT_28113] (Version 4.0) 
• To explore the effects of TRC105 and bevacizumab on circulating angiogenic 
protein biomarkers  
Methodology:  
This is a feasibility  study of TRC105 in combination with standard dose bevacizumab in a 
patient  with metastatic and refractory choriocarcinoma  for whom curative therapy is 
unavailable.  TRC105 will be administered weekly in combination with bevacizumab .  The 
patient  will receive  bevacizumab on days 1 and 15 of each 28 day cycle and will receive 
Page 3 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
TRC105 on days 8, 11, [ADDRESS_27444] weekly dose of TRC105 will be split with 3 mg/kg administered on cycle 1 
day 8 and 7 mg/kg  administered on cycle 1 day 11, and then the full dose of 10 mg/kg given 
on cycle 1 day 15 and weekly thereafter.  
Number of patients (planned):  
One patient  
Diagnosis and main criteria for inclusion:  
Inclusion Criteria:  
1. Willing ness and abi lity to consent for self to participate in study   
2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory 
tests, and other study procedures  
3. Measurable disease by [CONTACT_393] 1.1  and elevated serum β -hCG  
4. Histologically proven gestational trophoblastic disease that has  progressed des pi[INVESTIGATOR_28081]:   
1. Prior treatment with TRC105  
2. Serious dose -limiting toxicity related to prior bevacizumab  
3. Current treatment on another therapeutic clinical trial  
4. Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despi[INVESTIGATOR_28065] (initiation or adjustment of BP medication prior to study entry  is 
allowed provided that the average of 3 BP readings at a visit prior to enrollment is < 140/90 mm Hg)  
5. Symptomatic pericardial or pleural effusions  
6. Uncontrolled peritoneal effusions requiring paracentesis more frequently than every 2 
weeks  
7. Active bleeding or pathologic condition that carries a high risk of bleeding (i.e. hereditary hemorrhagic telangiectasia)  
8. Thrombol ytic or anticoagulant use (except to maintain i.v. catheters) within [ADDRESS_27445] day of study therapy  
9. Cardiac dysrhythmias of NCI CTCAE grade  ≥ [ADDRESS_27446] 6 months, unless 
treated for the condition and complete resolution has been documented by 
[CONTACT_28116] (EGD) within 28 days of sta rting study treatment  
Page 4 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency 
syndrome (AIDS) related illness  
14. Other severe acute or chronic medical or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or may 
interfere with the interpretation of study results and, in the judgment of the 
Investigator, would make the patient inappropriate for this study  
Investigational product dose and mode of administration:  
Following the appropriate premedication regiment, TRC105 is to be administered 
intravenously over 1 to 4 hours (+/ - 15 minutes) on days 8, 11, 15, and 22 of cycle 1 and on 
days 1, 8, 15 and 22 of all subsequent cycles .  There is a +/ - 15 minute window for all 
infusions.   
Duration of treatment:  
The patient  may continue on treatment  until disease progression, unacceptable toxicity or 
withdrawal of consent, or other reasons.   
The patient  should be withdrawn from study treatment if, in the opi[INVESTIGATOR_689], it 
is medically necessary, or if it is the wish of the patient.  In addition, the patient will be 
withdrawn from treatment in the case of:  
1. Disease Progression.  Progressive D isease as defined by a  rise of more than 10% 
above baseline or nadir in serum  β- hCG  on [ADDRESS_27447] to follow -up or noncompliant.  
4. Any TRC105 dose delay ≥ 8 weeks.  
5. Arterial thrombosis of any grade (including cerebrovascular ischemia, cardiac ischemia/infarction, or periphera l or visceral arterial ischemia) or grade 4 
thromboembolism. For grade 3 venous thromboembolism hold bevacizumab treatment .  IF the planned duration of full dose anticoagulation is < 2 weeks, 
bevacizumab should be held until the full dose anticoagulation period is over.  If the planned duration of full dose anticoagulation is > [ADDRESS_27448] a pathologic condition that carries high risk of bleeding (i.e. 
tumor involving major vessels).  2.  Subject has not had any hemorrhagic events on study.  3.  The subject has a stable dose of heparin or have an in -range INR (usually 
2-3) on a stable dose of warfarin prior to restarting bevacizumab.  4.  I f 
thromboemboli sm worsens/recurs upon resumption of bevacizumab, despi[INVESTIGATOR_28082], bevacizumab should be discontinued.  
Page 5 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Reference therapy, dosage and mode of administration:  
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and 
inhibits the biologic activity of human vascular endothelial growth factor (VEGF).  Bevacizumab will be administered intravenously at a dose of 1 0 mg/kg on day  1 and 15 of 
each 2 8-day cycle prior to TRC105 (except on cycle 1 day 1 when TRC105 is not to be 
administered)
.  The initial bevacizumab dose should be delivered over [ADDRESS_27449] 
infusion is well tolerated, the second infusion may be administered over 60 minutes. If the 60-minute infusion is well tolerated, all subsequent inf usions may be administered over 30 
minutes.  Following bevacizumab, the line should be flushed with normal saline before TRC105 administration 30 minutes later.  
Criteria for evaluation:  
Safety : 
A formally chartered in -house TRACON Safety Review Team will  review safety data. Safety 
assessments include adverse events (AEs), physical exams, performance status, laboratory results (complete blood counts and serum chemistry) and 12- lead ECG’s (i f the patient 
develop s an arrhythmia).   
Efficacy : 
Preliminary evidence of antitumor activity will be assessed by [CONTACT_28161] β -hCG tumor 
marker.  
Statistical methods:  
No statistical analyses are planned  
Page 6 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
 
TABLE OF CONTENTS  
1. SYNOPSIS  ...................................................................................................................3  
2. INTRODUCTION  ......................................................................................................16  
2.1. Background  .................................................................................................................16  
2.1.1.  Angiogenesis and Cancer  ...........................................................................................16  
2.1.2.  CD105 and Angiogenesis  ...........................................................................................16  
2.2. TRC105 Background  ..................................................................................................18  
2.2.1.  Studies with TRC105  ..................................................................................................18  
[IP_ADDRESS].  105ST101 Phase 1 Monotherapy  ................................................................................19  
[IP_ADDRESS].  Phase 1b 105ST102 Study with Bevacizumab  ...........................................................21  
[IP_ADDRESS].  Phase 2 105CC201 Single Patient Study of TRC105 with Bevacizumab ..................23  
2.2.2.  Description of Bevacizu mab .......................................................................................24  
[IP_ADDRESS].  Rationale for Adding TRC105 to Bevacizumab  .........................................................[ADDRESS_27450]  .......................................................................................................................29  
3. TRIAL OBJECTIVES AND PURPO SE ....................................................................30  
3.1. Primary:  ......................................................................................................................30  
3.2. Secondary:  ..................................................................................................................30  
4. INVESTIGATIONAL PLAN  .....................................................................................31  
4.1. Overall Study Design and Plan: Description  ..............................................................31  
4.1.1.  Trial Overview  ............................................................................................................31  
4.1.2.  Trial Procedures  ..........................................................................................................31  
[IP_ADDRESS].  Screening  ....................................................................................................................31  
[IP_ADDRESS].  Trial Period  .................................................................................................................[ADDRESS_27451] AWAL OF THE PATIENT  .......................................37  
5.1. Patient Inclusion Criteria  ............................................................................................37  
Page 7 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
5.2. Exclusion Criteria:  ......................................................................................................37  
5.3. Patient Withdrawal Criteria  ........................................................................................38  
6. TREATMENT OF THE PAT IENT ............................................................................39  
6.1. Description of TRC105 Study Drug ...........................................................................39  
6.2. Composition of TRC105 .............................................................................................39  
6.3. TRC105 Dose Levels  ..................................................................................................39  
6.4. TRC105 Packaging and Labeling ...............................................................................39  
6.5. TRC105 Storage and Shippi[INVESTIGATOR_007]  ...................................................................................39  
6.6. TRC105 Preparation  ...................................................................................................39  
6.7. TRC105 Administration  .............................................................................................40  
6.7.1.  TRC105 Dose Modification/Dose Interruptions  ........................................................[ADDRESS_27452] 1.1 ........................................................47  
[IP_ADDRESS].  Target Lesions  ............................................................................................................47  
Page 8 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
[IP_ADDRESS].  Non-Target Lesions  ....................................................................................................48  
[IP_ADDRESS].  Determination of Overall Response by [CONTACT_393] 1.1  ..................................................48  
8. ASSESSMENT OF SAFETY .....................................................................................50  
8.1. Safety Parameters  .......................................................................................................50  
8.1.1.  Laboratory Safety Assessments  ..................................................................................50  
[IP_ADDRESS].  Hematology, Serum Chemistry, Coagulation  .............................................................50  
[IP_ADDRESS].  Urinalysis  ....................................................................................................................50  
8.1.2.  Other Safety Assessments ...........................................................................................50  
[IP_ADDRESS].  Physical Examination  .................................................................................................50  
[IP_ADDRESS].  Vital Signs  ..................................................................................................................51  
[IP_ADDRESS].  Performance Status  .....................................................................................................51  
[IP_ADDRESS].  ECG  ............................................................................................................................51  
8.2. Adverse Events  ...........................................................................................................51  
8.2.1.  Definition of Adverse Event  .......................................................................................51  
8.2.2.  Serious Adverse Events  ..............................................................................................52  
[IP_ADDRESS].  Hospi[INVESTIGATOR_059]  ............................................................................................................53  
8.3. Reporting Adverse Events  ..........................................................................................54  
8.3.1.  Eliciting Adverse Event Information  ..........................................................................54  
8.3.2.  Adverse Event Reporting Period  ................................................................................54  
8.3.3.  Reporting Requirements  .............................................................................................54  
8.3.4.  Recording Adverse Events in the Case Report Forms  ................................................55  
8.3.5.  Grading of Adverse Event Severity  ............................................................................55  
8.3.6.  Relationship to TRC105 Study Drug ..........................................................................56  
8.3.7.  Exposure in Utero  .......................................................................................................56  
8.3.8.  Expectedness ...............................................................................................................56  
8.3.9.  Follow -up of Unresolved Adverse Events  ..................................................................56  
8.4. Safety Monitoring .......................................................................................................57  
9. OTHER ASSESSMENTS  ..........................................................................................58  
9.1. Other Laboratory Assessments  ...................................................................................58  
9.1.1.  Protein Biomarker  .......................................................................................................58  
10. STATISTICS  ..............................................................................................................59  
10.1.  Data Analysis  ..............................................................................................................59  
Page 9 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
10.1.1.  Analysis of Primary Objective....................................................................................59  
10.1.2.  Analysis of Secondary Objectives  ..............................................................................59  
[IP_ADDRESS].  Protein Biomarkers  .....................................................................................................[ADDRESS_27453] ACCESS TO SOU RCE DATA/DOCUMENTS  .........................................[ADDRESS_27454] (IRB)/Independent Ethics Committee (IEC)  ..................[ADDRESS_27455] of the Study  ......................................................................................62  
13.3.  Written Informed Consent  ..........................................................................................62  
13.4.  Patient Compensation  .................................................................................................62  
14. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  .......................................................63  
14.1.  Inspection of Records  .................................................................................................63  
14.2.  Retention of Records  ..................................................................................................63  
15. DEFINITION OF END OF  TRIAL  ...........................................................................65  
15.1.  End of Trial  .................................................................................................................65  
15.2.  TRACON Discontinuation Criteria  ............................................................................65  
16. PUBLICATION OF TRIAL  RESULTS  ....................................................................66  
17. FINANCING AND INSURANCE  .............................................................................67  
18. INVESTIGATOR PROTOCO L AGRE EMENT: 105CC201B .................................68  
19. REFERENCES  ...........................................................................................................69  
20. APPENDICES  ............................................................................................................73  
Appendix 1:  N ational Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE)  ..........................................................................................73  
Appendix 2:  ECOG Performance Status .......................................................................................74  
Appendix 3:  Avastin Package Insert  .............................................................................................[ADDRESS_27456] OF TABLES  
Table 1:  Emergency Contact [CONTACT_7171]  ...................................................................................2  
Table 2:   Abbreviations and Specialist Terms  ..........................................................................12  
Table 3:   Schedule of Assessments  ............................................................................................34  
Table 4:  Allowable TRC105 Dose Modifications  ....................................................................42  
Table 5:  Management of TRC105 Infusion Reactions  .............................................................43  
Page 10 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Table 6:  Response Evaluation Criteria in Solid Tumors  ..........................................................48  
Table 7:  Adverse Event Grading  ...............................................................................................55  
  
Page 11 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Table  2:  Abbreviations and Specialist Terms  
Abbreviation or specialist term  Explanation  
ADCC  Antibody -Dependent Cell -mediated Cytotoxicity  
AE Adverse Event  
AFP Alpha Fetoprotein  
AIDS  Acquired Immunodeficiency Syndrome  
ALKs  Activin receptor -Like Kinases  
ALT  Alanine Aminotransferase  
ANC  Absolute Neutrophil Count  
AST  Aspartate Aminotransferase  
AUC  Area Under the Curve  
AUC last Time of Last Measurable Concentration of Area Under the 
Curve  
BALB/c mice  Mouse Strain  
BUN  Blood Urea Nitrogen  
β-hCG  Beta human chorionic gonadotropin  
CA-125 Cancer Antigen -125 
CABG  Coronary Artery By[CONTACT_28099]® 
Prednisone  
CL Clearance  
Cmax Maximum Serum Concentration  
CPA  Cyclophosphamide  
CR Complete Response  
CRF  Case Report Form  
CT Computed Tomography  
CTC  Common Terminology Criteria  
dL Deciliter  
Page 12 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
DLT  Dose Limiting Toxicity  
DVT  Deep Vein Thrombosis  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
ECM  Extracellular Matrix  
EGFR  Epi[INVESTIGATOR_28083] -Linked ImmunoSorbent Assay  
EMA -CO Etoposide, methotrexate, actinomycin, cyclophosphamide, 
vincristine  
EMA -EP Etoposide, methotrexate, actinomycin, etoposide, cisplatin  
EOS  End of Study  
FDA  Food and Drug Administration  
G Gram  
GCP  Good Clinical Practice  
GTD  Gestational Trophoblastic Disease  
GTN  Gestational Trophoblastic Neoplasia  
HACA  Human Anti -Chimeric Antibodies  
HAMA  Human Anti -Murine Antibodies  
Her-[ADDRESS_27457]  
HIV Human Immunodeficiency Virus  
HRA  Health Regulatory Authority  
HUVECs  Human Umbilical Vein Endothelial Cells  
ICE Ifosfamide, carboplatin, etoposide  
ICH International Conference on Harmonization  
ID Identification  
IEC Independent Ethics Committee  
IgG Immunoglobulin G  
Page 13 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
IgM Immunoglobulin M  
INR International Normalized Ratio  
IP Intraperitoneal  
IRB Institutional Review Board  
i.v. Intravenous  
Kd Avidity Binding Constant  
Kg Kilogram  
L Liter  
LDH  Lactate Dehydrogenase  
LOQ  Limit of Quantification  
μL Microliter  
Mg Milligram  
mL Milliliter  
MAC  Methotrexate, actinomycin, cyclophosphamide  
MACA  Monkey Anti -Chimeric Antibody  
MAMA  Monkey Anti -Murine Antibody  
MI Myocardial Infarction  
Mm Millimeter  
MRI  Magnetic Resonance Imaging  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
NCIC  National Cancer Institute of Canada  
Ng Nanogram  
NHP  Nonhuman Primate  
NOAEL  No Adverse Effect Level  
PBS Phosphate -Buffered Saline  
PD Progressive Disease  
PDGF  Platelet Derived Growth Factor  
PlGF  Placental Growth Factor  
Page 14 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
pM Pi[INVESTIGATOR_28084]105  Soluble CD105/endoglin  
SCID  Severe Combined Immunodeficient  
SD Stable Disease  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
SGPT  Serum Glutamic Pyruvic Transaminase  
SN6j  Murine parent antibody of TRC105  
sVEGFR2  Soluble VEGF Receptor 2  
TGF-β Transforming Growth Factor  
TP/TE  Paclitaxel, cisplatin/paclitaxel, etoposide  
TSH  Thyroid Stimulating Hormone  
ULN  Upper Limit of Normal  
US [LOCATION_002] of America  
VEGF  Vascular Endothelial Growth Factor  
Page 15 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
2. INTRODUCTION  
2.1. Background  
2.1.1. Angiogenesis and Cancer  
Angiogenesis is required for the survival and growth of solid cancers [1, 2].  It is generally 
accepted that solid cancers have two phases, an avascular phase and a vascular phase [2].  During 
the initial avascular phase, tumors exist as small aggregates of malignant cells supported by [CONTACT_28100].  The progressive growth of solid cancers beyond 
clinically occult sizes requires the continuous formation of new blood vessels, a process known 
as tumor angiogenesis.  Tumor growth and metastasis require angiogenesis.  Therefore, inhibition of tumor angiogenesis and selective inhibition of the tumor vasculature represent 
potentially effective strategies for the prevention and treatment of solid cancers.   
Therapi[INVESTIGATOR_28085].  First, except for female reproduction and wound heal ing, 
angiogenesis in adults is generally part of a pathologic process such as tumor growth or choroidal neovascularization.  Second, treatments that interrupt tumor angiogenesis should apply broadly to all solid cancers.  Third, angiogenic targets are pres ent in the plasma or on endothelial 
cells themselves.  These targets are readily accessible to antibody treatments, in contrast to targets expressed within tumors that are more difficult for antibodies to access.  Fourth, angiogenic targets on vascular end othelial cells are less prone to genetic mutation than targets 
expressed by [CONTACT_28162].  As a result, development of resistance may be more predictable for agents that target endothelial cell functions than for those targeting cancer  
cells.  
Indeed, agents that target pathways required for tumor angiogenesis have an important role in the therapy of cancer patients.  The monoclonal antibody bevacizumab, which binds to the angiogenic cytokine VEGF, significantly prolongs overall survival for pat ients with advanced 
colorectal cancer or non -small cell lung cancer when added to standard chemotherapy regimens 
[3, 4].   Bevacizumab is also indicated for ren al cell cancer, breast cancer and malignant glioma 
[5-7] with published evidence of cli nical benefit in other solid tumor types.  Orally available 
small molecule VEGF inhibitors include sunitinib, sorafenib, pazopanib and axitinib, all of which have been shown to prolong survival in patients with metastatic renal cell cancer and/or hepatocel lular cancer [8-11].   
2.1.2. CD105 and Angiogenesis  
CD105 (endoglin) is a homodimeric cell membrane glycoprotein that was initially identified as a human leukemia- associated antigen [12] and later also found on endothelial cells [13, 14].  The 
expression pattern of CD105 is relatively restricted and CD105 is mainly expressed on immature 
B-lineage/myeloid leukemia cells and endothelial cells [12, 13]. CD105 is a TGF -β coreceptor 
that is essential for angiogenesis [15, 16].  CD105 is strongly expressed on the prolif erating 
vascular endothelium of solid tumors [14, 17]. All of these properties make CD105 a good target 
for the antiangiogenic therapy of cancer [18]. Vascular targeted therapy may be more effective 
for destroying large established tumors than conventional antiangiogenic therapy such as anti -
VEGF therapy [19].  In animal models, CD105 targeted therapy has demonstrated both vascular 
Page 16 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
targeting effects and antiangiogenic effects by [CONTACT_28102] [14 , 20-23]. 
Therefore, CD105 offers a novel alternative target relative to the VEGF inhibitors currently 
available for antiangiogenesis therapy.  CD105 expression is requi red for endothelial cell 
proliferation, and CD105 is upregulated in the setting of hypoxia through the induction of hypoxia -inducible factor -1-α (HIF -1-α) [24, 25].  CD105 has also been show to protect hypoxic 
cells from apoptosis [26].   
CD105 acts to modulate signaling of multiple kinase receptor complexes of the TGF -β 
superfamily, including T GF-β receptors, activin receptor -like kinases (ALKs) and activin 
receptors [27].  In the absence of CD105, activation of TGF -β receptors results in 
phosphorylation of SMAD proteins that inhibit endothelial cell growth.  However, activation of CD105 by [CONTACT_28163] F-β modulates SMAD protein phosphorylation.  The end result is release of the 
growth inhibitory effects of TGF -β receptor activation on endothelial.  Not surprisingly, 
prevention of CD105 activation by [CONTACT_14181] -CD105 antibody acts synergistically with TGF -β to 
inhibit endothelial cell growth [28].   
The expression of CD105 by [CONTACT_28103].  Targeted inactivation (knockout) of murine CD105 results in defective vascular 
development.  Mice lacking CD105 die in utero from defective vascular developm ent by 
[CONTACT_28104] 11 [16].   
CD105 is critical for normal human blood vessel development [29].  CD105 haplotype insufficiency causes a well -described syndrome known as hereditary hemorrhagic telangiectasia 
type 1 (HHT -1 or Osler-Weber -Rendu Syndrome).  HHT -1 is a rare autosomal dominant genetic 
disorder characterized by [CONTACT_28105], buccal, gastrointestinal mucosa and skin microvasculature.  Angiodysplasia also occurs in vessels from internal organs including the lungs, liver and brain [30].  The genotype is manifested in utero, but the phenotype 
does not become apparent for many years following birth.  Affected patients commonly present 
with epi[INVESTIGATOR_28055].  The phenotype of this disorder is limited to vascular effects, indicating the specific role of CD 105 in the vasculature [31].   
CD105 is highly expressed on the proliferating endothelial cells of tumor vessels including lung, breast, colorectal, gastric, liver, endometrial, renal cell, head and neck, and ovarian cancers.  In adults, CD105 expression can be measured on acti vated monocytes and endothelial cells, and 
expression levels on endothelial cells exceed those on activated monocytes by [CONTACT_3450] 10 -
fold [32, 33].   
Importantly, CD105 expression is increased following inhibition of the VEGF pathway.  CD105 
expression incre ased more than two -fold in human pancreatic cancers grown in mice treated with 
an antibody that binds VEGF [34].  As well, treatment of human bladder cancers grown in mice 
with an antibody that blocks activation of the VEGF receptor increased CD105 expression within 
the core tumor vasculature [35].   
CD105 expression is a prognostic factor in solid tumor patients.  Higher numbers of tumor 
vessels expressing CD105 have been correlated with poor prognosis in clinical studies of breast 
cancer [36, 37], lung cancer [38], prostate cancer [39, 40], colorectal cancer [41, 42], gastric 
cancer [43], endometrial cancer [44 ], astrocytic brain tumors [45], hepatocellular carcinoma [46], 
ovarian cancer [47, 48], esophageal adenocarcinoma [49], and head and neck cancer [50, 51].   
Page 17 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Plasma CD105 levels measured by [CONTACT_28106].  In one study, the mean plasma CD105 concentration in 76 patients with 
colorectal cancer 4 -fold higher than the mean value in 40 healthy subjects without cancer [41].   
In the study, a positive correlation was observed between CD105 concentration and stage of 
disease.  For example, patients with advanced cancer had higher plasma CD105 levels than those 
with early -stage disease (r=0.20, p=0.0470).  In another study, the mean sCD105 concentration 
in 59 patients with advanced metastatic solid cancer was 63.8 ng/mL versus 41.0 ng/mL in 
cancer patients without metastases, and 28.3 ng/mL in patients without a cancer diagnosis [52].  
In a study of breast cancer patien ts receiving hormonal therapy, the upper limit of normal for 
soluble CD105 was determined to be 8.70 ng/mL, and patients with elevated CD105 had shorter 
overall survival than those who did not [37].  These sCD105 concentrations are relati vely low 
compared to TRC105 concentrations > 100,000 ng/mL that were safely achieved in cancer 
patients treated with TRC105 monotherapy on Study 105ST101.  
CD105 is expressed directly on certain cancers in addition to its expression on the tumor vessels. Choriocarcinoma is a vascular cancer that arises f rom trophoblast tissue that densely expresses 
CD105.  CD105 has been shown to  induce trophoblastic outgrowth and migration.  Hence, 
patients with choriocarcinoma are viewed as excellent candidates for treatment with angiogenesis inhibitors, especially a therapy that directly targets CD105 expressed on choriocarcinoma.  
2.2. TRC105 Background   
TRC105 is a genetically engineered human/murine chimeric monoclonal antibody directed against human CD105 [53], a growth proliferation receptor found on the surface of normal and 
proliferating endothelial cells.   
The antibody is an IgG1 kappa immunoglobulin containing murine variable region sequences 
and human constant region sequences [53] .  TRC105 has an approximate molecular weight of 
148 kDa. TRC105 has a binding avidity for human CD105 of approximately 5 pM.  
SN6j, the murine parent antibody of TRC105, binds to human umbilical vein endothelial cells (HUVECs) with nearly identical avidity as TRC105.  SN6j has been shown to bind the tumor 
vasculature of malignant tissues including breast, colon, rectum, kidney an d lung cancers and to 
inhibit the growth of tumor xenografts [21 ].  Reactivity with tumor tissues is restricted to the 
tumor endothelium , as CD105 is not generally expressed on epi[INVESTIGATOR_28056] [20 ].  TRC105 
induces ADCC on proliferating HUVECs at low conentrations and induces apoptosis and growth 
inhibition at higher concentrations.  
In trophoblastic cell line TRC105 was shown to directly inhibit  growth in a dose dependent and 
methotrexate independent  manner .  
2.2.1. Studies with TRC105  
Several studies with TRC105 are underway or have been completed.  An open- label, phase 1, 
multicenter study of TRC105 (Study 105ST101) enrolled fifty patients, who were treated until disease progression with TRC105 at 0.01- 15 mg/kg/q2wk or 10 -15 mg/kg/wk.  Studies of 
TRC105 in prostate, bladder, and ovarian cancer and a phase 1b study of TRC105 in 
combination with bevacizumab have also been completed.  Ongoing studies include a phase 1b 
Page 18 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
study of TRC105 in combination with capecitabine in breast cancer, a ph ase 1b study of TRC105 
in combination with sorafenib in liver cancer, a phase 1b study of TRC105 in combination with 
axitinib in renal cell carcinoma, and phase 2 studies of TRC105 monotherapy in liver cancer and in combination with bevacizumab in glioblas toma multiforme (2 studies) and renal cell 
carcinoma.   
[IP_ADDRESS]. 105ST101 Phase 1 Monotherapy  
[IP_ADDRESS].1. 105ST101 Phase 1 Monotherapy Pharmacokinetics  
In Study 105ST101, TRC105 pharmacokinetics were assessed on patients enrolled at doses up to 15 mg/kg weekly.  Circulating TR C105 was not measurable above the lower limit of quantitation 
of the assay (78 ng/mL) in patients receiving doses below 0.3 mg/kg.  TRC105 was measurable above the target concentration based on preclinical data (200 ng/mL) for 4 hours at 0.3 mg/kg, 1 day a t 1 mg/kg, 5 days at 3 mg/kg, and 7 days at 10 mg/kg TRC105 dosed every two weeks.  
Serum concentrations expected to saturate CD105 binding sites (≥ 200 ng/mL) were achieved continuously at 15 mg/kg q2wk and 10 mg/kg weekly, and TRC105 accumulated at 15 mg /kg 
weekly.  
[IP_ADDRESS].2. 105ST101 Phase 1 Monotherapy Immunogenicity 
In Study 105ST101, serum samples for evaluation of TRC105 immunogenicity, including HAMA and HACA, were collected pre- dose on day 1 of each 28 day cycle, at the end of study, 
and then at 4 and 12 weeks after the end of study visit.  
HAMA and HACA data are available from the phase 1 monotherapy TRC105 trial.  Neither HAMA nor HACA were detected in patients treated with CHO -produced TRC105, which will be 
used for all future clinical trials, including this  study.  
[IP_ADDRESS].3. 105ST101 Phase 1 Monotherapy Safety  
A total of 50 patients were treated on Study 105ST101 with escalating doses of TRC105 at 0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 15 mg/kg every two weeks and then 10 and 15 mg/kg weekly.  Dose escalation proceeded stepwise until the top dose was reached.  The m aximum tolerated dose was 
exceeded at 15 mg/kg weekly and the recommended phase 2 dose of TRC105 was therefore determined to be 10 mg/kg weekly.  Three of 4 patients at 15 mg/kg weekly developed grade 3 hypoproliferative anemia (without leucopenia or throm bocytopenia) in cycle 2, and one of the 
three progressed to grade 4 in cycle 3.  Anemia was associated with accumulation of TRC105 and characterized by a low reticulocyte production index.  Additional laboratory and clinical evaluations excluded common cau ses of anemia including blood loss, hemolysis, plasma volume 
expansion, inadequate erythropoietin, iron deficiency, and vitamin B- 12 or folate deficiency.  
The anemia is believed to result from TRC105 -mediated suppression of  proerythroblasts, the 
only cel ls in the bone marrow known to express substantial levels of CD105 [54].  Anemia was 
reversible and manageable with dose reduction and standard supportive measures including erythropoietin and blood transfusion.   
Infusion reactions, anemia, fatigue, epi[INVESTIGATOR_28086]105.  The majority of treatment -related adverse events 
were grade 1 or 2. 
Page 19 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Infusion reactions, among the most common adverse events, were usually with the initial 
TRC105 dose and included one or more of the following signs or symptoms: rigors, 
bronchospasm, urticaria, hypertension, hypotension, tachycardia or bradycardia.  Infusi on 
reactions were initially reported at 1 mg/kg every 2 weeks for patients receiving TRC105 
produced in NS0 cells without premedication.  TRC105 produced in CHO cells was known to 
more potently engage ADCC in vitro  than TRC105 produced in NS0 cells.  Because of this, the 
initial dose level for patients receiving CHO -produced TRC105 was de -escalated to 0.3 mg/kg.  
Despi[INVESTIGATOR_28057]- escalation, the first two patients at 0.3 mg/kg treated with CHO -produced 
TRC105 experienced grade [ADDRESS_27458] dose in the absence of premedication.  The protocol was therefore amended to require a glucocorticoids - based 
premedication regimen and extend the initial infusion duration from 1 to 4 hours.   
The amendment mandating premedication and ext ended initial infusion duration successfully 
reduced the frequency and severity of infusion reactions and allowed dose escalation to continue. 
One additional patient who received CHO -produced TRC105 at 1 mg/kg developed a grade [ADDRESS_27459] dose given over 2 hours.  This patient had experienced a grade 2 
infusion reaction when the dose was administered over 4 hours.  In all three patients with grade 3 infusion reactions, TRC105 was not detectable in serum at the time of dosing, which a llowed de 
novo binding of TRC105 to CD105 expressing endothelium within the vasculature.  Grade 3 
infusion reactions were not observed in patients dosed at 10 or 15 mg/kg who maintained 
TRC105 serum levels known to saturate CD105 binding sites for the full  dosing interval.  At 
dose levels where continuous TRC105 serum levels were achieved, glucocorticoids were safely 
discontinued and the infusion duration reduced to 1 hour.  
Three patients developed grade 1 cutaneous telangiectasia on the trunk early in the course of therapy, all at dose levels of 10 or 15 mg/kg weekly that resulted in continuous serum levels of TRC105 known to saturate CD105 sites on human endothelium.  Grade 1 or 2 hemorrhage was 
reported, including intermittent postcoital vaginal bleeding (that also occurred prior to TRC105 
treatment), epi[INVESTIGATOR_3940], and superficial gingival bleeding.    
Grade 1 or 2 headaches were observed, mainly in patients treated at doses of TRC105 above 3 
mg/kg.  Headaches began the day following infusion and were general ly manageable with 
acetaminophen.  However, grade 2 headache in one patient at 15 mg/kg weekly prompted 
discontinuation prior to completion of the dose -limiting toxicity evaluation period.  Fatigue was 
one of the more common adverse events attributable to TRC105 and was more prevalent at doses above 3 mg/kg.   
One patient developed dose- limiting toxicity of grade 4 hemorrhage presenting as melena from a 
gastric ulcer within 5 days of the initial TRC105 infusion at 0.1 mg/kg.  He discontinued TRC105 treatmen t, was transfused 2 units of packed red blood cells and the bleeding resolved 
with nonsurgical management by [CONTACT_28107].  Serious bleeding was not 
observed following protocol amendment to exclude patients with a history of peptic ulcer dis ease 
(unless healing was documented) and patients on ulcerogenic medications including non -
steroidal anti -inflammatory drugs.  
Classic toxicities associated with VEGF inhibition, including hypertension, proteinuria and 
thrombosis were not prominent.  One p atient with recurrent anal cancer treated at 0.1 mg/kg 
developed proteinuria considered possibly related to TRC105, but proteinuria was also noted 
Page 20 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
prior to TRC105 dosing.  Transient hypertension (156/112) without QT changes occurred in a 
single patient one day following infusion of 15 mg/kg, and was controlled by a single dose of 
oral antihypertensive medication. There were no arterial or venous thromboembolic events, nor gastrointestinal or other perforations in these patients.    
[IP_ADDRESS].4. 105ST101 Phase 1 Monother apy Efficacy 
In study 105ST101 stable disease ≥ 2 months was observed in 21 of 45 patients (47%) and stable disease ≥ 4 months in 6 of 44 patients (14%).  Decreases in CEA, PSA, or CA -125 were noted in 
7 of 21 patients (33%) and a global decrease in key an giogenic biomarkers was observed with 
treatment.  One patient with castrate- refractory prostate cancer remains on TRC105 treatment 
after 6 years at a TRC105 dose of 0.01 mg/kg every 2 weeks.  He has an ongoing complete PSA response, with resolution of bone  pain and bone scan normalization. One patient with metastatic 
carcinosarcoma, manifested decreased tumor burden on computerized tomographic scanning and maintained stable disease for 20 months on therapy. The latter is especially notable when one considers that this patient had received three prior treatments --  carboplatin + paclitaxel for [ADDRESS_27460] favorable clinical  outcome and did so 
as a fourth- line therapy.   
[IP_ADDRESS]. Phase 1b 105ST102 Study with Bevacizumab  
[IP_ADDRESS].1. 105ST102 Summary of Safety  
Administration of TRC105 at a dose of 3 mg/kg weekly in combination with bevacizumab was well tolerated by [CONTACT_28164] (DLT) and 
dose escalation occurred per the protocol to cohort 2 (6 mg/kg TR105 weekly).  However, the 
concurrent administration of 6 mg/kg TRC105 and bevacizumab on day 1 resulted in the 
development of moderate or severe headaches (including two grade 3 headaches) in four of five treated patients.  The 6 mg/kg dose of TRC105 was tolerated when the initial TRC105 dose was 
delayed one week following bevacizumab dosing at 10 mg/kg every two weeks.  Tolerability 
was further improved when the initial dose of TRC105 was given over two days during the first week of TRC105 dosing, and dose escalation proceeded to the recommended phase 2 dose of 10 mg/kg TRC105 weekly.  At the recommended phase 2 dose of both drugs (10 mg/kg), TRC105 
serum concentration were present above target concentration continuously and immunogenicity 
was rarely observed.  
A total of [ADDRESS_27461] adverse events were graded as 1 or 2 and Grade 4 and 
5 suspected adverse even ts were not observed. Grade 3 suspected adverse reactions included 
anemia (the dose limiting toxicity of TRC105 established as a single agent; 9 patients), headache 
(4 patients; three of which occurred prior to adjusting the schedule of TRC105), fatigue (2 
patients), brain abscess (1 patient), infusion reaction (in a patient dosed at 6 mg/kg), and 
decreased appetite (1 patient). Headache was the most common suspected adverse event and 
Page 21 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
occurred in 31 patients (86.1%); three patients (7.9%) experienced migrai ne headaches (two of 
grade 1 and one of grade 2 severity). Headaches were treated with triptans and NSAIDs.  
Two patients experienced serious adverse suspected events as described below.  One of the grade 
3 headaches (in a patient dosed at 8 mg/kg without s plitting the initial TRC105 dose over two 
days) resulted in hospi[INVESTIGATOR_28058].  One patient dosed at 10 mg/kg of TRC105 experienced a serious suspected event of grade 3 brain abscess.  Serious adverse events, considered unrelated to TRC105 treatment, included: grade [ADDRESS_27462] myocardial infarction during a period of 
hemodynamic instability while hospi[INVESTIGATOR_057]; grade 3 ileus at the time of symptomatic disease 
progression; grade 5 disease progression; grade 3 left foot cellulitis; grade 3 recurrent 
pneumothorax; grade 3 small bowel obstruction; grade [ADDRESS_27463] one sign of the triad of epi[INVESTIGATOR_3940], gingival bleeding and telangiectasia, reflecting vascular 
ectasia characteristic of the Osler -Weber -Rendu syndrome of endoglin haplotype insufficiency 
(i.e., an autosomal dominant genetic disorder of heterozygous endoglin expression) was observed frequently.  One of these signs or symptoms (of grade 1 or 2 seve rity) was noted in one of three 
patients treated at 3 mg/kg, four of eight patients treated at 6 mg/kg, four of eight patients treated 
at 8 mg/kg and in all nineteen patients treated at 10 mg/kg of TRC105, generally within the first 
month of dosing.  These  signs and symptoms are an expected pharmacologic effects of TRC105 
binding to the endoglin receptor (i.e., they are characteristic of the Osler -Weber -Rendu 
syndrome, that is caused by [CONTACT_28109]), and were also observed routinely within t he first month of dosing of 10 mg/kg weekly in the single agent TRC105 dose escalation 
study.   
Infusion reactions were, as expected, more notable at lower doses, and were rare at the MTD of TRC105 of 10 mg/kg, when TRC105 serum concentrations were maintai ned continuously.  Two 
of nineteen patients (10%) dosed with 10 mg/kg of TRC105 each experienced a single infusion 
reaction of grade 2 severity, both with the initial dose of TRC105, that required a brief 
interruption of the infusion prior to completion of the scheduled dose.  
Clinically significant anemia was not reported in patients dosed with 3 mg/kg or 6 mg/kg of 
TRC105, was reported in three of seven patients (43%; all grade 3) dosed with 8 mg/kg of 
TRC105, and was observed in nine of 19 (47%; three of grade 2 and six of grade 3 severity) of patients dosed with 10 mg/kg of TRC105.  Anemia prompted transfusion of packed red blood 
cells in 10 patients and growth factors were used in five patients.  
Other, less frequent, suspected adverse reactions included hypothyroidism, periorbital edema 
(which was generally noted prior to splitting the initial dose of TRC105), gingival pain, nausea, 
oral pain, vomiting, edema, decreased appetite, dyspnea, nasal congestion, rash and flushing.  
Other adverse events character istic of each individual drug were not increased in frequency or 
severity when the two drugs were administered together.  Of note, the concurrent administration of bevacizumab and TRC105 did not potentiate the known toxicities of bevacizumab of 
hypertensio n, hemorrhage (including tumor- associated hemorrhage, and pulmonary hemorrhage 
or hemoptysis), or proteinuria.  Reversible posterior leukoencephalopathy syndrome (RPLS), 
congestive heart failure, fistulae, gastrointestinal perforation impaired wound healin g, and 
arterial thromboembolic events, were not observed.  
Page 22 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Notably, hypertension and proteinuria , known adverse events of bevacizumab, were rarely 
observed when bevacizumab was given with TRC105.  Mild and transient clinically significant 
hypertension or bl ood pressure increases were observed in five patients (13%; grade 3 in one 
case (prior to dosing with study drugs) and grade 2 in four cases) and mild transient proteinuria 
was observed in two patients (5%; both grade 2).  
[IP_ADDRESS].2. 105ST102 Summary of Efficacy 
The combination of TRC105 and bevacizumab was active in patients with advanced refractory 
cancer who had progressed on prior bevacizumab or other VEGF inhibitor treatment.  Thirty -
three patients had measurable disease (31 patients) or evaluable disease (2 patients) at baseline and received at least one follow up scan and were evaluable for the primary efficacy outcome of ORR by [CONTACT_393] 1.1.  Eighteen patients with measureable disease (58%) had a best response of 
stable disease or partial response.  Two patients ( 6%), both of whom had been treated with 
bevacizumab and chemotherapy prior to study entry and were then treated at the top dose level of 
TRC105 and bevacizumab, had RECIST 1.1-  defined partial responses, including one patient 
with colorectal cancer remained on treatment for more than 28 months.  A total of 14 patients (45%) had decreases in overall tumor burden, of whom 10 received prior VEGF inhibitor treatment (usually bevacizumab with chemotherapy).  Notably, the duration of treatment with 
TRC105 and bev acizumab of six patients ( 20% of those with measureable disease) exceeded the 
duration of treatment of the most recent treatment regimen containing a VEGF inhibitor (i.e., 
VEGFR TKI or bevacizumab), received prior to study entry.  These six patients had decreases in 
tumor burden and several were responders by [CONTACT_28110].  Time to progression 
ranged from 0 to 861 days.  Reductions in tumor markers ranging from 5% to 85% were 
observed in 15 of 28 (54%) patients with relevant tumor markers.  Three patients demonstrated 
clinical benefit throughout the study (patient 10038102 at cycle 12 day 22, patient 10018106 at 
cycle 7 day 22 and patient 10028101 at cycle 17 day 1); two of them continue to receive 
treatment under a continuation protocol (105CON101).  
[IP_ADDRESS]. Phase 2 105CC201  Single Patient Study of TRC105 with Bevacizumab  
A patient with metastatic and refractory gestational trophoblastic neoplasia was previously treated with a laparoscopic hysterectomy and the following chemotherapy regimens: EMA -CO, 
EMA -EP, TE -TP, ICE, autologous stem cell, and capecitabine.  Despi[INVESTIGATOR_28087]. She was en rolled on a single patient trial of TRC105 plus bevacizumab  
(protocol 105CC201). The patient experienced a complete response with normalization of her β -
hCG after [ADDRESS_27464] included grade 1 epi[INVESTIGATOR_3940], 
fatigue, and bloody gums, grade 2 headache and gingivitis, and grade 3 hypertension.  A 
TRC105 dose reduction to 8 mg/m
2 was required with the 4th cycle secondary to gingivit is. 
Consolidation therapy is ongoing.   
[IP_ADDRESS].1. Background on Choriocarcinoma  
Gestational trophoblastic disease (GTD) is the term used to describe a group of rare diseases that 
originate in the placenta and have the potential to locally invade the uterus and metastasize. The 
pathogenesis of GTD is unique because the maternal tumor arises from gestational rather than 
Page 23 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
maternal tissue.  The major histologic entities for this disease include complete molar pregnancy, 
partial molar pregnancy, invasive mole, and choriocarcinoma.  Molar pregnancies although 
benign are considered to be prema lignant because they have the capability of developi[INVESTIGATOR_28059] a 
malignancy. The term gestational trophoblastic neoplasia (GTN) is used when molar and non-
molar pregnancies become malignant, and comprise the morphologic entities of invasive mole 
and choriocarcinoma.  Choriocarcinoma consists of invasive, highly vascular and anaplastic trophoblastic tissue made up of cytotrophoblasts and syncytiotrophoblasts without villi. 
Choriocarcinoma metastasizes hematogenously and can follow any type of pregnancy, but mos t 
commonly develops after comple te hydatidiform mole .  The most common metastatic site is the 
lungs which are involved in over [ADDRESS_27465] relapse/resistance to monotherapy, multiagent chemotherapy regimens are 
used.  These regimens include EMA -CO, EMA -EP, TE-TP and are often able to produce cure for 
these women.  Rarely, if standard chemotherapy options have been ineffective there are reports of salvage with use of 5 -FU or stem cell transplant.   
2.2.2. Description of Bevacizumab  
Bevacizumab (Avastin®) is an IgG [ADDRESS_27466] cancer, 
glioblastoma, and metastatic renal cell carcinoma.   
[IP_ADDRESS]. Rationale for Adding TRC105 to Bevacizumab  
TRC105 is a novel angi ogenesis inhibitor that complements bevacizumab in preclinical models.  
Together, these antibodies may result in more effective angiogenesis inhibition in a patient with 
choriocarcinoma, given the vascular nature of this tumor and direct expression of CD105 on the 
cancer cells.  
Page 24 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
2.3. Patient Background  
The patient is a [ADDRESS_27467] chemothe rapy 
options available:  
• In February of [ADDRESS_27468] 
radiograph was negative;  CT showed > 20 pulmonary nodules. β -hCG was 667 and 
dilation and curettage confirmed choriocarcinoma . β-hCG increased  to 1,946. 
• The patient received [ADDRESS_27469] cycle. Pulmonary  lesions improved 
but the vascular uterine mass persisted . 
• Laparoscopic hysterectomy was completed on 26July2013  
• The patient received EMA -CO x [ADDRESS_27470] cycle. 
• On 9Jan2014, β -hCG increased  to 8.1. Chest CT showed left upper lobe lesion. Video 
assisted thoracoscopic resection revealed  pathology consistent with  choriocarcinoma. 
β-hCG was 38.3 on 23Jan2014. 
• The patient received EMA -EP from  30Jan2014 through 20Mar2014. Β-hCG 
normalized at cycle 2, and she received 4 cycles of consolidation . 
• By [CONTACT_11713]2014 β -hCG increased from 1.4 to 90. PET/CT was negative.  
• The patient received TP/TE from  7July2014 through 25Sept2014. On 7July2014, β -
hCG was  178.5 and decreased to a minimum value of 6.9 on 18Aug2014, and then 
started increas ing. 
• The patient was admitted to hospi[INVESTIGATOR_307] 28July2014 - 1Aug2014 for cough and fever. 
New pulm onary  changes were s een on CT (new ill -defined pulmonary nodules  that 
were indeterminant and may have represent ed inflammation  or malignant  disease), β-
hCG had decreased to 18.8 during that admission. 
• β-hCG was relatively stable on 9Sept2014 , but increas ed to 33 on 23Oct2014.  
• On 16Sept 2014, MRI revealed no convincing evidence of metastatic disease in the 
abdomen and a 1.1 cm right adrenal hemorrhagic  nodule without convincing 
enhancement.  
• On 19Sept 2014, PET/CT was negative.  
• On 24Oct 2014 the patient i nitiated treatment with  carboplatin AUC 4 and 
gemcitabine 800mg/m2.  β-hCG was  57.2  
• On 13Nov 2014 (C2D1 of carbo/gem ), β-hCG was 33.4; On  C2D8, β -hCG was 6.7.  
• On 4Dec 2014 (C3D1 of carbo/gem ) β-hCG  was 2.9. 
• On 11Dec 2014 (C3D8 of carbo/gem), β -hCG was  6.9 
Page 25 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
• On 18Dec 2014, β -hCG was  6.3. 
• On 24Dec 2014 (C4D1 of carbo/gem ), β-hCG  was 5.8 
• On 31Dec 2014 (C4D8 of carbo/gem), β -hCG  was 9.2. 
• On 8Jan 2015 (Off  treatment  week ), β-hCG was 9.6.  Subsequent β -hCGs noted to 
increase to 32 and then 76. 
• The patient began ICE treatment on 23 Jan2015. β -hCG wa s 106.  
• The second cycle of ICE began on 12 Feb2015. β -hCG was 79.  
• The third cycle of ICE began on 5Mar 2015.  β -hCG was  55.2.  
• On 26Mar 2015, β -hCG was  57 
• On 2 Apr2015 β -hCG was 197, and the patient began treatment with  capecitabine at  
2500mg/m2 divided twice daily  (2500 mg qAM, 2000 mg q PM). 
• On 7May 2015, β -hCG was 351.5. PET/CT showed enlarging and PET enhancing  
right adrenal lesion. Percutaneous biopsy  revealed  choriocarcinoma.  
• On 28May2015 the patient underwent laparoscopic right adrenalectomy. Path ology  
confirm ed choriocarcinoma with positive margin. Plan had been for re -resection. 
However, repeat imaging on 6/19/15 showed new bilateral pulmonary nodules too 
small to be FDG avid but concerning for met astatic disease.  
• On 25June2015 the patient s tarted on Ola parib 400 mg twice daily and progression 
was noted  after 2 cycles.  
• On 24Aug2015 the patient s tarted single agent c arboplatin for palliation and remains 
with persistent disease. 
2.4. Potential Risks and Benefits to Human Patients  
2.4.1. Potential Risks  
TRC105 
Grade [ADDRESS_27471] been the source of gingival bleeding and epi[INVESTIGATOR_3940].  Telangiectasia are also seen in patients with hereditary hemorrhagic telangiectasia (HHT), a disease of CD105 haplotype 
Page 26 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
insufficiency.  Patients with HHT are at risk of hemorrhage from abnormal blood vessels and this 
could be  exacerbated by [CONTACT_28112]105.  Other contraindications to TRC105 therapy 
include a history of significant hemorrhage or tumors located in the central chest or another 
location where bleeding is associated with high morbidity.  All patients treated  with TRC105 
should be monitored for signs of hemorrhage and the risks and benefits of drug treatment reevaluated in any patient with hemorrhage.  
Premedication including the use of glucocorticoids is required prior to infusion of TRC105 to 
reduce the frequ ency and severity of infusion reactions.  Infusion reactions following TRC105 
dosing generally occur with the first TRC105 dose and include a grade 4 vasovagal reaction that 
resolved without sequellae.  Signs and symptoms of TRC105 infusion reactions include 
hypertension, hypotension, dyspnea, bronchospasm, chills/rigors, chills, sweats, fever, nausea, 
tachycardia, bradycardia, EKG changes, flushing, urticaria, pruritus, and headache, generally of grade 1 and 2 severity. Potential infusion reactions seen wi th other therapeutic antibodies include 
angioedema, asthenia, throat irritation, rhinitis, vomiting, joint pain, fatigue and neurologic disorders including inflammation of the spi[INVESTIGATOR_20793]/or brain.  
Hypersensitivity reactions with infusions are a potential r isk for sensitized patients, and TRC105 
should be used with caution in patients with known hypersensitivity to any component of the drug product.  Host anti -TRC105 antibodies to the murine or human portions of CHO -produced 
TRC105 are rare.  In general, the  risk of immunogenicity to therapeutic chimeric antibodies is 
small (<10%) and the clinical significance of immunogenicity is not well defined.  The current trial will collect serial blood samples for anti -product antibody concentrations to further 
charact erize the immunogenicity of TRC105 and potential clinical implications.  
Grade 3 cerebrovascular hemorrhage resulting in hemiparesis occurred in one patient with hepatocellular cancer who was thrombocytopenic (who entered the study with a platelet count of 60,000/uL) in a study of TRC105 with sorafenib.  A grade 2 transient ischemic attached was 
reported in a study of TRC105 and pazopanib. Transient Grade 3 hepatic encephalopathy 
occurred in one patient with cirrhosis and hepatocellular carcinoma who received TRC105 in combination with sorafenib.   Grade 3 pancreatitis was also observed in this study.  Grade 5 
intracranial hemorrhage occurred in one glioblastoma patient with markedly abnormal blood clotting parameters in a study of TRC105 with bevacizumab.  A patient with glioblastoma 
developed temporary confusion and slurred speech following treatment with TRC105 and 
bevacizumab that required hospi[INVESTIGATOR_28061].  Another patient with glioblastoma 
who underwent resection and had a history of an abnormal collection of cerebral spi[INVESTIGATOR_28088] a grade 2 cerebral spi[INVESTIGATOR_28062].  
Grade 3 myocardial infarction (non- Q wave infarct associated with hypertension following an 
infusion reaction) was observed in a patient with hepatocellular cancer f ollowing treatment with 
TRC105 that resolved without sequelae.  In addition, a Grade 5 myocardial infarction occurred in 
a patient with coronary artery disease who received TRC105 in combination with sorafenib. 
Patients with evidence of active coronary art ery disease are excluded from participation in this 
trial (see exclusion criteria).   
Adult respi[INVESTIGATOR_28063]105 with pazopanib, from which the patient recovered. Of note, interstitial lung disease has been  added as an adverse drug reaction and warning/precaution to the core 
Page 27 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
safety information for pazopanib.  Pneumothorax (collapsed lung) has been observed in trials of 
TRC105 administered with a VEGFR TKI in patien ts with lung metastases.  
A patient with renal cell carcinoma treated with TRC105 and axitinib developed grade [ADDRESS_27472] been observed rarely. 
Grade 3 infected lipoma/cyst was observed in a Phase [ADDRESS_27473] been observed in fewer than 5% of patients and have largely been considered unrelated to treatment with TRC105.  
Grade [ADDRESS_27474] also been reported.  A patient 
receiving treatment wit h TRC105 and sorafenib developed self- limited pancreatitis of grade 2 
severity.  
Bevacizumab  
Side effects associated with the use of bevacizumab include gastrointestinal perforation, hypertension, impaired wound healing, an increased incidence of arterial thromboembolic 
events, venous thromboembolic events (including pulmonary embolism), hemorrhag e (including 
tumor- associated hemorrhage, mucocutaneous hemorrhage, and pulmonary hemorrhage or 
hemoptysis), proteinuria, rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS), congestive heart failure, fistulae, hypothyroidism, hypersen sitivity reactions, headache 
and infusion reactions. Increased rates of severe neutropenia, febrile neutropenia, or infection 
with severe neutropenia (including some fatalities) have been observed in patients treated with 
some myelotoxic chemotherapy regim ens plus bevacizumab in comparison to chemotherapy 
alone.  
No specific studies in animals have been performed to evaluate the effect of bevacizumab on fertility. There are no adequate and well -controlled studies in pregnant women.  
Immunoglobulins are excreted in milk, although there are no data specifically for bevacizumab 
excretion in milk. Since bevacizumab could harm infant growth and development, women should 
Page 28 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
be advised to discontinue breastfeeding during bevacizumab therapy and not to breast feed for at 
least [ADDRESS_27475] dose of bevacizumab.   
 
Computed Tomography (CT) Scans  
The patient  will be exposed to a small amount of radiation as a result of the CT scans required in 
this study.  This degree of exposure has not been associated with harmful health effects. In addition, the frequency of CT scans performed in this study is similar to the standard of care 
frequency.  
Venipuncture  
The patient  could also experience side effects from venipuncture for tests that will be done as 
part of this  study including pain, tenderness or bruising at the site of collection, and rarely 
infection may occur at the spot where the needle is inserted.  
Other Risks  
This patient has had a hysterectomy so any concerns to unborn children are not an issue for this study.   
2.4.2. Potential Benefits  
TRC105 is an investigational product, and its efficacy has not been established.  It is possible that the administration of TRC105 in combination with bevacizumab may result in clinical benefit (i.e., tumor response or prolonged stable disease) beyond the benefit that is expected 
from bevacizumab alone.  
2.5. Conduct  
This clinical trial will be conducted in compliance with the protocol, GCP, and the applicable regulatory requirements.  
Page 29 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
3. TRIAL OBJECTIVES AND  PURPOSE  
3.1. Primary:  
• To determine PFS , and ORR of one patient with metastatic and refractory 
choriocarcinoma by [CONTACT_28160] β -hCG  
3.2. Secondary:  
• To assess To determine PFS and ORR of one patient with metastatic and refractory 
choriocarcinoma by [CONTACT_393] 1.1  
• To determine the frequency and severity of adverse events as assessed by [CONTACT_28113] (Version 4.0) 
• To explore the effects of TRC105 and bevacizumab on circulating angiogenic protein 
biomarkers  
Page 30 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
4. INVESTIGATIONAL PLAN  
4.1. Overall Study Design and Plan: Description  
4.1.1. Trial Overview  
This is a sin gle patient protocol of TRC105 in combination with standard dose bevacizumab in 
one patient with metastatic and refractory choriocar cinoma for whom curative therapy is 
unavailable. TRC105 will be administered weekly in combination with bevacizumab.  The 
patient will receive bevacizumab on days [ADDRESS_27476] weekly dose of TRC105 should be split with 3 mg/kg administered on cycle 1 day 8 and  the balance of the weekly TRC105 dose administered on cycle 1 day 11, and then the full dose 
given on cycle 1 day 15 and weekly thereafter.  
4.1.2. Trial Procedures  
All on -study procedures are permitted within the time window indicated in the Schedule of 
Assessments ( Table 3).  
[IP_ADDRESS]. Screening  
The following screening procedures must be performed within [ADDRESS_27477] day of 
study therapy.  Hematology , serum chemistry, coagulation, and urinalysis collected within 7 days 
of cycle 1 day 1 do not need to be repeated. The following will be performed according to the 
Schedule of Assessments ( Table 3).  
• Patient signature [CONTACT_28182] (IRB) approved informed consent form. Prior to undergoing any study -specific procedure, the patient must read 
and sign the current Institutional Review Board (IRB) approved informed consent 
form.  The patient  may sign consent prior to the 30 day screening period. 
• Medical history, prior  cancer therapy, prior cancer surgery, prior radiation therapy, 
drug allergies, disease present at screening, primary diagnosis and demographics.  
• Physical examination including examination of all major body systems, ECOG performance status, and vital signs . 
• Hematology, coagulation (PT or INR) and serum chemistry to be performed locally.  
• Urinalysis to be performed locally.  
• CT or MRI scans of chest, abdomen and pelvis in addition to any other applicable 
sites of disease. Brain and bone scans to be performed i f metastasis is suspected prior 
to starting the study.  
• Single tracing 12 -Lead ECG (QT, PR and QRS intervals and heart rate will be 
captured).  
• Assessment of Adverse Events (serious and nonserious) from the date of informed 
consent. 
Page 31 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
• Assessment of concomitan t medications from 30 days prior to the start of study 
treatment.  
[IP_ADDRESS]. Trial Period  
Hematology , blood chemistry, urinalysis, and physical examination  do not need to be repeated 
on cycle 1 day 1 if acceptable screening assessments are performed within 7 days pr ior to the 
start of study therapy. On days of dosing, all assessments should be performed prior to dosing 
with the combination of TRC105 and bevacizumab unless otherwise indicated in the Schedule of 
Assessments. The patient  will initially receive 2 cycles (approximately 8 weeks) of treatment.  If 
the patient demonstrates a response of CR, PR or SD, she  will be eligible for additional treatment 
until progression.  Each cycle is 4 weeks in duration. The following will be performed according to the Schedule of  Assessments ( Table 3).  
• Physical examination including examination of all major body systems, ECOG 
performance status, and vital signs.  
o Assessment of vital signs during TRC105 infusion: Vital signs are to be 
assessed pre -infusion (within 30 minutes of starting TRC105 infusions) and 
every 30 minutes during the infusion.  Vital signs should be monitored more frequently and/or beyond the completion of the infusion if medically indicated (e.g. if the patient experiences an infusion reaction that has not yet resolved).  
• Hematology, coagulation (PT or INR) and serum chemistry to be performed locally.  
• Urinalysis to be performed locally. Microscopic analysis should be performed as 
clinically indicated.  
• Blood sampling for tumor markers (e.g. β -hCG), to be analyzed locally.  
• Blood sampling for angiogenic protein biomarkers.  Samples will be analyzed by a 
third party laboratory (see laboratory manual for specific instructions regarding 
collection, processing, storage and shipment). 
• CT or MRI scans of chest, abdomen and/or pelvis in addition to any other applicable 
sites of disease. Scan of the chest, abdomen, and pelvis to be performed on- study as 
outline d in the assessment table. Known areas of disease should be consistently 
followed throughout the study.  Assessments should be performed whenever disease progression is suspected.  Allowable window for tumor imaging studies is +/ - 7 days. 
Brain and bone sc ans are to be performed if metastasis is suspected.  
• Administration of TRC105. TRC105 diluted in normal saline will be administered according to the schedule of assessments as a 1 to 4 hour infusion (+/ - 15 minutes) 
following premedication (see Section  6.7 and Table 3). TRC105 will be administered 
intravenously utilizing an infusion pump.  TRC105 must be administered using a low protein binding, non-DEHP infusion set with a 0.2 micron downstream filter.  
Duration of infusion administration may be increased as medically necessary. The 
allowable dosing window is +/ - 2 days. 
• Administration of bevacizumab on day 1 and 15 of each 28- day cycle as described in 
the bevacizumab package insert.  
Page 32 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
• Assessment of TRC105 and bevacizumab drug accountability.  
• Assessment of adverse events.  
• Assessment of concomitant medications and concomitant treatments.  
4.1.3. End of Study Assessments  
Assessments need to be completed if they were not completed during the previous 2 weeks on 
study.   The following will be performed according to the Schedule of Assessments ( Table 3).  
• Physical examination including examination of all major body syst ems, ECOG 
performance status, and vital signs.  
• Hematology, coagulation (PT or INR) and serum chemistry to be performed locally.  
• Urinalysis to be performed locally. Microscopic analysis should be performed as 
clinically indicated.  
• Blood sampling for tumor m arkers (e.g. serum β -hCG), to be analyzed locally.  
• Blood sampling for angiogenic protein biomarkers.  Samples will be analyzed by a 
third party laboratory (see laboratory manual for specific instructions regarding collection, processing, storage and shipme nt). 
• CT or MRI scans of chest, abdomen and pelvis in addition to any other applicable 
sites of disease.  
• Assessment of adverse events.  
• Assessment of concomitant medications and concomitant treatments.  
4.1.4. Post Treatment Follow -up 
The following will be performed  according to the Schedule of Assessments ( Table 3 ). Adverse 
events should be followed for 28 days after completion of study protocol  
• Assessment of adverse events. The Investigator should continue to report any related 
or possibly related adverse events that occur beyond the adverse event reporting 
period. 
• Assessment of concomitant medications and concomitant treatments.  
• Long term survival telephone c all every 2 months for 2 years following 
discontinuation. 
 
Page 33 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Table 3:   Schedule of Assessments   
 
 
 Screening
Day -30Day 1 
[1,2]Day 8 
[1]Day 11
[1]Day 15 
[1]Day 22 
[1]Day 1 
[1]Day 8 
[1]Day 15 
[1]Day 22 
[1]Day 1 
[1]Day 8 
[1]Day 15
[1]Day 22
[1] 28 DaysEvery 2 
Months
Baseline Documentation
Informed Consent [4] X
Medical/Oncology History [5] X
Physical Examination [6] X X X X X
Vital Signs [7] X X X X X X X X X X X X X X X
Laboratory Studies
Hematology [8] X X X X X X X X X X X
Coagulation [8] X X X X
Blood Chemistry [8] X X X X X X X X
Thyroid Stimulating Hormone [8] X X X X X
Urinalysis [9] X X X X X
Treatment w/ Study Drug
TRC105 Dosing [10]X X X X X X X X X X X X 
Bevacizumab Dosing [11] X X X X X X 
Tumor Assessments
CT or MRI Scans [12] X X Cycles 4, 
6, 8 etc. X
Other Clinical Assessments
12-Lead ECG [13] X
Concomitant Medications/Treatments [14] X X X X X X X X X X X X X X X X
Baseline Signs and Symptoms [15] X
Adverse Events [15] X X X X X X X X X X X X X X X
Special Laboratory Assessments
Protein Biomarkers [16] X X X X
Tumor Markers [17] X X X X X
Long Term Follow-Up
Phone Call Long Term Follow-Up X
*Allowable window for each visit within the cycle is +/- 2 day unless otherwise stated
**Allowable window for Post Treatment Follow-up is +/- 1 weekProtocol Activities*Cycle 3+
Responding Patients [18]End
of
Study
[3]*Cycle 1 *Cycle 2**Post Treatment 
Follow-up [19]
Page 34 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Schedule of Assessments Footnotes 
1. Days of Treatment with TRC105: All assessments should be performed prior to dosing with TRC105/bevacizumab unless otherwise 
indicated.  Each cycle is 28 days in  duration. . 
2. Cycle 1 day 1: Hematology, blood chemistry, urinalysis, and physical examination not required if acceptable screening assessment is 
performed within 7 days prior to the start of treatment on cycle 1 day 1.  
3. End of Study: Assessments do not need to be repeated if performed within the previous 2 weeks (previous 4 weeks for radiologic 
tumor assessments). Follow -up visits should occur [ADDRESS_27478] dose of TRC105 study drug as outlined in the Schedule of 
Assessme nts.  
4. Informed Consent: Must be obtained prior to undergoing any study specific procedure and may occur prior to the 30- day screening 
period. 
5. Medical/Oncologic History and Demographics: To include information on prior anticancer therapy.  
6. Physical  Examination: Examination of major body systems and ECOG performance status.  
7.  Vital Signs:  Heart rate, temperature, blood pressure, respi[INVESTIGATOR_697], weight. Assessment of Vital Signs during TRC105 Infusion: 
Vital signs are to be assessed pre- infusion (within 30 min of starting TRC105 infusions) and every 30 minutes during the infusion.  Vital 
signs should be monitored more frequently and/or beyond the completion of the infusion if medically indicated (e.g. if the pa tient 
experiences an infusion reactio n that has not yet resolved).   
8. Hematology, Chemistry & Coagulation:  Testing to be performed locally.  If the patient has a Monday visit she may complete safety 
lab assessments on the Friday prior to the visit. In addition to the assessments scheduled for the clinical trial, patients should undergo 
assessment as appropriate to ensure safe treatment. Thyroid stimulating hormone (TSH) is to be collected at screening and on day 1 of 
each cycle.  
9. Urinalysis:  To be performed locally. Microscopic analysis s hould be performed as clinically indicated.  
10. TRC105 Administration: IV TRC105 diluted in normal saline will be administered as outlined in the schedule of assessments.    
11. Bevacizumab Administration: Commercially available bevacizumab will be administered per the package insert in this study. The 
patient  will receive 10 mg/kg as outlined in the schedule of assessments.   
12.    CT or MRI Tumor Imaging: Images of chest, abdomen, and pelvis to be performed at screening and on -study as outlined in the 
assessment table. Known areas of disease should be consistently followed throughout the study.  Assessments should be perform ed 
whenever disease progression is suspected. Allowable window for tumor imaging s tudies is +/ - [ADDRESS_27479].  
13. 12-Lead ECG: Single tracing 12 -lead ECG will be performed at screening (pre- dose). If the patient develops a n arrhythmia, the ECG 
should be repeated on day 1 of each subsequent cycle. 
14. Concomitant Medications and Treatments: Concomitant medications and treatments will be recorded from [ADDRESS_27480] dose of study treatment.  
Page 35 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
15. Baseline Signs and Symptoms and Adverse Events: The patient  must be followed for safety from the day of informed consent until 
at least [ADDRESS_27481] resolved or are determined to 
be “chronic” or “stable”, whichever is later.  Adverse events occurring prior to the initiation of the study treatment will b e considered 
"Baseline- Signs and Symptoms ” and will be recorded on “Medical Histo ry and Baseline Signs and Symptoms” case report forms. Events 
that occur from the time the patient has taken the first dose of bevacizumab and/or TRC105 study drug through [ADDRESS_27482] 
dose of bevacizumab and/or TRC105 study drug (whichever is la ter) will be recorded on “Adverse Event” CRFs. Any serious AE that is 
possibly related to TRC105 occurring from the time of first dose or at any point after the reporting period must be promptly reported to 
TRACON. 
16. Protein biomarkers:  5 mL of plasma (K 3EDTA) will be collected as indicated in the schedule of assessments and stored at 
approximately -70°C to be analysed by a central laboratory. Samples will be batch shipped every [ADDRESS_27483] -party laboratory for 
analysis. See separate laboratory gu ide for further collection and shipment information. 
17. Tumor markers: Will be collected and analysed locally as indicated in the schedule of events (e.g.: β -hCG)  
18. Cycle 3+ Treatment: If the patient  demonstrates  a response of CR, PR or SD will be elig ible for additional treatment until 
progression as long as TRC105 drug supply is available.  
19. Follow -up:  The initial follow -up visit should occur [ADDRESS_27484] dose of TRC105. Phone calls for long term follow -up 
to be conducted every 2 months for 2 years following the end of study visit.  
 
Page 36 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
5. SELECTION AND WITHDR AWAL OF THE PATIENT  
5.1. Patient Inclusion Criteria  
1. Willingness and ability to consent for self to participate in study   
2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, 
and other study procedures  
3. Measurable disease by [CONTACT_393] 1.1 and elevated serum β -hCG  
4. Histologically proven choriocarcinoma that has progressed despi[INVESTIGATOR_28089]  
5.2. Exclusion Criteria:   
1. Prior treatment with TRC105  
2. Serious dose -limiting toxicity related to  prior bevacizumab  
3. Current treatment on another therapeutic clinical trial  
4. Uncontrolled chronic hypertension defined as sy stolic > 140 or diastolic > 90 despi[INVESTIGATOR_28065] (initiation or adjustment of BP medication prior to study entry is allowed 
provided that the average of 3 BP readings at a visit prior to enrollment is < 140/90 mm Hg) 
5. Symptomatic pericardial or pleural effusions  
6. Uncontrolled peritoneal effusions requiring paracentesis more frequently than every 2 weeks  
7. Active bleeding or pathologic condition that carries a high risk of bleeding (i.e. hereditary hemorrhagic telangiectasia)  
8. Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within [ADDRESS_27485] day  of study therapy  
9. Cardiac dysrhythmias of NCI CTCAE grade ≥ [ADDRESS_27486] 6 months, unless treated for the condition and complete resolution has been documented by [CONTACT_28116] (EGD) within 28 days of starting study tre atment  
13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness   
14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study partici pation or may interfere with the 
Page 37 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
interpretation of study results and, in the judgment of the Investigator, would make the 
patient inappropriate for this study  
5.3. Patient Withdrawal Criteria  
Patient  will be withdrawn from study treatment if, in the opi[INVESTIGATOR_689], it is 
medically necessary, or if it is the wish of the patient.  If the patient  does  not return for a 
scheduled visit, every effort should be made to contact [CONTACT_476].   In any circumstance, every effort 
should be made to document patient outc omes.  Data to be collected at the end of study visit are 
described in the Schedule of Assessments ( Table 3).  Patient  will be followed for at least [ADDRESS_27487] additional 
data. In addition, the patient  will be withdrawn from treatment in the case of:  
1. Disease Progression.  Progressive Disease as defined as a  rise in serum β -hCG of more 
than 10% above baseline or nadir on [ADDRESS_27488] to follow -up or noncompliant.  
4. Patient has a TRC105 dose delay ≥ 8 weeks. 
5. Arterial thrombosis of any grade (including cerebrovascular ischemia, cardiac 
ischemia/infarction, or peripheral or visceral arterial ischemia)  or grade 4 
thromboembolism . For grade 3 venous thromboembolism hold bevacizumab treated.  I f 
the planned duration of full dose anticoagulation is < 2 weeks, bevacizumab should be 
held until the full dose anticoagulation period is over.  If the planned duration of full dose 
anticoagulation is > [ADDRESS_27489] a 
pathologic condition that carries high risk of bleeding (i.e. tumor involving major vessels).  2.  Subject has not had any hemorrhagic events on study.  3.  The subject has a stable dose of hepari n or have an in- range INR (usually 2 -3) on a stable dose of warfarin 
prior to restarting bevacizumab.  4.  I f thromboemboli sm worsens/recurs upon 
resumption of bevacizumab, despi[INVESTIGATOR_28053], bevacizumab should be discontinued. 
Page 38 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
6. TREATMENT OF THE PATIE NT 
6.1. Description of TRC105 Study Drug 
TRC105 is a genetically engineered human/murine chimeric monoclonal antibody directed 
against human CD105 found on the surface of proliferating endothelial cells.   
6.2. Composition of TRC105  
TRC105 is an IgG1, kappa immunogl obulin containing murine light - and heavy -chain variable 
region sequences and human constant region sequences.  TRC105 has an approximate molecular 
weight of 148 kDa.  
6.3. TRC105 Dose Levels  
The p atient will receive  10 mg/kg TRC105 weekly in combination with 10 mg/kg bevacizumab  
every other week on a q 28 day cycle .  
6.4. TRC105 Packaging and Labeling 
 TRC105 may  be provided in one or more of the following presentations : 
 Phosphate Buffered Saline Formulation (7 mg TRC105/mL)  
• 210 mg TRC105/30 mL single -use vial  
or 
20 mM L -Histidine/L -Histidine Monohydrochloride, 240 mM Trehalose,  
0.01% Polysorbate  20 Formulation (25 mg TRC105/mL)  
• 100 mg TRC105/4 mL single -use vial  
• 400 mg TRC105/[ADDRESS_27490] be stored upright between 2 °C and 8 °C (36 °F to 46 °F).  
6.6. TRC105 Preparation  
TRC105 will be prepared in the pharmacy and diluted into normal saline using appropriate 
aseptic technique.  TRC105 will be administered using an in -line 0.[ADDRESS_27491] been 
observed.  Multiple vials will be required for a single dose.  The following formulae should be used to calculate the volume of TRC105 to be added to normal saline:  
• Patient weight (kg) × dose level ( mg/kg) divided by [CONTACT_28117]105 concentration (mg/mL) = 
volume of TRC105 (mL) to be administered. 
The volume of TRC105 that is to be administered can be rounded up or down to the nearest 1.0 mL; in the case of an increment of 0.5 mL the volume should be rounded up.  The maximum 
Page 39 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
weight that should be used for dose calculation in this study is 85 kg (note: there is not a 
weight restriction for enrollment purposes).   The patient weight will be assessed on the day of 
treatment and used for calculation of each TRC105 dose. The calculated volume of TRC105 will 
be diluted with normal saline.  Appropriate judgment should be exercised in withdrawing an 
adequate amount of saline necessary to permit injection of the appropriate volume of antibody 
into a normal saline bag in a ccordance with the dose needed.  The final TRC105 concentration 
must be between 0.3 mg/mL and 10 mg/mL.  The prepared TRC105 must be gently inverted 
several times in order to ensure a homogeneous solution. The diluted infusion solution of 
TRC105 should be used within 8 hours of preparation if stored at room temperature, or within 24 hours of dilution if stored at 2° to 8°C (36º to 46ºF). The expi[INVESTIGATOR_28066].  If the diluted infusion solution of TRC105 cannot be infused within 8 hours of preparation 
(i.e.: the prepared infusion is at room temperature for more than 8 hours), a second bag will be prepared that contains the balance of the planned dose that was not already delivered. The 
prepared solution should not be frozen. 
6.7. TRC105 Administration  
The patient  should be encouraged to drink abundant fluid (e.g. two eight ounce glasses of juice) 
prior to the first treatment.  Intravenous hydration prior to and during therapy is left to the discretion of the Investigator, but should be considered if the patient is thought to be volume 
depleted.  
The following TRC105 premedications should be administ ered 2 hours to 30 minutes prior to the 
start of each infusion:   
• Acetaminophen 650 mg p.o. x 1  
• Methylprednisolone 100 mg i.v. will be given prior to the Cycle 1 Day 8 and 
Cycle 1 Day 11 infusions  only .  In addition, methylprednisolone will be given in 
the case of a delay of ≥  10 days between any two doses or if the patient develops 
an infusion reaction > grade 2 during the immediate prior infusion.  
• Famotidine 20 mg i.v. or p.o. (or similar H2 blocker) x 1. Famotidine (or similar 
H2 blocker) may be discontinued starting with Cycle 2 in the absence of infusion 
reactions with the prior dose. 
• Cetirizine 10 mg i.v. or p.o. x 1 (or similar oral or intravenous antihistamine). 
Cetirizine (or similar oral or intravenous antihistimine) may be discontinued 
starting with Cycle [ADDRESS_27492] study site 
procedures .  
Page 40 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Following the appropriate premedication  regimen, the patient will receive TRC105 on days 8, 
11, [ADDRESS_27493] weekly dose 
of TRC105 will be split with 3 mg/kg administered on cycle 1 day 8 and infused over 4 hours (+/- 15 minute s) and 7 mg/kg administered on cycle 1 day 11 and infused over 2 hours (+/ - 15 
minutes) , and then the full dose of 10 mg/kg given on cycle 1 day 15 and weekly thereafter and 
will be administered over 1 hour (+/ - 15 minutes).  The p atient must complete at l east one 4 hour 
infusion (+/ - 15 minutes) without the development of any infusion reactions, in order to reduce 
the subsequent TRC105 infusion to 2 hours (+/ - 15 minutes) and complete a 2 hour infusion (+/ - 
15 minutes) without the development of any infusi on reactions in order to reduce subsequent 
TRC105 infusions to 1 hour (+/ - 15 minutes).  If the  patient develop s infusion reactions of any 
kind they should be managed appropriately (see Section  6.7.2 ) and the patient is not permitted to 
reduce the duration of the next planned infusion. In the event a dose cannot be completed on a given day, the balance of the planned dose may be administ ered the following day with 
premedication at the rate of infusion planned for the prior day.  
The rate of TRC105 infusion must not exceed 25 mg/min.  When the i.v. bag containing TRC105 is empty, flush the i.v. line with a [ADDRESS_27494] be recorded in the source documents.  
If the patient misses a weekly TRC105 dose (i.e., ≥ 10 days between doses), the 
methylprednisolone dose should be reinstituted as per the init ial infusion and first TRC105 dose 
should be administered over two days as was done for the initial dose.   
6.7.1. TRC105 Dose Modification/Dose Interruptions  
TRC105 dose reductions are allowed for grade 3 or 4 related adverse events that resolve to grade 
1 or ba seline (including anemia).  Treatment dose delays cannot exceed 8 consecutive weeks 
(i.e., both TRC105 and bevacizumab dosing held). However, if the  patient cannot tolerate 
bevacizumab or TRC105 therapy , demonstrates  a response of complete response (CR), partial 
response (PR) or stable disease (SD) with the combination and is thought to benefit from 
continued single agent therapy , the patient  may continue on study on TRC105 or bevacizumab 
alone.  
TRC105 and bevacizumab should be held for two weeks prior and for two weeks following surgical procedures.  
  
Page 41 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Table  4: Allowable TRC105 Dose Modifications  
Toxicity Attributed to 
TRC105  Dose Adjustment for Next Dose of TRC105 (% of Starting Dose)  
Grade 1 or 2  Maintain Dose Level  
Grade 3 or 4   
• 1st appearance  80% 
• 2nd appearance  60% 
• 3rd appearance  Discontinue treatment permanently  
Note: If the patient  is dose  reduced and subsequently misse s a dose whereby [CONTACT_28165]105 following the break needs to be split into two doses, 3 mg/kg should be given on the 
first day and the remainder of the dose (i .e., 5 mg/kg in the case of a dose reduction to 8 mg/kg) 
will be given [ADDRESS_27495] her TRC105 therapy interrupted.  TRC105 therapy may resume once the following 
criteria are met:   
• The patient is on a stable dose of heparin, low molecular weight heparin, coumadin, 
or other anticoagulant.  
• If on coumadin, the patient has an in range INR for therapeutic anticoagulation (usually between 2 and  3). 
• The patient has a platelet count > 50,000  or baseline.  
• The patient has not had a hemorrhagic event of grade 2 or higher while on study.  
• The patient does not have a pathological condition that carries a high risk of bleeding 
(e.g., tumor involving major vessels).  
• The patient is benefiting from TRC105 therapy (no evidence of disease progression).   
The INR should be monitored weekly before each dose of TRC105 for the first 4 weeks, and then once per cycle thereafter (or more often as clinically indicated ).  The patient  should not 
receive TRC105 until the INR is ≤ 3. 
6.7.2. Management of TRC105 Infusion Reactions  
If the  patient  experiences a grade 2 or higher adverse reaction during infusion, the infusion 
should be interrupted and the patient treated accordingly.  Antipyretic, antihistamine, antiemetic, 
anti-inflammatory, or other symptomatic medications including epi[INVESTIGATOR_28090].  For grade 2 and certain grade 3 infusion reactions, the infusion may be restarted 
(i.e., the same day) at half of the previous rate if and when the infusion reaction has resolved, and 
then increased per patient tolerance to  a maximum of 25 mg/min .  For grade 4 infusion reactions, 
the infusion should not be restarted and the patient should be discontinued from study treatment.  
Page 42 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Infusion reactions will be recorded as AEs in the case report form.  Interventions should be 
docume nted as concomitant medications or concomitant treatments as appropriate.   
Table 5:  Management of TRC105 Infusion Reactions  
Infusion Reaction 
Severity  Recommended Management  
Grade 1 (mild)  1. No intervention  
2. Continue infusion unless symptoms worsen  
Grade 2 (moderate)  1. Interrupt infusion  
2. Treat with symptomatic medicationsa 
3. Resume infusion at half the previous rate when infusion- related 
symptoms improve to grade 1 or less.  
Grade 3 (severe)  1. Interrupt infusion  
2. Treat with symptomatic medicationsa 
3. Monitor patient until infusion -related symptoms resolve, including 
hospi[INVESTIGATOR_17116]  
4. Withdraw patient from study unless other factors that contributed to the 
infusion reaction are identified and corrected  
Grade 4 (life -
threatening)  1. Discontinue infusion  
2. Treat with symptomatic medicationsa 
3. Hospi[INVESTIGATOR_28068]  
4. Withdraw from study  
aSymptomatic medications may include but are not limited to diphenhydramine 50 mg i.v. and/or hydrocortisone 
100 mg i.v. (for fever, rash, hypoxia, or other hypersensitivity reactions), meperidine 50- 100 mg i.v. (for shaking 
chills/rigors), oxygen by [CONTACT_28119] (for hypoxia), epi[INVESTIGATOR_238] 0.5 mg i.m. (for hypotension or 
bronchospasm), albuterol inhaler or nebulizer (for bronchospasm ), i.v. fluids (for hypotension), and ondansetron 
0.15 mg/kg i.v. (for nausea).  
6.7.3. TRC105 Study Drug Accountability  
The Investigator must maintain an accurate accounting of TRC105 supplied by [CONTACT_28120].  
During the study, the following information must be record ed: 
• Date of receipt, quantity and lot number of the TRC105 study drug received from 
TRACON  
• ID number of the patient to whom the product is dispensed  
• The date(s) and quantity of the product dispensed 
• Dates and quantity of product returned, lost or accidentally or deliberately destroyed  
Investigational Drug Accountability Logs should be maintained by [CONTACT_28166].  
Page 43 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
6.7.4. TRC105 Study Drug Handling and Disposal  
TRC105 must be stored upright between 2 °C and 8 °C (36 °F to 46 °F). The Investigator should 
not return clinical study materials to TRACON unless specifically instructed to do so by 
[CONTACT_28120].  Disposal of TRC105 should occur in accordance with institutional  policy. The Site 
Pharmacist will be responsible for documenting the destruction (according to institutional 
requirements) of used or expi[INVESTIGATOR_28069]. 
6.8. Bevacizumab Packaging 
Bevacizumab is available as 100 mg pack containing one 4 mL single -dose vial and 400 mg pack 
containing one 16 mL single -dose vial.  
6.9. Bevacizumab Preparation  
Commercially available bevacizumab will be utilized in this study.  The pa tient will receive 10 
mg/kg on day 1 and day 15 of each 28- day cycle.  Bevacizumab should be prepared accordin g to 
institutional policy and using aseptic technique.  Withdraw the necessary amount of 
bevacizumab and dilute to the required administration volume with 0.9% sodium chloride solution.  The concentration of the final bevacizumab solution should be kept wi thin the range of 
1.4-16.5 mg/mL as described in the Avastin PI ( Appendices  – Appendix 3).  
6.10. Bevacizumab Administration  
The pat ient will receive 10 mg/k g on day 1 and day 15 of each 4- week cycle.  Bevacizumab 
should be administered as a 90 minute infusion on cycle 1 day 1.  Subsequent infusion times can 
be reduced by 30 minutes down to a minimum infusion time of 30 minutes if tolerated 
(Appendices  – Appendix 3).  Bevacizumab will be administered according to institutional 
guidelines.  
6.10.1. Bevacizumab Dose Modification  
Dose reduction of bevacizumab for adverse reactions is not recommended.  If indicated, bevacizumab should either be discontinued or temporarily suspended, see bevacizumab package insert for specific information related to different adverse events.  If discontinuation of 
bevacizumab is clinicall y indicated, and the patient demonstrated a response of complete 
response (CR), partial response (PR) or stable disease (SD), she will be eligible for additional 
treatment with TRC105 alone until progression as long as TRC105 drug supply is available.  
6.11. Bevacizumab Drug Accountability  
Commercial bevacizumab will be utilized in this study , thus the site will follow institutional 
guidelines regarding drug accountability for commercial product.  
6.12. Bevacizumab Handling and Disposal  
Bevacizumab vials [100 mg (ND C [ZIP_CODE] -060- 01) and 400 mg (NDC [ZIP_CODE] -061-01)] are stable 
at 2−8°C (36−46°F). Bevacizumab vials should be protected from light. Do not freeze or shake. 
Page 44 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Diluted bevacizumab solutions may be stored at 2−8°C (36−46°F) for up to [ADDRESS_27496] been 
observed. Partially used vials should be properly destroyed according to institution guidelines.  
6.13. Concomitant Medications  
No other approved or investigational anticancer treatment will be permitted during the study period, including chemotherapy, biological response modifiers, immunotherapy, or radiotherapy.   
If the patient is on low dose aspi[INVESTIGATOR_28091] s he may continue it  if medically indicated. If the  
patient is on NSAIDs on study for more than three consecutive days should also receive peptic ulcer disease (PUD) prophylaxis with an H2 or proton pump blocker. 
Narcotic analgesics, nonsteroidals , anti -inflammatory drugs, and triptans (e.g. sumatriptan) may 
be offered as needed for relief of pain or headaches.  Triptans are recommended for patients who 
experience a migraine headache following dosing, and may be taken prior to the occurrence of 
headache, as a prophylactic medication . Antihistamines and decongestants may be offered for the 
treatment of sinus congestion.  
Packed red blood cell, colony stimulating factors, and platelet transfusions should be administered as clinically indicated.   
6.14. Treatment Compli ance  
6.14.1. TRC105  
All TRC105 infusions will occur at the trial site under the direct supervision of the treating physician or his or her designee.  
6.14.2. Bevacizumab  
All bevacizumab infusions will occur at the trial site under the direct supervision of the treating 
physician or his or her designee. 
6.15. Patient Enrollment  
This is a single patient trial.  She will be consented and enrolled at DFCI and followed by [CONTACT_28167] 45 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
7. ASSESSMENT OF EFFICA CY 
7.1. Tumor Assessment by β -hCG  
The primary efficacy assessment will be best overall response as defined in Section 7.3.1.  
Determination of antitumor efficacy will be based on serum β -hCG measurements and 
investigators will make treatment decisions based on these assessments.   
Serum tumor marker (β -hCG) assessments will be performed at screening, and as outlined in the 
Schedule of Assessments ( Table 3). 
7.1.1. Definition  of Tumor Response  
• Complete response (CR)  is defined as normalization of  serum β -hCG  on two 
consecutive measurements separated by [CONTACT_28114]  
• Partial response ( PR) is defined as >  50% decrease of ser um β -hCG from baseline 
on consecutive measurements separated by [CONTACT_28114].  
• Progressive disease (PD)  is defined as a rise in β -hCG of > 10% above the starting 
value or prior nadir on consecutive measurements separated by [CONTACT_28114] . 
• Stable disease (SD)  is defined as absence of response or progression on three 
consecutive β -hCG measurements separated by [CONTACT_28114]  
7.2. Radiologic al Tumor Assessment  
A secondary  efficacy assessment will be best overall response as defined in Section 7.3.1.  The 
determination of radiologic ant itumor efficacy will be based on objective tumor assessments 
made by [CONTACT_28168] 1.1 [55].  All lesions will be classified as 
Target or Nontarget lesions at the Screening visit.  Each lesion designation will be maintained through the course of the study.  
The same metho d and technique should be used to characterize each identified and reported 
lesion at Screening, during the study treatment period, and at the End of Study visit. Imaging -
based evaluation over clinical examination is the required technique when both could be used to 
assess the antitumor effect of the treatment.  Clinical Oncology review of all tumor 
measurements is desired.  
Whenever possible, clinical evaluation of superficial lesions should not be used as the sole form 
of measurement.  However, when necess ary, color photograph with metric caliber is acceptable.  
Tumor evaluation by [CONTACT_28124] (PET) scan or by [CONTACT_28169].  
Radiological tumor assessments will be performed at screening, as outlined in th e Schedule of 
Assessments ( Table 3), and whenever disease progression is suspected.  Another tumor 
assessment will be performed at the End of Study Visit if an assessment has not been performed 
within the prior [ADDRESS_27497] 4 weeks after the initial documentation of response.   
Measurability of Tumor Lesions  
Page 46 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
At Screening, individual tumor lesions will be categorized by [CONTACT_28170]-target according to the RECIST 1.1 criteria described below.  
• Measurable:  Lesions that can be accurately measured in at least one dimension 
(longest diameter to be recorded) as ≥ [ADDRESS_27498] scan.  Clinical lesions 
will only be considered measurable when they are superficial (e.g. skin nodules, palpable lymph nodes) and ≥ [ADDRESS_27499] be measured with 
calipers.  
• Non-Measurable:   All other lesions, including small lesions and bone lesions, 
leptomeningeal di sease, ascites, pleural or pericardial effusions, lymphangitis of the 
skin or lung, abdominal masses that are not confirmed and followed by [CONTACT_28171], previously irradiated lesions, and disease documented by [CONTACT_28126] (e.g. by [CONTACT_28172]).  
7.3. Recording Radiologic Tumor Measurements  
Measurable lesions up to a maximum of 5 lesions representative of all involved organs (with a 
maximum of 2 lesions per organ) should be identified as target lesions and measured and 
recorded at Screening and at the stipulated intervals during treatment.  Target lesions should be 
selected on the basis of their size (lesion with the longest diameters) and their suitability for accurate repetitive measurements (either by [CONTACT_14217]).  Target lesions 
may include lymph nodes with a short ax is > [ADDRESS_27500] diameter will be recorded for each target lesion (with the exception of lymph nodes, 
where the short axis will be used). The sum of the diameter for all target lesions at Screening will 
be calculated and recorded as the baseline su m diameter to be used as reference to further 
characterize the objective tumor response of the measurable dimension of the disease during 
treatment.  All measurements should be performed using a caliper or ruler and should be 
recorded in metric notation in  millimeters.  
All other lesions (or sites of disease) should be identified as non- target lesions and should also be 
recorded at baseline.  Measurements are not required and these lesions should be followed as “present”, “stable”, “absent”, “increased” or “decreased”.  
7.3.1. Definitions of Tumor Response  by [CONTACT_393] 1.1  
[IP_ADDRESS]. Target Lesions  
• Complete response (CR)  is defined as the disappearance of all target lesions and 
normalization of her ser um β -hCG. 
• Partial response (PR)  is defined as a ≥ 30% decrease in the sum of the  dimensions 
of the target lesions taking as a reference the baseline sum dimensions.  
• Progressive disease (PD)  is defined as a ≥ 20% relative increase and ≥ [ADDRESS_27501] sum of the dimensions recorded since the treatment started, or 
the appearance of one or more new les ions and rise of her serum β -hCG.  
Page 47 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
• Stable disease (SD)  is defined as neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD taking as a reference the smallest sum of the 
dimensions since the treatment started.  
[IP_ADDRESS]. Non-Target Lesions  
• Complete response (CR)  is defined as the disappearance of all non -target lesions and 
normalization of tumor marker levels to ≤ ULN.  
• non-CR/non -PD is defined as a persistence of ≥ 1 non- target lesions and/or 
maintenance of tumor marker levels > ULN.  
• Progressive disease (PD)  is defined as unequivocal progression of existing non-
target lesions, or the appearance of ≥ 1 new lesions. 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stable disease and progressive disease.  
[IP_ADDRESS]. Determination of Overall Response by [CONTACT_393]  1.[ADDRESS_27502] increase in the size of one or more non- target lesions is usually 
not sufficient to qualify for unequivocal progression status.  
Table 6: Response Evaluation Criteria in Solid Tumors 
Target Lesionsa Non-target Lesionsb New Lesionsc Overall Response  
CR CR No CR 
CR non- CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all evaluated  Any Response  Yes or No  Not Evaluable  
PD Any Response  Yes or No  PD 
Any Response  PD Yes or No  PD 
Any Response  Any Response  Yes PD 
aMeasurable lesions only.  
bMay include measurable lesions not followed as target lesions or non -measurable lesions.  
cMeasurable or nonmeasurable lesions.  
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest 
Page 48 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
measurements recorded since the treatment started).  The patient’s best r esponse assignment will 
depend on the achievement of both measurement and confirmation criteria.  
NOTE:  If the patient  has a  global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time her best response should 
be reported as “symptomatic deterioration.”  Every effort should be made to document the 
objective progression even after discontinuation of treatment.   
Page 49 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
8. ASSESSMENT OF SAFETY  
8.1. Safety Parameters  
Safety will be characterized in terms of the incidence, timing, severity (graded by [CONTACT_28129] [NCI] Common Terminology Criteria for A dverse Events [CTCAE], Version 
4.0), seriousness, and relatedness of adverse events and laboratory abnormalities.  In addition, physical examination, vital signs, and ECOG performance status will be serially monitored.  Laboratory safety analyses will be b ased on the local laboratory data, and will include 
hematology, serum chemistry (including liver and kidney function), urinalysis, and coagulation profil e.  In addition, an ECG will be recorded at baseline and as clinically indicated throughout 
the study.   
8.1.1. Laboratory Safety Assessments  
Abnormal and clinically significant laboratory tests should be recorded as adverse events.  
[IP_ADDRESS]. Hematology, Serum Chemistry, Coagulation  
Assessments will be performed at the time  points indicated in the Schedule of Assessments 
(Table 3) and analyzed at local laboratories.  Investigators may have additional blood tests performed for the purpose of planning treatment administration, or for following adverse events as clinically indicated.  
• Hematology: CBC with differential and platelet count  
• Coagulation: Prothrombin Time (PT) or Internalized Normalized Ration (INR) will 
be assessed  
• Serum Chemistry: Total bilirubin, alanine tran saminase (ALT), aspartate 
transaminase (AST), alkaline phosphatase, total protein, albumin, sodium, potassium, 
bicarbonate, chloride, calcium, phosphorus, blood urea nitrogen, creatinine, thyroid 
stimulating hormone (TSH), and glucose  
[IP_ADDRESS]. Urinalysis  
Urine ana lysis will be performed at time points indicated in the Schedule of Assessments ( Table 
3) and analyzed by [CONTACT_28130]. Microscopic analysis sho uld be performed as clinically 
indicated.  
8.1.2. Other Safety Assessments  
[IP_ADDRESS]. Physical Examination  
A physical examination including, but not limited to, general appearance, head, eyes, ears, nose, 
throat, neck, heart, chest, abdomen, musculoskeletal, extremities, sk in, lymph nodes, 
neurological genitourinary (as appropriate), and rectal (as appropriate) will be assessed at time     
points indicated within the Schedule of Assessments (Table 3).  The physical examination will 
include examination of known and suspected sites of disease.   
Page 50 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
[IP_ADDRESS]. Vital Signs  
Heart rate, temperature, blood pressure, respi[INVESTIGATOR_28092] ( Table 3). Assessment of vital signs during 
TRC105 infusion: Vital signs are to be ass essed pre -infusion and every 30 minutes during the 
infusion.  Vital signs should be monitored more frequently and/or beyond the completion of the 
infusion if medically indicated (e.g. if the patient experiences an infusion reaction that has not 
yet resolved).  
[IP_ADDRESS]. Performance Status  
The ECOG scale will be used to assess performance status at Screening.  
[IP_ADDRESS]. ECG  
A single 12 -lead (with a 10 –second rhythm strip) tracing will be used for all ECGs.  It is 
preferable that the machine used has a capacity to calculate st andard intervals automatically. 
ECG will be performed according to the Schedule of Assessments ( Table 3) and as clinically 
indicated throughout the study.  
8.2. Adverse Events  
All observed or volunteered adverse events regardless of suspected causal relationship to 
TRC105 study drug and/or bevacizumab will be reported as described below.  
8.2.1. Definition of Adverse Event  
An adverse event is any untoward medical occurrence in a trial patient who is administered a drug or biologic (medicinal product); the event may or may not have a causal relationship with the medicinal product.  Examples of adverse events include, but are not limited to the following:  
• Clinically significant symptoms and signs including:  
o Worsening of signs and symptoms of the malignancy under trial (disease 
progression without worsening of signs and symptoms assessed by 
[CONTACT_28131]).  
o Signs and symptoms resulting from drug overdose, abuse, misuse, withdrawal, sensitivity, dependency, interaction or toxicity.   
o All possibly related and unrelated illnesses, including the worsening of a 
preexisting illness.  
o Injury or accidents.  Note that if a medical condition is known to have caused 
the injury or accident (hip fracture from a fall secondary to dizziness), the medical condition (dizziness) and the outcome of the accident (hip fracture 
from a fall) should be r eported as 2 separate adverse events.   
o Symptoms or signs resulting from exposure in utero . 
Page 51 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
• Abnormalities in physiological testing or physical examination findings that require 
clinical intervention or further investigation (beyond ordering a repeat confirmatory test).  
• Laboratory abnormalities that meet any of the following (Note: merely repeating an 
abnormal test, in the absence of any of the below conditions, does not constitute an 
adverse event.  Any abnormal test result that is determined to be an error  does not 
require reporting as an adverse event.):  
o Test result that is associated with accompanying symptoms  
o Test result that requires additional diagnostic testing or medical/surgical 
intervention  
o Test result that leads to a change in TRC105 study drug do sing outside of 
protocol -stipulated dose adjustments or discontinuation from the trial, 
significant additional concomitant drug treatment, or other therapy  
o Test result that is considered to be an adverse event by [CONTACT_28173]  
8.2.2. Serious Adverse Events  
An adverse event that meets one or more of the following criteria/outcomes is classified as 
serious:  
• Results in death  
• Is life- threatening (at immediate risk of death)  
• Requires in patient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability/incapacity  
• Results in congenital anomaly/birth defect  
• Other important medical events that may not result in death, be life- threatening, or 
require hospi[INVESTIGATOR_708], based upon appropriate 
medical judgment, they may jeopardize the patient or may require medical or surgical 
intervention to prevent one of the outcomes listed above. Examples of such events are intensive treatment in an emergency room for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or the development of 
drug dependence or drug abuse.  
Serious also includes any other event that the Investigator or sponsor judges to be serious, or which is defined as serious by [CONTACT_28174] t he country in which the event occurred.   
Progression of the malignancy under study (including signs and symptoms of progression) 
should not be reported as serious adverse events unless the outcome is fatal during the trial or 
within the safety reporting p eriod. Hospi[INVESTIGATOR_28093].  If the malignancy has a fatal 
outcome during the trial or within the safety reporting period, then the event leading to death 
must b e recorded as an adverse event and as a serious adverse event with CTC grade 5.  
Page 52 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
The onset date of an SAE is defined as the date on which the event initially met serious criteria 
(e.g., the date of admission to a hospi[INVESTIGATOR_307]).  The end date is the date on whi ch the event no longer 
met serious criteria (e.g., the date the patient was discharged from a hospi[INVESTIGATOR_307]).  
[IP_ADDRESS]. Hospi[INVESTIGATOR_28073] -patient hospi[INVESTIGATOR_059], or prolongation of an existing 
hospi[INVESTIGATOR_059], are considered serious.  Any initial admission, even if the duration is less than 24 hours is considered serious. In addition, any transfer within the hospi[INVESTIGATOR_4591]/intensive care 
unit is considered serious (e.g., transfer from the psychiatric wing to a medical floor or transfer from a medical floor to a coronary care unit). However, the following hospi[INVESTIGATOR_28074]:  
• Rehabilitation facility admission  
• Hospi[INVESTIGATOR_28075]  
• Respi[INVESTIGATOR_4594]  
• Skilled nursing facility admission  
• Nursing home admission 
• Emergency room visit  
• Same day surgery  
• Hospi[INVESTIGATOR_28094]:  
o Admission for treatment of preexisting condition not associated  with the 
development of a new adverse event or with a worsening of the preexisting 
condition  
o Social admission  
o Administrative admission (e.g. for yearly p hysical exam)  
o Protocol -specified admission during a clinical trial  
o Optional admission not associated with a precipi[INVESTIGATOR_10244] 
(e.g. for elective cosmetic surgery)  
o Preplanned treatments or surgical procedures  
o Admission exclusively for the  administration of blood products  
• Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery, 
should not be reported as adverse events.  The medical condition for which the 
procedure was performed should  be reported if it meets the definition of an adverse 
event (e.g. acute appendicitis that begins during the adverse event reporting period 
should be reported as an adverse event and the appendectomy should be recorded as a 
concomitant treatment).  
Page 53 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
8.3. Reporting  Adverse Events  
8.3.1. Eliciting Adverse Event Information  
The Investigator is to report all directly observed adverse events and all adverse events 
spontaneously reported by [CONTACT_28134].  In addition, each 
trial patient wi ll be questioned about adverse events at each clinic visit following initiation of 
treatment.  The question asked will be, “Since your last clinic visit have you had any health 
problems?”  
8.3.2. Adverse Event Reporting Period  
Safety information for each patient w ill be collected from the date of informed consent.  Adverse 
events occurring prior to the initiation of the study treatment will be considered "baseline- signs 
and symptoms ” and will be recorded on corresponding case report forms. The adverse event 
reporti ng period for this trial begins when the patient  have  taken the first dose of bevacizumab 
and/or TRC105 study drug and ends [ADDRESS_27503] dose of bevacizumab and/or TRC105 
study drug is administered whichever is later.  All adverse events that occur on trial for this 
patient  during the adverse event reporting period specified in the protocol must be reported to 
TRACON, whether or not the event is considered study treatment -related .  In addition, any 
known untoward event that occurs beyond the adverse event reporting period that the 
Investigator assesses as possibly related to the investigational medication/product should also be 
reported as an adverse event.  
8.3.3. Reporting Requirements  
Each adverse event is to be classified by [CONTACT_28175].  This 
classification of the gravity of the event determines the reporting procedures to be followed.  If a 
serious adverse event occurs, reporting will follow local and international regulations, as appropriate. 
The Investigator must notify  the Sponsor of any event that meets one of the criteria for an SAE 
immediately upon learning of the event.  This notification should be made to:  
Charles Theuer, MD, PhD  
TRACON Pharmaceuticals Inc.  
[ADDRESS_27504] Phone:  (858) 550 -0780 x233  
Cell Phone:  (858) 344 -9400  
Email: [EMAIL_437]  
Following this notification, the Investigator will report the SAE via the AE CRF via the data 
management system.  The initial AE CRF is to be up dated with followed more detailed adverse 
event information within 5 calendar days of the event.  
Page 54 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
In the rare event that the Investigator does not become aware of the occurrence of a serious 
adverse event immediately (for example, if a patient initially seeks treatment elsewhere), the 
Investigator is to report the event immediately upon learning of it and document his/her first awareness of the serious adverse event.  
TRACON Pharmaceuticals Inc. may also be contact[CONTACT_28136] 24 hours a day at ([PHONE_416]. 
Each SAE should be followed until resolution, or until such time as the Investigator determines 
its cause or determines that it has become stable.  Information pertaining to follow -up of SAEs 
should also be sent to the TRACON Pharmaceuticals Inc.  
Serious adverse events that are unexpected and associated with use of the study medication will 
be reported to the US Food and Drug Administration (FDA) and all participating clinical sites by 
[CONTACT_28137].  For events which are fatal or life- threatening, unexpected, and 
associated with use of the investigational product, a [ADDRESS_27505], a written report will 
be made no more than 15 calendar days from the date TRACON learns of the event. 
Participating clinical sites will be notified of these events in parallel.  
All adverse events, including SAEs, are t o be reported on the adverse event CRFs.  
8.3.4. Recording Adverse Events in the Case Report Forms  
The Investigator is to report all directly observed adverse events and all adverse events spontaneously reported by [CONTACT_28138].  In addition, each trial pati ent will be questioned 
about adverse events. All adverse events that meet the criteria specified in Section  8.2.1 are to be 
recorded on patient source documents and on the CRFs.  Adverse events should be reported using concise medical terminology. 
 
8.3.5. Grading of Adverse Event Severity  
To report adverse even ts on the CRFs, the Investigator will use the severity grading as described 
in NCI CTCAE Version 4.0.   
Every effort should be made by [CONTACT_28139]. If the Investigator is unable to assess severit y because the term is not described in NCI 
CTCAE Version 4.0, severity of MILD, MODERATE, SEVERE, LIFE -THREATENING, or 
FATAL may be used to describe the maximum intensity of the adverse event. For purposes of consistency, these intensity grades are defined  as follows:  
Table 7: Adverse Event Grading  
Grade  Non-CTCAE Severity  Definition  
1 Mild  Does not interfere with patient’s usual function  
2 Moderate  Interferes to some extent with patient’s usual function  
3 Severe  Interferes significantly with patient’s usual function  
4 Life-Threatening  Results in immediate risk of patient’s death  
Page 55 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Grade  Non-CTCAE Severity  Definition  
5 Fatal  Results in patient’s death  
Note the distinction between the severity and the seriousness of an adverse event.  A severe 
event is not necessarily a serious event.  For example, a headache may be severe (interferes 
significantly with patient’s usual function) but would not be classifi ed as serious unless it met 
one of the criteria for serious events.     
8.3.6. Relationship to TRC105 Study Drug  
In this study, TRC105 study drug is given in combination with bevacizumab.  The relationship of 
an adverse event to TRC105 study drug should be classi fied by [CONTACT_28140]:  
• Suspected Adverse Reaction: There is a reasonable possibility that TRC105 caused the adverse event (i.e.: there is evidence to suggest a causal relationship between 
TRC105 and adverse event). 
• Not rel ated: there is no reasonable possibility that the adverse event is associated with 
TRC105 study drug.  
AEs related to TRC105 study drug or bevacizumab are considered Adverse Drug Reactions (ADR). 
8.3.7. Exposure in Utero  
This patient is status post a hysterectomy so no exposure in utero is possible.  
8.3.8. Expectedness  
All adverse events and adverse drug reactions are reaction considered “unexpected” if it not 
listed in the investigator brochure or not listed at the specificity  or severity that has been 
observed.   For example, under this definition, hepatic necrosis would be unexpected (by [CONTACT_14213]) if the investigator brochure referred only to elevated hepatic enzymes or hepatitis.  Similarly, cerebral thromb oembolism and cerebral vasculitis would be unexpected (by 
[CONTACT_14214]) if the investigator brochure listed only cerebral vascular accidents. 
"Unexpected," as used in this definition, also refers to adverse events or suspected adverse 
reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned 
as occurring with the particular drug under investigation. 
8.3.9. Follow -up of Unresolved Adverse Events  
All adverse events should be followed until they are resolved or the Investigator assesses them as 
chronic or stable.  Any increase or decrease in adverse event grade should be recorded as a new 
adverse event.  
All serious  and those non- serious events assessed by [CONTACT_28142]/product should continue to be followed even after the patient’s 
participation in the trial is over.  Such events should be followed until they resolve or until the 
Page 56 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Investigator assesses them as “chronic” or “stable.”  The event should also be documented on the 
adverse event CRF.  
8.4. Safety Monitoring 
The TRACON Clinical Team will monitor safety throughout the study via the following 
activities:  
• Surveillance for SAEs according to regulatory guidelines  
• Routine monitoring of non- serious adverse experiences as they are recorded in the 
case report forms and the source documents at study sites  
• A formally chartered TRACON in -house Safety Review Team that i ncludes, among 
other staff, two physicians  
• Periodic teleconferences with the Principal Investigators to share experiences and 
ensure communication  
• Toxicity information that may affect the treatment of this patient  on this study will be 
promptly communicated in writing to all participating clinical sites and institutions 
participating in this clinical trial.  
Page 57 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
9. OTHER ASSESSMENTS  
9.1. Other Laboratory Assessments  
9.1.1. Protein Biomarker  
A 5 mL K 3EDTA plasma blood sample will be collected on the days indicated within the 
Schedule of Assessments ( Table 3).  Samples will be stored at approximately -70 °C and batch 
shipped to Fisher BioServices  Inc. (10 Forge Park, Franklin, MA [ZIP_CODE]) for storage until the 
time of analysis.  Duke University Medical Center will analyze plasma for several biomarkers 
including but not limited to VEGF, PDGF, and TGFβ. Please see the separate laboratory guide 
for further collection and shipment information.  
Page 58 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
10. STATISTICS  
10.1. Data Analysis  
Due to the exploratory nature of this study, no inferential analyses are planned, and no 
imputation of missing data will be done.   
10.1.1. Analysis of Primary Objective  
PFS and ORR will be calculated form the time of cycle [ADDRESS_27506] 1.1 and the frequency and severity of toxicities , efficacy, and angiogenic protein biomarkers will be 
evaluated as described below.  
[IP_ADDRESS]. Protein Biomarkers  
Angiogenic protein biomarker data if the patient received at least one dose of study drug will be 
listed by [CONTACT_28143]. 
Page 59 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
11. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS  
All data entered on CRFs/eCRFs must be verifiable within the patient’s ’ source documents 
(written or electronic record).  The Investigator/institution guarantees TRACON representatives 
and appropriate regulatory authorities direct access to the original source records for the duration 
of the agreed study record retention period.  Printouts of source records that are electronically obtained and stored will not be acceptable for audit/inspection unless provided as certified exact 
copi[INVESTIGATOR_28077].     
Legally protected subject ident ification and other personal health information must be securely 
stored with limited access by [CONTACT_28144]. Unless secure provisions are 
established by [CONTACT_28145] (or designee) to perform remote monitoring of 
electro nic source records, TRACON (or designee) will review source records/data on site and 
will not remove any such protected health information.   
 
Page 60 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
12. QUALITY CONTROL AND QUALITY ASSURANCE  
Monitoring visits to clinical investigator sites will be made by [CONTACT_28176].   
The trial site will also be subject to possible inspection by [CONTACT_21980] (IRB) or 
independent ethics committee ( IEC) or other appropriate regulatory authority. The trial site is 
also subject to quality assurance (QA) audits performed by [CONTACT_28146].  
It is important that the Investigator(s) and their relevant personnel are available during the monit oring visits, audits, and inspections and that sufficient attention, time, and support is 
devoted to the process.  
TRACON and its representatives will be governed by [CONTACT_5279], good clinical 
practice standards, and internal SOPs for the conduc t of monitoring visits and QA audits.    
Page 61 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
13. ETHICS  
13.1. Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) 
It is the responsibility of the Investigator to have approval of the trial protocol, protocol 
amendments, informed consent forms, and advert isements from the IRB/IEC before the p atients  
is consented for participation on the trial. All correspondence and other evidence of appropriate and timely communications with the IRB/IEC should be retained in the Investigator/site files. Copi[INVESTIGATOR_28078] /IEC approvals should also be forwarded to TRACON.  
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is where the change is necessary to eliminate apparent immediate hazards to the patient .  In that 
event, the Investigator must notify the IRB/IEC and TRACON in writing within [ADDRESS_27507] their origin in the Declaration of Helsinki (see ICH E6, § 2.1).  
13.3. Written Informed Consent  
The informed consent form language must be agreed upon by [CONTACT_28148]/IEC and must be in compliance with ICH GCP, local regulatory requirements, and legal requirements. 
The informed consent information must not be changed without prior approval by T RACON and 
the IRB/IEC. The informed consent form used in this trial, and any changes made during the 
course of the trial, must be approved by [CONTACT_28150]/IEC and TRACON, or designee, before 
use.  
It is the responsibility of the Investigator to give the  patient full and adequate verbal and written 
information regarding the objective and procedures of the trial and the possible risks involved.  
This information must be provided to the patient prior to undertaking any trial -related procedure.  
The p atient mus t be informed about her right to withdraw from the trial at any time.  
Furthermore, it is the responsibility of the Investigator to ensure the patient is  appropriately 
informed before obtaining her signed and dated consent. Signatures from the investigator  
conducting the informed consent discussion should also be obtained prior to undertaking any trial-related procedure. Consent by a legally authorized representative is not permitted. Should an 
impartial witness be needed, ICHE6 requirements for impartial w itnesses will apply.  
The Investigator will retain the original the patient’s signed consent form in the Investigator/site 
files.  
13.4. Patient Compensation  
The patient will not be compensated for participation in this trial; this will be outlined to  the 
patient  informed consent form. 
Page 62 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
14. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  
14.1. Inspection of Records  
CRF’s are required and should be completed for the patient wh en she receives treatment with 
TRC105 and beva cizumab .  The completed original CRFs are the sole property of TRACON and 
should not be made available in any form to third parties without written permission from 
TRACON (except for authorized representatives of the HRA and in accordance with HIPAA regulations). 
It is the Investigator’s responsibility to ensure completion and to review and approve all CRF 
data. The investigator will sign off on his/her data per patient.  These signatures serve to attest that the investigator has reviewed and approved the information contained on the case report 
forms and that the information is complete, accurate, and true.   At all times, the Investigator has 
final personal responsibility for the accuracy and authenticity of all clinical and laboratory data entered on the CRFs.   
The use of electronic CRFs (eCRFs) to capture study data using  automated computerized data 
capture systems does not change the principles and requirements for collecting study data.  The 
investigator still retains final personal responsibility for eCRF data and any associated data 
pertaining to it (e.g. metadata incl uding any record of change to the originally recorded data).  
The investigator’s signed approval of the eCRF data serves to attest that the electronic data and 
all of its associated metadata (including changes) has been reviewed and accepted as complete, 
accurate, and true for this patient . 
All CRF/eCRF data must be verifiable in the patient’s source records by [CONTACT_28177].  TRACON will review CRF data as compared to source records in an attempt to 
identify missing and spurious data and notify the investigator of findings so that proper corrections can be made.  TRACON representatives (monitors and auditors), and regulatory 
inspectors shall have direct access to the original source records in its original recorded format: 
electronic or hardcopy.   
TRACON (or its designee) will perform all data management functions associated with the 
study.  Data will be captured electronically.  Automated data verification (“edit checks”) will be 
used to ensure that the data are logical and consistent. Any inconsi stencies will be queried for 
clarification or correction as appropriate by [CONTACT_977].   
14.2. Retention of Records  
To allow for appropriate evaluations and/or audits by [CONTACT_28178], the Investigator agrees to keep records, including the identity of the  patient (sufficient information to 
link records, CRFs and hospi[INVESTIGATOR_1097]), all original signed informed consent forms, copi[INVESTIGATOR_4600], source documents, and detailed records of treatment disposition.  The Investigator should retai n these records according to local regulations or as specified in the Clinical Trial 
Agreement, whichever is longer.   
If the Investigator relocates, retires, or for any reason withdraws from the study, then TRACON 
should be prospectively notified.  The st udy records must be transferred to an acceptable 
designee, such as another Investigator, another institution, or to TRACON.  The Investigator 
Page 63 of 75
 
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
must inform TRACON of any such transfer of responsibilities and properly identify the person or 
institution assumi ng the responsibility.  The responsible investigator/institution must obtain 
TRACON’s written permission before disposing of any records.  
Page 64 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
15. DEFINITION OF END OF  TRIAL  
15.1. End of Trial  
End of trial in all participating countries is defined as the time at which the patient enrolled in the 
study has completed treatment on study.  
15.2. TRACON Discontinuation Criteria  
Premature termination of this trial may occur because of a regulatory authority decision, change 
in opi[INVESTIGATOR_1100]/IEC, drug safety problems, or at the discretion of TRACON.  In addition, 
TRACON retains the right to discontinue development of TRC105 at any time.  
TRACON reserves the right to discontinue the trial ,, but intends only to exercise this right for 
valid scientific or administrative reasons. If  the trial is prematurely terminated or discontinued, 
TRACON will promptly notify the Investigator.  After notification, the Investigator must contact 
[CONTACT_28153] a [ADDRESS_27508] extent possible.  
Page 65 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
16. PUBLICATION OF TRIAL  RESULTS  
Publication of trial results is discussed in the Clinical Trial Agreement.  
Page 66 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
17. FINANCING AND INSURA NCE  
Financing and Insurance are discussed in the Clinical Trial Agreement.  
Page 67 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
18. INVESTIGATOR PROTOCO L AGREEMENT: [ADDRESS_27509] be submitted to the appropriate 
IRB/IEC.  
 
 
Investig ator Name (PLEASE PRINT):  ______________________________________________ 
 
 
 
Signature: _________________________________________________Date: _______________  
 
Please sign and return this agreement to:  
TRACON Pharmaceuticals, Inc.  
Attn: Clinical Operations  
[ADDRESS_27510] 
San Diego, CA  [ZIP_CODE] 
 
Please keep a copy for your records. 
 
Page 68 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
19. REFERENCES  
1. Carmeliet, P., Angiogenesis in health and disease.  Nat Med, 2003. 9 (6): p. 653- 60. 
2. Folkman, J. and Y. Shing, Angiogenesis.  J Biol Chem, 1992. 267(16): p. [ZIP_CODE]- 4. 
3. Hurwitz, H., et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic 
colorectal cancer.  N Engl J Med, 2004. 350(23): p. 2335- 42. 
4. Sandler, A., et al., Paclitaxel -carboplatin alone or with bevacizumab for non- small -cell lung 
cancer.  N Engl J Med, 2006. 355(24): p. 2542- 50. 
5. Miller, K.D., et al., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previ ously treated metastatic breast cancer.  J Clin Oncol, 2005. 
23(4): p. 792- 9. 
6. Friedman, H.S., et al., Bevacizumab alone and in combination with irinotecan in recurrent 
glioblastoma.  J Clin Oncol, 2009. 27(28): p. 4733- 40. 
7. Escudier, B., et al., Phase I II trial of bevacizumab plus interferon alfa- 2a in patients with 
metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.  J Clin Oncol, 2010. 
28(13): p. 2144- 50. 
8. Escudier, B., et al., Sorafenib in advanced clear -cell renal -cell carc inoma.  N Engl J Med, 2007. 
356(2): p. 125- 34. 
9. Llovet, J.M., et al., Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med, 2008. 359(4): 
p. 378- 90. 
10. Motzer, R.J., et al., Sunitinib versus interferon alfa in metastatic renal -cell carcinoma.  N Engl J 
Med, 2007. 356(2): p. 115- 24. 
11. Rini, B.I., Vascular endothelial growth factor -targeted therapy in metastatic renal cell carcinoma.  
Cancer, 2009. 115([ADDRESS_27511]): p. 2306- 12. 
12. Haruta, Y. and B.K. Seon, Distinct human leukemia- associated cell surface glycoprotein GP160 
defined by [CONTACT_28154]6.  Proc Natl Acad Sci U S A, 1986. 83(20): p. 7898- 902.  
13. Gougos, A. and M. Letarte, Identification of a human endothelial cell antigen with monoclonal 
antibody 44G4 produced against a pre- B leukemic  cell line.  J Immunol, 1988. 141(6): p. 1925- 33. 
14. Seon, B.K., et al., Long- lasting complete inhibition of human solid tumors in SCID mice by 
[CONTACT_28179].  Clin 
Cancer Res, 1997. 3 (7): p. 1031- 44. 
15. Cheifetz, S., et al., Endoglin is a component of the transforming growth factor -beta receptor 
system in human endothelial cells.  J Biol Chem, 1992. 267(27): p. [ZIP_CODE]- 30. 
16. Li, D.Y., et al., Defective angiogenesis in mice lacking endoglin.  Science, 1999. 284(5419): p. 
1534- 7. 
Page 69 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
17. Burrows, F.J., et al., Up -regulation of endoglin on vascular endothelial cells in human solid 
tumors: implications for diagnosis and therapy.  Clin Cancer Res, 1995. 1 (12): p. 1623- 34. 
18. Seon, B.K., Expre ssion of endoglin (CD105) in tumor blood vessels.  Int J Cancer, 2002. 99(2): p. 
310- 1; author reply 312. 
19. Horsman, M.R. and D.W. Siemann, Pathophysiologic effects of vascular -targeting agents and the 
implications for combination with conventional therapi[INVESTIGATOR_014].  Cancer Res, 2006. 66(24): p. [ZIP_CODE]- 39. 
20. Matsuno, F., et al., Induction of lasting complete regression of preformed distinct solid tumors by 
[CONTACT_28180] -endoglin monoclonal antibodies.  Clin Cancer 
Res, 1999. 5 (2): p. 371- 82. 
21. Takahashi, N., et al., Antiangiogenic therapy of established tumors in human skin/severe 
combined immunodeficiency mouse chimeras by [CONTACT_14181] -endoglin (CD105) monoclonal antibodies, 
and synergy between anti -endoglin antibody and cyclophosphamide.  Cancer Res, 2001. 61(21): 
p. 7846- 54. 
22. Tsujie, M., et al., Anti -tumor activity of an anti -endoglin monoclonal antibody is enhanced in 
immunocompetent mice.  Int J Cancer, 2008. 122(10): p. 2266- 73. 
23. Uneda, S., H. Toi, and B.K. Seon, Anti -endogli n monoclonal antibodies are effective for 
suppressing metastasis and the primary tumors by [CONTACT_28157].  Int J Cancer, 
2009. 125: p. 1446.  
24. Guo, B., et al., CD105 inhibits transforming growth factor -beta -Smad3 signalling.  Anticancer Res, 
2004. 24(3a): p. 1337- 45. 
25. Warrington, K., et al., Functional role of CD105 in TGF -beta1 signalling in murine and human 
endothelial cells.  Anticancer Res, 2005. 25(3B): p. 1851- 64. 
26. Sanchez -Elsner, T., et al., Endoglin expression is regulated by [CONTACT_28181] -beta pathways.  J Biol Chem, 2002. 
277(46): p. [ZIP_CODE]- 808. 
27. Barbara, N.P., J.L. Wrana, and M. Letarte, Endoglin is an accessory protein that interacts with the 
signaling receptor c omplex of multiple members of the transforming growth factor -beta 
superfamily.  J Biol Chem, 1999. 274(2): p. 584- 94. 
28. She, X., et al., Synergy between anti -endoglin (CD105) monoclonal antibodies and TGF -beta in 
suppression of growth of human endothelial  cells.  Int J Cancer, 2004. 108(2): p. 251- 7. 
29. van Laake, L.W., et al., Endoglin has a crucial role in blood cell -mediated vascular repair.  
Circulation, 2006. 114(21): p. 2288- 97. 
30. Lenato, G.M. and G. Guanti, Hereditary Haemorrhagic Telangiectasia (HHT): genetic and 
molecular aspects.  Curr Pharm Des, 2006. 12(10): p. 1173- 93. 
31. Sabba, C., et al., Life expectancy in patients with hereditary haemorrhagic telangiectasia.  Qjm, 
2006. 99(5): p. 327- 34. 
Page 70 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
32. Lastres, P., et al., Regulated expression on hu man macrophages of endoglin, an Arg- Gly-Asp-
containing surface antigen.  Eur J Immunol, 1992. 22(2): p. 393- 7. 
33. Pece, N., et al., Mutant endoglin in hereditary hemorrhagic telangiectasia type [ADDRESS_27512], 1997. 100(10): p. 2568- 79. 
34. Bockhorn, M., et al., Differential vascular and transcriptional responses to anti -vascular 
endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.  Clin 
Cancer Res, 2003. 9(11): p. 4221- 6. 
35. Davis, D.W., et al., Regional effects of an antivascular endothelial growth factor receptor 
monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B -V bladder 
cancer xenografts.  Cancer Res, 2004. 64(13): p. 4601- 10. 
36. Kumar, S., et al., Breast carcinoma: vascular density determined using CD105 antibody correlates 
with tumor prognosis.  Cancer Res, 1999. 59(4): p. 856- 61. 
37. Vo, M.N., et al., Elevated plasma endoglin (CD105) predicts decreased response and survi val in a 
metastatic breast cancer trial of hormone therapy.  Breast Cancer Res Treat, 2008.  
38. Tanaka, F., et al., Evaluation of angiogenesis in non- small cell lung cancer: comparison between 
anti-CD34 antibody and anti -CD105 antibody.  Clin Cancer Res, 2001. 7(11): p. 3410- 5. 
39. El-Gohary, Y.M., et al., Endoglin (CD105) and vascular endothelial growth factor as prognostic 
markers in prostatic adenocarcinoma.  Am J Clin Pathol, 2007. 127(4): p. 572- 9. 
40. Svatek, R.S., et al., Preoperative plasma endoglin levels predict biochemical progression after 
radical prostatectomy.  Clin Cancer Res, 2008. 14(11): p. 3362- 6. 
41. Li, C., et al., Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.  Br J 
Cancer, 2003. 88(9): p. 1424- 31. 
42. Romani, A.A., et al., The risk of developi[INVESTIGATOR_28095]105- positive vessel count.  J Surg Oncol, 2006. 93(6): p. 446- 55. 
43. Ding, S., et al., Comparative evaluation of microvessel density determined by [CONTACT_398]34 or CD105 in 
benign and malignant gastric lesions.  Hum Pathol, 2006. 37(7): p. 861- 6. 
44. Erdem, O., et al., CD105 expression is an independent predictor of survival in patients with 
endometrial cancer.  Gynecol Oncol, 2006. 103(3): p. 1007- 11. 
45. Yao, Y., et al., Prognostic significance of microvessel density determined by [CONTACT_2017] -
CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti -CD31 
monoclonal  antibody.  Neuropathology, 2005. 25(3): p. 201- 6. 
46. Yang, L.Y., et al., Correlation between CD105 expression and postoperative recurrence and 
metastasis of hepatocellular carcinoma.  BMC Cancer, 2006. 6 : p. 110. 
Page 71 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
47. Rubatt, J.M., et al., Independent prognostic relevance of microvessel density in advanced 
epi[INVESTIGATOR_28080]31, CD105, p53 status, and angiogenic 
marker expression: A Gynecologic Oncology Group study.  Gynecol Oncol, 2009. 112(3): p. 469-
74. 
48. Taskiran, C., e t al., The prognostic value of endoglin (CD105) expression in ovarian carcinoma.  Int 
J Gynecol Cancer, 2006. 16(5): p. 1789- 93. 
49. Saad, R.S., et al., Endoglin (CD105) and vascular endothelial growth factor as prognostic markers 
in esophageal adenocarcino ma. Hum Pathol, 2005. 36(9): p. 955- 61. 
50. Kyzas, P.A., N.J. Agnantis, and D. Stefanou, Endoglin (CD105) as a prognostic factor in head and 
neck squamous cell carcinoma.  Virchows Arch, 2006. 448(6): p. 768- 75. 
51. Marioni, G., et al., Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma.  Acta Otolaryngol, 2006. 126(6): p. 633- 9. 
52. Takahashi, N., et al., Association of serum endoglin with metastasis in patients with colorectal, 
breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.  
Clin Cancer Res, 2001. 7 (3): p. 524- 32. 
53. Shiozaki, K., et al., Antiangiogenic chimeric anti -endoglin (CD105) antibody: pharmacokinetics 
and immunogenicity in nonhuman primates and effects of doxorubicin.  Cancer Immunol 
Immunother, 2006. 55(2): p. 140- 50. 
54. Rokhlin, O.W., et al., Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow.  J Immunol, 1995. 154(9): p. 4456- 65. 
55. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST 
guideline (version 1.1).  Eur J Cancer, 2009. 45(2): p. 228- 47. 
 
 
Page 72 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
20. APPENDICES  
Appendix 1:  National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE)  
 
The NCI CT CAE (Version 4.0) should be used to assess Adverse Events and may be reviewed 
on-line at the following NCI website:  
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010- 06-14_QuickReference_8.5x11.pdf   
Page 73 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Appendix 2:  ECOG Performance Status 
 
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out  work of a light 
or sedentary nature, e.g., light house work, office work.  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of waking hours.  
3 Capable of only limited self -care, confined to  bed or chair more than 50% of waking hours.  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair.  
5 Dead.  
   
Page 74 of 75  
  
[IP_ADDRESS] Clinical Protocol   105CC201B Protocol  06Oct2015 
______________________________________________________________________________ 
Appendix 3:  Avastin Package Insert  
The FDA approved bevacizumab package insert should be referenced and may be reviewed on -
line at the following FDA website:  
http://www.gene.com/gene/products/information/pdf/avastin -prescribing.pdf  
 
Page 75 of 75  
  